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Abstract	
	
Hepatocyte	growth	 factor	 receptor	 substrate	 (HRS)	 is	a	component	of	 the	ESCRT-0	
complex.	 It	 is	 involved	 in	 the	 sorting	 of	 ubiquitylated	 receptors	 into	 the	 lumen	 of	
multivesicular	bodies	(MVBs),	thus	targeting	them	for	lysosomal	degradation.	HRS	is	
highly	 phosphorylated	 in	 response	 to	 stimulation	 by	 various	 growth	 factors,	 but	
despite	this,	the	functional	role	of	its	phosphorylation	is	still	contentious.	Preliminary	
data	 from	our	 laboratory	 suggested	 that	HRS	may	 also	 act	 as	 a	 signalling	 adaptor,	
involved	 in	 the	 crosstalk	 between	 receptor	 tyrosine	 kinases	 (RTKs)	 and	 G	 protein	
couple	receptors	(GPCRs).	In	order	to	investigate	this	hypothesis,	I	first	examined	the	
EGF	dependent	interactors	of	HRS	by	mass	spectrometry.	I	then	developed	tools	for	
the	measurement	of	endosomal	cAMP	production	and	PKA	signalling.		
	
My	data	suggests	that	HRS	interacts	with	the	E3	ligase	deltex3-like	(DTX3L)	in	an	EGF	
dependent	manner.	Although	an	association	between	these	proteins	has	previously	
been	 made,	 its	 EGF	 dependence	 is	 novel.	 DTX3L	 has	 previously	 been	 shown	 to	
modulate	the	recruitment	of	HRS	to	endosomes	in	response	to	stimulation	of	the	G-
protein	coupled	receptor	CXCR4.	This	new	finding	offers	a	theoretical	means	through	
which	 different	 receptor	 classes	 could	 crosstalk	 and	 elicit	 an	 integrated	 signalling	
response.	
	
I	further	show	that	GFP-HRS	is	recruited	directly	to	newly	formed	vesicles	containing	
EGF	and	its	receptor.	Recruitment	of	HRS	to	endosomes/vesicles	in	response	to	TGFα,	
but	 not	 EGF,	 is	 partly	 dependent	 on	 phospho-tyrosine	 residues	 Y329	 and	 Y334.	
Furthermore,	HRS	has	 recently	been	 implicated	 in	 the	 recruitment	of	 the	 recycling	
complex	WASH	to	endosomes.	This,	combined	with	the	previous	observation,	suggests	
that	phosphorylation	of	these	two	sites	may	be	involved	in	receptor	recycling.		
	 iii	
Overall,	 my	 thesis	 generates	 new	 tools	 for	 the	 study	 of	 HRS	 function	 and	 for	 the	
analysis	of	endosomal	 signalling.	 I	provide	evidence	 for	 the	 role	of	HRS	 in	RTK	and	
GPCR	 crosstalk	 alongside	 providing	 insights	 into	 the	 mechanisms	 governing	
recruitment	of	HRS.		
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‘Sorting	of	receptors	at	the	endosome	has	been	proposed	to	play	a	role	in	modulating	
signalling	through	controlling	the	balance	between	receptor	cycling	and	degradation.	
More	 recently	 the	 concept	 of	 specific	 receptor	 signalling	 outputs	 associated	 with	
passage	through	the	endosomal	pathway	has	been	established.	Proof	of	principle	was	
provided	by	studies	of	receptor	tyrosine	kinases,	with	the	best	characterised	example	
being	the	EGFR.	However,	this	concept	may	transfer	to	GPCRs	and	associated	cAMP	
signalling.	Current	models	suggest	a	second	wave	of	activation	occurs	at	endosomal	
membranes,	 leading	 to	 prolonged	 cAMP	 signals	 and	 downstream	 effects	 on	
endosomal	acidification	mediated	by	PKA.	Furthermore,	 localised	generation	of	the	
cAMP	dictates	signalling	outcomes.	Hitherto,	studies	have	used	global	measurements	
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of	cAMP	but	there	 is	an	unmet	need	for	direct	visualisation	of	cAMP	generation	at	
endosomes.	We	are	developing	endosomal	localised	reporters	for	cAMP	generation	
and	 PKA	 activation	 and	 will	 provide	 details	 of	 their	 characterisation	 to	 date.	 The	
ultimate	goal	is	to	combine	these	with	defined	perturbations	of	endosomal	trafficking	
allowing	for	an	increase	the	granularity	of	our	understanding	of	these	effects.	
	
Important	for	ushering	a	receptor	through	to	degradation,	 is	 its	 internalisation	 into	
the	endosomal	lumen	and	formation	of	MVB’s.	A	process	which	is	controlled	by	the	
ESCRT	machinery.	Later	on,	trafficking	was	shown	to	regulate	signal	transduction	by	
having	distinct	signalling	outcomes	 from	the	plasma	membrane,	as	opposed	to	the	
signalling	outcomes	from	the	endosome.	An	aim	for	the	lab	is	to	determine	whether	
the	ESCRT	machinery	is	involved	in	this	phenomena	by	acting	as	a	signalling	platform.	
Here	 we	 describe	 the	 development	 and	 characterisation	 of	 endosomally	 localised	
biosensors	for	the	cAMP	pathway.	Through	this	we	aim	to	further	the	field	by	directly	
visualising	and	measuring	cAMP	produced	at	the	endosomes	and	begin	to	dissect	the	
mechanisms	involved	in	governing	endosomal	cAMP,	and	GPCR,	signalling.’	
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Chapter	one:	Introduction	
1.1.	Endocytic	pathway	overview	
	
The	endocytic	pathway	is	a	series	of	morphologically	distinct	compartments	that	allow	
cells	to	deal	with	internalised	material.	The	steps	within	this	pathway	are	involved	in	
many	cellular	processes	such	as,	protein	degradation,	regulation	of	receptor	signalling	
and	the	immune	system.	The	physical	properties	of	each	compartment,	along	with	a	
complex	array	of	regulating	proteins,	allow	for	the	correct	sorting	and	trafficking	of	
any	internalised	cargoes.	Disruption	to	the	organisation	of	endocytic	compartments	
has	been	implicated	in	diseases	ranging	from	cancer	to	various	forms	of	dementia.	
	
1.1.1.	Endocytosis	
	
Endocytosis	is	the	cellular	process	by	which	extracellular	material	is	taken	into	the	cell.	
There	are	many	types	of	endocytosis	that	can	broadly	be	categorised	into	macro-	or	
micro-endocytosis.	Macro-endocytosis	describes	the	process	of	how	the	cell	intakes	
large	 quantities	 of	 extracellular	 material,	 whether	 it	 be	 by	 macropinocytosis	 or	
phagocytosis	used	by	cells	of	the	 immune	system	to	 ingest	pathogens.	This	type	of	
endocytosis	is	often	referred	to	as	cell	eating	or	drinking.	Micro-endocytosis,	as	the	
name	suggests,	is	a	much	smaller	scale	form	of	internalisation,	typically	smaller	than	
200nm	 (Kumari,	 Mg	 et	 al.	 2010).	 Micro-endocytosis	 can	 first	 be	 categorised	 by	
whether	it	takes	place	in	lipid	raft	or	non-lipid	raft	domains	(El-Sayed	and	Harashima	
2013).	Outside	of	lipid	rafts,	Clathrin-mediated	endocytosis	(CME)	is	the	primary	form	
of	micro-endocytosis	and	the	most	widely	researched	endocytic	pathway.	Endocytosis	
occurring	within	lipid	raft	domains	can	be	further	defined	by	the	associated	molecules	
involved.	 These	 are:	 Caveolae-mediated,	 Flotillin-dependent,	 GRAF1-dependent,	
ArF6-dependent	 and	RhoA-dependent	endocytosis	 (El-Sayed	and	Harashima	2013).	
These	 mechanisms	 of	 endocytosis	 are	 generally	 less	 selective	 than	 CME.	 GRAF1-
dependent	endocytosis	has	been	proposed	to	be	responsible	for	the	uptake	of	larger	
proteins	(Bhagatji,	Leventis	et	al.	2009).		
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Evidence	for	endocytosis	dates	back	to	the	19th	century,	when	it	was	observed	that	
cells	 could	 internalise	 litmus	 paper	 into	 acidic	 compartments	 (Roth	 2006).	 In	 the	
1930’s	macrophages	were	 imaged	 internalising	extracellular	 fluid,	estimating	that	a	
macrophage	could	internalise	the	equivalent	of	a	third	of	its	own	cell	volume	per	hour.		
Then,	 in	 1964,	 Roth	 and	 Porter	 imaged	 the	 sequence	 of	 events	 that	 lead	 to	 the	
formation	 of	 endocytic	 vesicles	 in	 Aedes	 aegypti	 oocytes	 by	 electron	 microscopy,	
describing	 invagination	 of	 the	 membrane,	 formation	 of	 coated	 pits	 and	 the	
subsequent	pinching	off	of	the	endocytic	vesicle	(Roth	and	Porter	1964).	A	few	years	
later,	the	molecular	coat	on	internalised	vesicles	was	described	as	a	regular	cage-like	
structure	 (Kanaseki	 and	 Kadota	 1969).	 The	 major	 component	 of	 this	 coat	 was	
identified	as	clathrin	in	1975	(Pearse	1975,	Pearse	1976).	Around	the	same	time,	work	
by	Anderson,	Brown	and	Goldstein,	described	the	ligand-induced	internalisation	of	the	
low-density	lipoprotein	(LDL)	receptor.	They	discovered	a	mutation	in	the	LDL	receptor	
that	prevented	it	from	clustering	within	coated	pits,	effectively	linking	the	binding	of	
a	 ligand	 to	 the	 assembly	 of	 clathrin	 coated	 pits	 (Anderson,	 Brown	 et	 al.	 1977,	
Anderson,	Goldstein	et	al.	1977,	Goldstein,	Anderson	et	al.	1979).	A	process	that	 is	
now	 known	 as	 receptor-mediated	 endocytosis.	 Later	 this	 form	 of	 endocytosis	was	
shown	 to	 induce	 receptor	 internalisation	 with	 stimulation	 of	 insulin,	 EGF	 and	 α2-
macroglobin	(Maxfield,	Schlessinger	et	al.	1978).		
	
Despite	the	cave-like	morphology	of	caveolae	first	being	described	in	1953	by	George	
Palade,	 it	wasn’t	until	 1992	 that	 caveolin	was	 identified	as	 the	 coat	 component	of	
these	structures	(Kurzchalia,	Dupree	et	al.	1992,	Rothberg,	Heuser	et	al.	1992).	This	
form	of	endocytosis	is	less	well	understood	than	clathrin-mediated	endocytosis.		
	
1.1.2.	Endosomes	
	
Endosomes	are	a	complex	series	of	endocytic	compartments	involved	in	the	sorting,	
recycling	and	degradation	of	internalised	material	and	trans-membrane	proteins.	They	
can	be	categorised	 into	various	subtypes,	based	on	their	morphology,	 function	and	
associated	 proteins	 and	 phospholipid	 species.	 These	 subtypes	 are:	 the	 early	
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endosome,	also	referred	to	as	sorting	endosomes,	the	recycling	endosome	and	the	
late	endosomes,	also	known	as	multivesicular	bodies	(MVBs)	(Figure	1.1).		
	
1.1.3.	Early	endosomes	
	
During	 the	1970’s,	extensive	 research	went	 in	 to	 the	study	of	endocytosis,	but	 the	
destination	 of	 internalised	 vesicles	 was	 unclear	 (Roth	 2006).	 Roth	 and	 Porter	
suggested	that	small	vesicles	fuse	to	form	larger	vesicles,	based	on	the	observation	of	
different	 sized	 yolk	 filled	 vesicles	 in	 their	 experiments.	 In	 1980,	 studies	 into	 the	
endocytosis	of	viruses	provided	an	insight	into	the	fate	of	endocytic	vesicles	(Helenius,	
Kartenbeck	et	al.	1980).	Viruses	were	bound	to	cells	at	low	temperatures	to	prevent	
their	internalisation.	The	cells	were	fixed	after	being	warmed	for	varying	amounts	of	
time.	Initially,	single	virions	are	observed	in	small,	coated	vesicles.	After	a	few	more	
minutes,	multiple	virions	are	found	within	larger,	uncoated	vesicles,	and	at	later	time	
points	 in	MVBs	and	 lysosomes.	A	few	years	 later	 in	1983,	Geuze	et	al.	would	use	a	
double	 labelling	 immunogold	 combined	 with	 cryoEM	 to	 show	 that	 the	
asialoglycoprotein	 receptor	 and	 its	 ligand	were	 trafficked	 to	 a	 distinctive	organelle	
(Geuze,	Slot	et	al.	1983).	Here	the	ligand	would	accumulate	in	the	organelles	lumen,	
with	the	receptor	concentrated	in	tubular	extensions.	They	named	this	organelle	CURL	
(compartment	of	uncoupling	receptor	from	ligand).	This	organelle	 is	now	known	as	
the	sorting	endosome.	
	
The	 sorting	endosome	 is	 the	 first	organelle	 to	 receive	endocytosed	material.	 From	
here,	this	material	is	then	sorted	for	either	degradation	or	recycling.	The	morphology	
of	this	organelle	greatly	aids	in	this	function.	It	is	estimated	that	approximately	60-70%	
of	the	luminal	volume	is	in	the	vesicular	body	and	the	tubular	extensions	account	for	
50-80%	 of	 its	 surface	 area	 (Mukherjee,	 Ghosh	 et	 al.	 1997).	 This	 morphology	
encourages	the	recycling	of	receptors	and	the	degradation	of	ligands	(Dunn,	McGraw	
et	al.	1989).	Receptors	and	transmembrane	proteins	are	directed	towards	degradation	
by	 being	 sequestered	 into	 intraluminal	 vesicles	 (ILVs)	 of	 the	 maturing	 endosome,	
whereas,	 those	 designated	 for	 recycling	 are	 either	 trafficked	 directly	 back	 to	 the	
plasma	membrane	or	towards	the	tubular	network	of	the	recycling	endosome.	
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1.1.4.	Late	endosomes/MVBs	
	
Multivesicular	bodies	were	discovered	in	the	1950’s	by	electron	microscopy	(EM),	due	
to	 their	 distinctive	 morphology	 (Sotelo	 and	 Porter	 1959).	 MVBs	 contain	 small	
intraluminal	 vesicles	 which	 form	 from	 the	 limiting	 membrane	 of	 the	 maturing	
endosome.	 Studies	 from	Stanley	Cohen	and	 colleagues	 in	 the	 late	1970’s	 followed	
ferritin-conjugated	EGF	which	had	been	internalised.	They	show	that	this	tagged	EGF	
passes	 through	 MVBs	 en	 route	 to	 the	 lysosome	 (Gorden,	 Carpentier	 et	 al.	 1978,	
Haigler,	McKanna	et	al.	1979).	In	the	following	decade	it	was	shown	that	the	EGFR	was	
sorted	with	EGF	into	the	lumen	of	MVBs	(Miller,	Beardmore	et	al.	1986).	It	was	not	
clear,	 however,	 if	 material	 sorted	 for	 degradation	 at	 the	 sorting	 endosome	 was	
subsequently	trafficked	to	MVBs	or	sorting	endosomes	matured	into	MVBs	over	time.	
This	question	was	answered	 in	1992	by	Dunn	et	al.	who	provided	evidence	for	 the	
maturation	of	sorting	endosomes	(Dunn	and	Maxfield	1992).		
	
MVBs	 are	 formed	 through	 the	 loss	 of	 material	 destined	 for	 recycling	 and	 the	
accumulation	of	material	designated	for	degradation	(Katzmann,	Odorizzi	et	al.	2002).	
This	material	is	internalised	into	the	endosomal	lumen	to	form	ILVs,	a	process	which	
is	controlled	by	the	ESCRT	machinery	(described	in	section	1.2.6).	MVBs	were	shown	
to	fuse	directly	with	lysosomes	in	1996	(Futter,	Pearse	et	al.	1996).	By	the	end	of	the	
decade,	it	was	known	that	segregation	of	active	receptors	into	ILVs	was	important	for	
the	down	regulation	of	receptor	signalling	by	removing	the	active	kinase	domain	away	
from	the	cytosol	(Ceresa	and	Schmid	2000).	Disruption	to	the	components	involved	in	
this	process	can	lead	to	tumourgenesis	(Di	Fiore	and	Gill	1999).	
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1.1.5.	Markers	of	endocytic	membranes	
	
The	different	endocytic	compartments	can	be	identified	morphologically	by	EM.	The	
resolution	of	 light	microscopy	 is	generally	not	high	enough	to	 identify	their	distinct	
morphological	features	(Ullrich,	Reinsch	et	al.	1996).	It	is	therefore	necessary	to	use	
markers	to	identify	the	different	classes	of	endosomes.	This	can	be	achieved	by	using	
the	specific	proteins	or	lipid	species	associated	with	each	compartment.		
Figure	1.1	Simplified	overview	of	the	endocytic	pathway.	Once	bound	to	its	ligand,	
a	receptor	is	internalised	into	the	cell,	forming	a	vesicle.	The	vesicle	then	traffics	to	
the	early	endosome	for	further	sorting.	From	here,	the	receptor	can	be	recycled	
back	to	plasma	membrane	via	actin	rich	domains,	a	process	primarily	mediated	by	
the	 retromer	 and	WASH	 complex.	 Alternatively,	 the	 receptor	 can	 be	 sorted	 for	
degradation	 through	 interaction	 with	 the	 ESCRT	 machinery,	 leading	 to	
internalisation	 into	 the	 lumen	 of	 the	 endosome	 and	 the	 formation	 of	 the	
multivesicular	body	(MVB).	The	MVB	then	fuses	with	a	 lysosome,	 leading	 to	the	
degradation	of	its	contents	by	digestive	enzymes.	Phosphotidylinositide	lipids	are	
responsible	for	the	identification	of	each	of	the	Endo-membranes.	
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Markers	of	the	early	endosome	include:	PtdIns(3)P,	VPS34,	Rab5,	Rab4	and	EEA1.	Rab5	
is	 a	 small	 GTPase	 that	 mediates	 the	 fusion	 of	 endocytic	 vesicles	 with	 the	 early	
endosome	(Gorvel,	Chavrier	et	al.	1991,	Bucci,	Parton	et	al.	1992).	Rab5	is	responsible	
for	the	recruitment	of	the	class	III	PI-3	kinase,	VPS34	(Christoforidis,	Miaczynska	et	al.	
1999).	VPS34	generates	PtdIns(3)P	on	early	endosomes.	PtdIns(3)P	 is	an	 important	
lipid	species,	as	it	is	responsible	for	the	recruitment	and	localisations	of	FYVE	(Fab1,	
YOTB,	 Vac1	 and	 EEA1)	 domain	 containing	 proteins	 to	 early	 endosomes	 (Gillooly,	
Simonsen	et	al.	2001).	The	most	widely	used	protein	marker	of	early	endosomes	is	the	
Rab5	effector,	EEA1.	EEA1	is	recruited	to	early	endosomes	by	the	dual	interaction	with	
Rab5	 and	 with	 PtdIns(3)P	 though	 its	 FYVE	 domain	 (Mu,	 Callaghan	 et	 al.	 1995,	
Stenmark,	Aasland	et	al.	1996).		
	
In	conjunction	with	Rab5,	Rab4	and	Rab21	are	also	present	on	early	endosomes	(van	
der	Sluijs,	Hull	et	al.	1991,	Simpson,	Griffiths	et	al.	2004).	Rab4	is	responsible	for	the	
trafficking	of	material	from	the	early	endosome	to	the	recycling	endosome	(van	der	
Sluijs,	Hull	et	al.	1992).	Rab4	is	also	present	on	this	compartment,	but	the	predominant	
Rab	species	on	 the	 recycling	endosome	 is	Rab11	 (Ullrich,	Reinsch	et	al.	1996).	The	
function	of	Rab21	is	less	well	understood	but	has	been	shown	to	be	involved	in	the	
endosomal	 sorting	of	 integrins	 (Pellinen,	Arjonen	et	al.	2006,	Pellinen,	Tuomi	et	al.	
2008).	
	
Specific	markers	of	the	MVB/late	endosome	are	difficult	to	come	by	as	many	of	the	
components	of	MVBs	are	also	present	at	other	endocytic	compartments	(Hanson	and	
Cashikar	2012).	Lamp1	and	Lamp2	can	both	be	observed	on	late	endosomes,	but	are	
also	markers	of	the	lysosome	(Carlsson,	Roth	et	al.	1988).	These	proteins	can	be	used	
as	markers	 for	 the	 late	 endosome	when	used	 in	 conjunction	with	 the	mannose	6-
phosphate	 receptor	 (CIMPR).	 This	 receptor	 ferries	 proteins	 between	 the	 Golgi	
complex	and	endosomes,	but	is	not	present	on	lysosomes	(Geuze,	Slot	et	al.	1985).	
The	co-occurrence	of	these	two	markers	can	effectively	define	late	endosomes.		
As	the	endosome	matures,	PIKFyve	is	recruited	via	interaction	with	PtdIns(3)P	and	its	
FYVE	domain	(Sbrissa,	Ikonomov	et	al.	2002).	PIKFyve	is	responsible	for	the	generation	
of	PtdIns(3,5)P2	from	PtdIns(3)P	(Sbrissa,	Ikonomov	et	al.	1999).	Despite	PtdIns(3)P	still	
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being	present	on	late	endosomes	in	small	amounts,	PtdIns(3,5)P2	is	the	predominant	
PtdIns	lipid	species	present	on	MVBs.	Similarly,	small	amounts	of	Rab5	are	still	present	
on	late	endosomes,	but	due	to	the	decreasing	levels	of	PtdIns(3)P,	the	levels	of	Rab5	
also	 decrease	 as	 the	 endosome	 matures	 (Woodman	 and	 Futter	 2008).	 Rab5	 is	
subsequently	replaced	by	Rab7,	the	major	Rab	species	of	MVBs,	in	a	process	known	
as	the	Rab5-to-Rab7	conversion	(Rink,	Ghigo	et	al.	2005).	
	
1.2.	Degradation	
	
The	1930’s	work	by	Schoenheimer	described	the	dynamic	nature	of	proteins	through	
the	study	of	rats	fed	with	stable	isotope-labelled	amino	acids	(Schoenheimer,	Ratner	
et	al.	1939).	Now,	we	know	that	there	are	three	main	modes	of	degradation	present	
within	 cells.	 These	 degradation	 pathways	 are	 associated	 with	 the	 lysosome,	
autophagosome,	and	the	proteasome.	The	small	8.5kDa	protein,	ubiquitin,	is	involved	
in	all	three	of	these	pathways	(Clague	and	Urbe	2010).	
	
1.2.1.	Discovery	of	the	Lysosome	
	
The	 first	 of	 these	 pathways	 to	 be	 discovered	 was	 the	 lysosome	 in	 the	 1950’s	 by	
Christian	de	Duve	(de	Duve	2005).	Initially	interested	in	carbohydrate	metabolism	and	
insulin	response	 (de	Duve	2004),	de	Duve	applied	centrifugation	techniques,	which	
had	recently	been	developed	by	Albert	Claude	(Claude	1946),	 in	order	to	study	the	
distribution	of	the	enzyme;	acid	phosphatase	(Appelmans,	Wattiaux	et	al.	1955).	The	
enzyme	was	distributed	jointly	across	a	primarily	mitochondrial	fraction	and	a	lighter	
fraction	 consisting	 of	 smaller	 granules	 termed	 microsomes.	 By	 adjusting	 the	
centrifugation	 protocol,	 they	 were	 able	 to	 separate	 an	 additional	 fraction,	 which	
contained	the	acid	phosphatase	within	it,	instead	of	the	enzyme	being	spread	amongst	
the	microsome	and	mitochondrial	fractions.	De	Duve	subsequently	searched	for	other	
enzymes	that	might	be	concentrated	with	this	fraction.	His	group	found	a	collection	
of	 four	more	 hydrolases	 that	 also	 had	 an	 acid	 optimum	 pH	 and	 all	 acted	 on	 very	
different	targets	(De	Duve,	Pressman	et	al.	1955).	This	gave	rise	to	the	notion	that	the	
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particles	isolated	within	this	fraction	functioned	as	digestive	compartments.	The	term	
‘lysosome’	was	 subsequently	 given	 to	 these	particles	 from	 the	Greek	words	 ‘lysis’,	
meaning	digestive,	and	‘soma’,	meaning	body.	Soon	after	lysosomes	were	visualised	
via	EM,	first	in	purified	lysosomal	fractions	and	then	in	sections	of	liver	tissue	(Novikoff,	
Beaufay	et	al.	1956).	
	
1.2.2.	Discovery	of	autophagy	
	
Further	EM	studies	would	later	give	rise	to	the	second	degradative	pathway	known	as	
autophagy,	or	‘self-eating’.	EM	studies	of	mouse	kidney	tubule	cells	would	show	the	
presence	of	an	unusual	vacuole	that	often	times	contains	cellular	components	such	as	
mitochondria	(Novikoff,	Beaufay	et	al.	1956,	Clark	1957).	Similarly,	acid-phosphatase	
positive	 compartments	 had	 also	 been	 identified	 to	 contain	 mitochondria.	 These	
compartments	could	be	induced	by	stimulation	with	glucagon	and	along	with	careful	
EM	 the	 sequential	 formation	 of	 the	 pre-autophagosomal	 structure	 (PAS)	 was	
elucidated	by	Arstila	and	Trump	(Ashford	and	Porter	1962,	Arstila	and	Trump	1968).	
This	pathway	is	initiated	by	the	formation	of	a	small	membrane	‘sac’.	This	membrane	
sac	then	extends	to	form	a	C-shaped	membrane	that	begins	to	engulf	a	portion	of	the	
cytosol.	The	membrane	continues	to	extend	until	the	two	ends	fuse	together,	forming	
a	 double	 membraned	 organelle	 called	 the	 autophagosome,	 which	 at	 this	 point	 is	
devoid	 of	 hydrolytic	 enzymes.	 The	 autophagosome	 then	 fuses	 with	 the	 lysosome	
forming	the	single-membraned	structure	called	the	autophagolysosome.	The	 inner-
membrane	of	the	autophagosome,	along	with	the	luminal	contents,	is	thus	degraded	
by	the	hydrolytic	enzymes	present	within	the	lysosome.		
	
Despite	 the	 term	 ‘autophagy’	 being	 coined	 in	 1963,	 the	 proteins	 responsible	 for	
autophagy	were	not	identified	until	the	1990’s	(Ohsumi	2014).	A	genetic	Yeast	screen	
by	Yoshinori	Ohsumi	would	determine	a	 series	of	 genes	 involved	 in	 the	process	of	
autophagy.	 Now	 termed	 autophagy-related	 (Atg)	 genes,	 almost	 all	 of	 the	
proteins/genes	 identified	 were	 completely	 uncharacterised	 (Tsukada	 and	 Ohsumi	
1993,	Nakatogawa,	Suzuki	et	al.	2009).	
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1.2.3.	Discovery	of	the	proteasome	and	the	ubiquitin	system	
	
Either	by	endocytosis	or	via	the	autophagosome,	the	lysosome	was	believed	to	be	the	
primary	site	for	degradation.	However,	these	methods	of	degradation	couldn’t	easily	
explain	the	varying	half-life	or	the	energy	requirement	for	degradation	of	intracellular	
proteins	(Ciechanover	2005).	Furthermore,	Studies	into	haemoglobinopathies	found	
that	 reticulocytes,	 which	 do	 not	 contain	 lysosomes,	 are	 able	 to	 rapidly	 degrade	
abnormal	 haemoglobin	 (Rabinovitz	 and	 Fisher	 1964).	 Disruption	 of	 lysosomal	
degradation	 by	 treatment	 with	 chloroquine	 effectively	 abolishes	 degradation	 of	
extracellular	proteins,	but	had	no	effect	on	the	degradation	of	short-lived	intracellular	
proteins	(Poole,	Ohkuma	et	al.	1977).	It	was	not	until	1977,	more	than	two	decades	
after	 the	 initial	 identification	 of	 the	 lysosome,	 that	 an	 ATP-dependent	 protein	
degradation	 pathway	 separate	 from	 the	 lysosome	 was	 discovered	 (Etlinger	 and	
Goldberg	1977).	This	work	was	carried	out	in	Reticulocyte	lysates	and	in	an	attempt	to	
identify	the	components	of	the	new	degradative	system	led	to	the	 identification	of	
ATP-dependent	 proteolysis	 factor-1	 (APF-1),	 an	 8,500Da	 peptide	 that	 is	 covalently	
attached	to	target	substrates	via	an	isopeptide	bond	(Ciechanover,	Hod	et	al.	1978).	
Around	 the	 same	 time,	 ubiquitin	 was	 characterised	 as	 a	 post-translational	
modification	of	the	side	chain	of	lysine	residues	on	Histone	2A	(Goldknopf	and	Busch	
1977).	 The	 characteristics	 of	 the	 bond	 between	 ubiquitin	 and	 Histone	 2A	 shared	
remarkable	similarities	to	that	of	APF-1,	as	well	as	being	the	same	size,	and	after	a	
series	of	experiments	the	two	proteins	were	shown	to	be	one	of	the	same	(Wilkinson,	
Urban	et	al.	1980).		
	
Soon	 after	 the	 rest	 of	 the	 components	 of	 the	 ubiquitin	 conjugating	 pathway	were	
deciphered.	 The	 pathway	 consists	 of	 a	 cascade	 of	 three	 enzymes	 leading	 to	 the	
addition	of	ubiquitin	to	the	target	substrate	(Hershko,	Heller	et	al.	1983).	The	first	class	
of	enzymes	 in	 this	cascade	 is	 the	ubiquitin-activating	enzyme	 (E1),	 followed	by	 the	
ubiquitin-carrier	 protein	 (E2)	 and	 finally	 the	 ubiquitin-protein	 ligase	 (E3).	 The	 E1	
enzyme	binds	 to	 free	ubiquitin.	 The	ubiquitin	 is	 then	passed	 from	 the	E1	 to	an	E2	
enzyme.	From	here,	the	ubiquitin	molecule	is	either	ligated	directly	to	the	substrate	
with	the	help	of	an	E3	ligase,	as	seen	with	the	RING	class	of	E3	ligases,	or	the	ubiquitin	
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molecule	is	accepted	by	the	E3	prior	to	being	ligated	to	the	target	substrate,	as	seen	
with	HECT	E3	ligases	(Figure	1.2).	There	is	also	another	class	of	E3	ligases	called	RING	
between	RING	(RBR)	that	contains	RING	domains	but	function	more	similarly	to	the	
HECT	class	of	E3	 ligases.	Today	there	are	over	a	1000	components	of	 the	ubiquitin	
system,	 falling	 into	 these	 three	 categories	 of	 enzymes	 and	 along	 with	 a	 class	 of	
enzymes	 responsible	 for	 the	 cleavage	 of	 ubiquitin	 called	 deubiquitylating	 enzymes	
(DUBs).	The	protease	complex	responsible	for	the	degradation	of	proteins	targeted	by	
ubiquitin	was	identified	as	the	26S	proteasome	complex	in	1988,	providing	the	final	
piece	to	the	ubiquitin-proteosome	degradation	system	(Arrigo,	Tanaka	et	al.	1988).		
	
	
	
1.2.4.	Ubiquitin	as	a	signal	for	lysosomal	degradation	
	
For	 the	 next	 decade	 after	 the	 discovery	 of	 the	 proteasome,	 it	 was	 believed	 that	
ubiquitin	was	primarily	the	signal	 for	degradation	via	the	proteasome.	 In	1998,	the	
first	 example	 from	 a	 study	 showed	 that	 ubiquitin	 is	 also	 responsible	 for	 targeting	
Figure	1.2	Ubiquitin	 ligase	cascade.	An	E1	enzyme	will	bind	ubiquitin	 through	a	
thioester	bond,	requiring	ATP	hydrolysis	in	order	to	do	so.	The	E1	enzyme	will	then	
pass	the	ubiquitin	on	to	an	E2	enzyme.	The	E2	enzyme	will	then	interact	with	an	E3	
ligase	in	order	to	the	attach	the	ubiquitin	to	the	side	chain	of	lysine	on	the	substrate	
protein.	Depending	on	the	type	of	E3	ligase,	this	 is	done	either	by	attaching	the	
ubiquitin	directly	to	the	substrate	from	the	E2,	or	by	passing	the	ubiquitin	onto	the	
E3	and	then	again	to	the	substrate.	Opposing	the	action	of	 the	E3	 ligases,	are	a	
family	of	enzymes	called	deubiquitinating	enzymes	(DUBs).	
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transmembrane	 proteins	 to	 be	 degraded	 via	 the	 lysosome.	 The	 yeast	 G-protein	
coupled	receptor	(GPCR),	Ste2,	activates	the	mitogen-activated	protein	(MAP)	kinase	
pathway	in	response	to	stimulation	with	a	peptide	hormone,	α-factor	(Terrell,	Shih	et	
al.	 1998).	 This	 receptor	 is	 sorted	 into	 the	 lumen	 of	 MVBs	 en-route	 to	 vacuole	
degradation;	however,	mutation	of	the	lysine	residues	within	its	cytoplasmic	domain	
prevents	 the	down	regulation	of	 this	 receptor.	Further	evidence	 that	ubiquitin	can	
target	proteins	for	lysosomal	degradation	came	when	ubiquitin	was	fused	to	a	stable	
plasma	 membrane	 ATPase,	 resulting	 in	 its	 internalisation	 and	 degradation	 (Shih,	
Sloper-Mould	et	al.	2000).		
	
The	role	ubiquitin	plays	in	targeting	proteins	to	lysosomal	degradation	is	a	little	less	
straightforward	 (Katzmann,	 Odorizzi	 et	 al.	 2002).	 The	 ubiquitin-ATPase	 chimera	
mentioned	above	suggests	that	ubiquitin	acts	as	a	signal	for	internalisation.	This	idea	
is	 supported	 by	 a	 reduced	 uptake	 of	 the	 Ste2	 lysine	 mutant.	 For	 other	 proteins	
however,	 internalisation	 is	not	affected	by	defects	 in	 their	ubiquitylation.	 Ste6	and	
Fur4,	 for	 example,	 accumulate	 in	 pre-vacuolar	 compartments	 instead	 of	 being	
degraded	 by	 the	 vacuole	 (Dupre	 and	 Haguenauer-Tsapis	 2001,	 Losko,	 Kopp	 et	 al.	
2001).	These	examples	clearly	show	a	role	for	ubiquitin	as	being	important	for	sorting	
after	internalisation.		
	
In	mammalian	cells,	the	chemokine	receptor,	CXCR4,	is	still	internalised	but	no	longer	
degraded	 when	 its	 lysine	 residues	 are	 mutated	 and	 it	 cannot	 be	 ubiquitylated	
anymore	(Marchese	and	Benovic	2001).	The	EGFR	is	ubiquitylated	by	the	E3	ligase,	
Cbl	(Joazeiro,	Wing	et	al.	1999,	Yokouchi,	Kondo	et	al.	1999).	Mutations	to	Cbl	don’t	
prevent	the	internalisation	of	the	receptor	but	do	prevent	it	from	being	degraded	by	
the	lysosome	(Levkowitz,	Waterman	et	al.	1999,	Waterman,	Levkowitz	et	al.	1999).	
Conversely,	 overexpression	 of	 wild	 type	 Cbl	 leads	 to	 increased	 EGFR	 degradation	
(Thien,	Walker	et	al.	2001).	The	viral	oncogene,	v-Cbl,	displays	a	dominant	negative	
effect	over	wild	type	Cbl	by	competing	for	EGFR	binding,	but	is	unable	to	add	ubiquitin,	
preventing	the	receptor	from	being	sorted	towards	the	lysosome	for	degradation.	This	
leads	to	sustained	EGFR	activation	and	tumour	formation	(Blake,	Shapiro	et	al.	1991).		
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1.2.5.	Ubiquitin-binding	domains	
	
Much	like	the	phosphorylation	of	tyrosine,	serine	and	threonine	residues	provides	a	
new	binding	site	on	proteins,	the	addition	of	ubiquitin	to	substrates	also	provides	a	
new	 site	 that	 other	 proteins	 can	 interact	with.	 In	 order	 to	 interact	with	 ubiquitin,	
proteins	 need	 a	 ubiquitin-binding	 domain	 (UBD).	 There	 are	 many	 different	 UBDs,	
which	have	different	affinities	for	either	mono-	or	poly-ubiquitin	chains,	and	even	for	
different	chain	links,	providing	context	specific	ubiquitin	binding	(Hicke,	Schubert	et	
al.	2005,	Dikic,	Wakatsuki	et	al.	2009).	The	first	UBD	to	be	identified	was	the	ubiquitin	
interacting	motif	(UIM)	of	the	proteasome	subunit,	S5A	(Young,	Deveraux	et	al.	1998).	
The	 sequence	 of	 this	 motif	 was	 subsequently	 used	 in	 a	 bioinformatics	 search	 to	
identify	 other	 ubiquitin	 binding	 proteins	 (Hofmann	 and	 Falquet	 2001).	 Yeast	 two	
hybrid	 (Y2H)	experiments	using	ubiquitin	as	bait,	 along	with	 further	bioinformatics	
analysis	of	ubiquitylating	and	deubiquitylating	enzyme	sequences,	would	lead	to	the	
identification	of	even	more	UBDs	(Hofmann	and	Bucher	1996,	Shih,	Prag	et	al.	2003).	
A	summary	of	UBDs	is	shown	in	table	1.1.	
	
UBDs	 can	 be	 found	 on	 many	 endosomal	 proteins.	 Since	 ubiquitin	 is	 a	 signal	 for	
lysosomal	degradation,	components	of	the	endosomal	sorting	machinery	require	the	
ability	 to	 recognise	 and	 interact	 with	 ubiquitylated	 cargo	 (Katzmann,	 Babst	 et	 al.	
2001).	This	allows	for	the	efficient	sorting	of	proteins	destined	for	degradation.		
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1.2.6.	The	ESCRT	machinery	
	
At	its	core,	the	ESCRT	(endosomal	sorting	complex	required	for	transport)	machinery	
is	comprised	of	four	complexes	(ESCRT	0-III,	table	1.2)	that	recognise	cargo	and	create	
membrane	curvature	(Henne,	Buchkovich	et	al.	2011).	They	are	vital	for	the	formation	
of	 MVBs,	 appropriate	 trafficking	 of	 membrane	 proteins	 to	 the	 lysosome	 and	
attenuation	of	receptor	signalling	like	growth	factor	signalling	pathways	(Figure	1.3).	
Due	 to	 this,	dysfunction	of	 the	ESCRT	complexes	can	 lead	various	diseases	 such	as	
cancer	and	dementia	(Li	and	Cohen	1996,	Saksena	and	Emr	2009).	
	
Ubiquitin	
binding	domain	
Class	 Example	protein	 Refs	
CUE	 α-Helix	 Vps9	 	(Prag,	Misra	et	al.	2003)	
dUIM	 α-Helix	 HRS	 	(Hirano,	Kawasaki	et	al.	2006)	
GAT	 α-Helix	 GGA3,	TOM1	 	(Akutsu,	Kawasaki	et	al.	2005)	
GLUE	 PH	domain	 EAP45	 	(Slagsvold,	Aasland	et	al.	2005)	
IUIM	 α-Helix	 RABEX5	 	(Lee,	Tsai	et	al.	2006)	
Jab1/MPN	 Other	 Prp8	 	(Bellare,	Small	et	al.	2008)	
NZF	 Zinc	Finger	(ZnF)	 Vps36	 	(Alam,	Sun	et	al.	2004)	
PAZ	 Zinc	Finger	(ZnF)	 USP5	 	(Reyes-Turcu,	Horton	et	al.	2006)	
PFU	 Other	 Doa1	 	(Fu,	Zhou	et	al.	2009)	
PRU	 PH	domain	 RPN13	 	(Schreiner,	Chen	et	al.	2008)	
SH3	 Other	 Sla1	 	(Stamenova,	French	et	al.	2007)	
UBA	 α-Helix	 NBR1	 	(Kirkin,	Lamark	et	al.	2009)	
UBAN	 α-Helix	 NEMO	 	(Rahighi,	Ikeda	et	al.	2009)	
UBC	 Ubc-like	domain	 UBCH5	 	(Brzovic,	Lissounov	et	al.	2006)	
UBM	 α-Helix	 Polymerase	iota	 	(Bienko,	Green	et	al.	2005)	
UBZ	 Zinc	Finger	(ZnF)	 Polymerase-h	 	(Bienko,	Green	et	al.	2005)	
UEV	 Ubc-like	domain	 TSG101	 	(Sundquist,	Schubert	et	al.	2004)	
UIM	 α-Helix	 S5a/Rpn10,	STAM	 	(Terrell,	Shih	et	al.	1998)	
VHS	 α-Helix	 STAM,	HRS	 	(Mizuno,	Kawahata	et	al.	2003)	
ZnF	A20	 Zinc	Finger	(ZnF)	 RABEX5	 	(Penengo,	Mapelli	et	al.	2006)	
Table	1.1	List	of	the	different	ubiquitin-binding	domains	that	have	been	identified.	
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The	components	of	 the	ESCRT	machinery	were	 initially	 identified	 in	Saccharomyces	
cerevisiae	yeast	in	a	large	genetic	screen	that	looked	for	mis-trafficking	of	the	vacuolar	
glycol	protein	CPY,	and	later	for	morphological	defects	in	the	yeast	vacuole	(Rothman	
and	Stevens	1986,	Banta,	Robinson	et	al.	1988,	Robinson,	Klionsky	et	al.	1988).	Genes	
identified	 in	the	screens	are	now	known	as	Vacuolar	protein	sorting	(Vps)	mutants.	
These	 Vps	 mutants	 can	 be	 further	 characterised	 in	 to	 classes	 depending	 on	 the	
morphological	defect.	All	components	of	the	ESCRT	machinery	are	classified	as	‘Class	
E’	 Vps	 mutants,	 which	 are	 defined	 by	 enlarged	 endosomes	 (Raymond,	 Howald-
Stevenson	et	al.	1992).	Membrane	proteins	were	shown	to	traffic	to	the	vacuole	via	
MVBs	 through	 studies	 with	 carboxypeptidase	 S	 (CPS)	 (Odorizzi,	 Babst	 et	 al.	 1998,	
Reggiori	and	Pelham	2001).	Further	studies	with	a	chimera	protein	of	CPS	and	His3	
would	 establish	 that	 the	 enlarged	 endosomes	 seen	 in	 class	 E	 mutants	 is	 due	 to	
defective	 sorting	 into	 the	 endosomal	 lumen	 (Odorizzi,	 Katzmann	 et	 al.	 2003,	
Katzmann,	Sarkar	et	al.	2004).		
	
Figure	 1.3	 Overview	 of	 the	 ESCRT	 machinery.	 Ubiquitylated	 receptors	 at	 the	
endosome	are	recognised	by	the	ESCRT-0	complex	comprised	of	HRS	and	STAM.	As	
this	 complex	 can	 bind	 to	multiple	 ubiquitin	molecules,	 it	 corrals	 receptors	 into	
clathrin	 coated	 microdomains	 before	 passing	 the	 receptor	 on	 to	 the	 ESCRT-I	
complex.	 This	 in	 turn	 passes	 the	 receptors	 on	 the	 ESCRT-II,	 which	 also	 recruits	
ESCRT-III.	 The	 ESCRT-III	 complex	 is	 responsible	 for	 the	 invagination	 of	 the	
endosomal	 membrane,	 by	 forming	 long	 chains	 of	 Snf7,	 which	 form	 coiled	
structures.	This	coiled	structure	also	acts	like	a	‘fence’,	preventing	the	receptors	
from	escaping.	Deubiquitinating	enzymes	(DUBs)	also	act	to	remove	the	ubiquitin	
from	the	receptors	to	be	used	again.	
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Complex	 Yeast	protein	name	 Metazoan	protein	name	
ESCRT-0	
Vps27	 HRS	
Hse1	 STAM	
ESCRT-I	
Vps23	 TSG101	
Vps28	 VPS28	
Vps37	 VPS37	
Mvb12	 MVB12	
ESCRT-II	
Vps22	 EAP30	
Vps36	 EAP45	
Vps25	 EAP20	
ESCRT-III	
Vps2	 CHMP2	
Vps20	 CHMP6	
Vps24	 CHMP3	
Snf7	 CHMP4	
Vps60	 CHMP5	
Did2	 CHMP7	
	
As	well	as	being	involved	in	MVB	formation,	ESCRT	proteins	has	also	been	associated	
with	 various	 other	 cellular	 processes.	 These	 include:	 cell	 abscission,	 viral	 budding,	
exosome	secretion	and	nuclear	envelope	reformation	(Garrus,	von	Schwedler	et	al.	
2001,	Carlton	and	Martin-Serrano	2007,	Nabhan,	Hu	et	al.	2012,	Olmos,	Hodgson	et	
al.	2015).	Much	of	the	more	recent	research	looking	at	ESCRT	function	is	examining	
the	alternate	functions	of	these	complexes	(Campsteijn,	Vietri	et	al.	2016).	
	
1.2.7.	ESCRT-I	
	
ESCRT-I	was	the	first	complex	to	be	described	in	the	early	2000’s	(Katzmann,	Babst	et	
al.	2001).	The	complex	consists	of	TSG101,	Vps28,	Vps37	and	hMvb12	being	identified	
as	a	 subunit	 a	 few	years	 later	 (Bishop	and	Woodman	2001,	Bache,	 Slagsvold	et	al.	
2004,	 Chu,	 Sun	 et	 al.	 2006).	 ESCRT-I	 interacts	 with	 membranes	 only	 by	 weak	
Table	1.2	Yeast	and	mammalian	homologues	of	the	ESCRT	machinery	
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electrostatic	interactions	(Kostelansky,	Schluter	et	al.	2007)	but	requires	interactions	
with	ESCRT-0	for	recruitment	to	endosomal	membranes	(Bache,	Brech	et	al.	2003,	Lu,	
Hope	 et	 al.	 2003).	 From	 its	 crystal	 structure,	 we	 can	 see	 that	 this	 complex	 is	 an	
elongated	heterotetramer,	with	coiled-coil	body	and	a	globular	head	(Kostelansky,	Sun	
et	al.	2006).	ESCRT-I	interacts	with	both	ESCRT-0	and	ESCRT-II	at	opposite	ends	of	its	
structure	with	cargo	recognition	occurring	through	a	UEV	domain	on	TSG101	and	a	
UBD	on	Mvb12.	The	UEV	domain	of	TSG101	is	also	responsible	for	interacting	with	a	
P(S/T)AP-like	motif	on	HRS	of	ESCRT-0	(Katzmann,	Stefan	et	al.	2003),	an	interaction	
that	is	mimicked	by	HIV	Gag	proteins	(Pornillos,	Higginson	et	al.	2003).	
	
1.2.8.	ESCRT-II	
	
ESCRT-II,	along	with	ESCRT-III,	was	described	a	few	years	after	ESCRT-I.	 It	forms	a	Y	
shaped	 heterotetramer	 comprised	 of	 EAP30,	 EAP45	 and	 two	 EAP20’s	 (Babst,	
Katzmann	et	al.	2002,	Langelier,	von	Schwedler	et	al.	2006).	EAP30	and	EAP45	form	
the	base	while	the	two	EAP20’s	form	the	arms	of	the	Y	structure	(Hierro,	Sun	et	al.	
2004,	Teo,	Perisic	et	al.	2004).	ESCRT-II	binds	to	Vps28	of	ESCRT-I	via	a	GLUE	domain	
on	EAP45	(Gill,	Teo	et	al.	2007).	In	yeast	VPS36	(EAP45),	the	GLUE	domain	contains	
two	NZF	domains,	which	are	responsible	for	its	interaction	with	ESCRT-I	(Teo,	Gill	et	
al.	2006).	The	GLUE	domain	of	mammalian	EAP45,	however,	doesn’t	contain	 these	
NZF	 domains,	 but	 is	 still	 able	 to	 interact	 with	 ESCRT-I.	 The	 GLUE	 domain	 is	 also	
responsible	for	binding	to	PtdIns(3)P	with	high	affinity	(Slagsvold,	Aasland	et	al.	2005).	
The	two	EAP20	arms	are	responsible	for	binding	to	Vps20	(CHMP6)	of	the	next	ESCRT	
complex,	ESCRT-III.	
	
1.2.9.	ESCRT-III	
	
ESCRT-III	is	the	final	ESCRT	complex	recruited	to	the	endosomal	membrane	and	is	the	
complex	responsible	for	causing	membrane	curvature	and	the	eventual	formation	of	
the	ILV	(Henne,	Buchkovich	et	al.	2011).	 It	consists	of	CHMP2,	CHMP3,	CHMP4	and	
CHMP6	in	mammalian	cells	but	due	to	the	fact	that	this	complex	 is	unstable	 in	the	
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cytosol	it	is	difficult	to	crystallise	(Babst,	Katzmann	et	al.	2002).	Further	to	this,	ESCRT-
III	monomers	do	not	localise	to	the	endosome	by	themselves	(Zamborlini,	Usami	et	al.	
2006,	Shim,	Kimpler	et	al.	2007).	Recruitment	of	ECRT-III	occurs	when	EAP20	subunit	
from	ESCRT-II	binds	to	CHMP6	(Teo,	Perisic	et	al.	2004).	CHMP6	then	recruits	CHMP4,	
which	forms	long	polymer	chains	(Teis,	Saksena	et	al.	2008,	Saksena,	Wahlman	et	al.	
2009).	These	chains	are	then	capped	by	CHMP3	and	the	final	subunit,	CHMP2,	is	also	
recruited.	CHMP4	chains	can	also	recruit	various	accessory	proteins	as	well	as	DUBs	
to	remove	the	ubiquitin	chains	from	the	cargo	targeted	for	degradation,	in	order	to	
preserve	the	ubiquitin	pool	within	the	cell	 (Luhtala	and	Odorizzi	2004,	Schmidt	and	
Teis	2012).		
	
1.2.10.	ESCRT-0	
	
The	 last	complex	to	be	described	as	an	ESCRT	complex	was	ESCRT-0.	This	complex,	
consisting	 of	 Hepatocyte	 growth	 factor	 receptor	 substrate	 (HRS)	 and	 Signal	
transducing	 adaptor	 molecule	 (STAM),	 had	 already	 been	 identified	 prior	 to	 being	
described	as	an	ESCRT	complex	and	was	already	known	as	a	class	E	Vps	mutant	(Asao,	
Sasaki	et	al.	1997,	Bache,	Raiborg	et	al.	2003).	They	became	associated	with	the	rest	
of	the	ESCRT	machinery	through	studies	looking	into	viral	budding	of	HIV	(Clague	and	
Urbe	2003).	HIV	hijacks	 the	ESCRT	machinery	 in	order	 to	bud	out	of	 T	 cells	 at	 the	
plasma	membrane	(Pornillos,	Garrus	et	al.	2002).	Viral	Gag	proteins	bind	to	TSG101	of	
the	ESCRT-I	complex,	leading	to	the	recruitment	of	the	rest	of	the	machinery	(Garrus,	
von	Schwedler	et	al.	2001).	Studies	showed	that	this	was	through	a	P(S/T)AP	motif	on	
the	viral	proteins	(Pornillos,	Alam	et	al.	2002).	Analysis	of	the	human	genome	would	
reveal	the	same	motif	on	HRS	(Pornillos,	Higginson	et	al.	2003).	The	ESCRT-0	complex	
is	 the	 first	 point	 of	 contact	 a	 ubiquitylated	 receptor	 will	 have	 with	 the	 ESCRT	
machinery	and	is	essential	for	the	initiation	of	the	ESCRT	pathway	at	endosomes	and	
the	 formation	 of	MVBs.	 ESCRT-0	 is	 also	 required	 for	MVB	 formation	 in	Drosophila	
melanogaster,	mice	and	yeast,	 indicating	that	 its	role	 is	conserved	among	different	
species	(Raymond,	Howald-Stevenson	et	al.	1992,	Komada	and	Soriano	1999,	Lloyd,	
Atkinson	 et	 al.	 2002).	 The	 primary	 role	 of	 this	 complex	 is	 thought	 to	 be	 to	 corral	
ubiquitylated	receptors	in	order	for	them	to	subsequently	be	internalised	into	an	ILV	
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(Urbé,	Sachse	et	al.	2003).	This	is	achieved	by	the	multiple	domains	capable	of	binding	
to	ubiquitin	on	both	STAM	and	HRS	(Raiborg	and	Stenmark	2002).	
	
1.2.11.	HRS	
	
HRS	is	an	86kDa	protein	initially	identified	as	a	substrate	for	hepatocyte	growth	factor	
(HGF)	 receptor	 (Komada	 and	 Kitamura	 1995).	 HRS	 is	 recruited	 to	 endosomal	
membranes	via	its	FYVE	domain,	which	interacts	with	PtdIns(3)P	(Gaullier,	Simonsen	
et	al.	1998,	Raiborg,	Bremnes	et	al.	2001).	HRS	also	contains	a	double	sided	ubiquitin	
interacting	motif	 (UIM),	as	well	 as	a	VHS	domain	 that	 is	also	capable	of	binding	 to	
ubiquitin,	 Golgi-localised,	 γ-adaptin	 ear	 homology	 domain	 (GGA)	 proteins	 interact	
with	 ubiquitin	 via	 VHS	 domains	 (Bilodeau,	 Urbanowski	 et	 al.	 2002).	 Though	 these	
domains	only	weakly	bind	 to	ubiquitin,	 they	 allow	HRS	 to	 gather	 the	ubiquitylated	
receptors	 in	 clathrin	 coated	 regions	 on	 endosomes	 (Raiborg,	 Bache	 et	 al.	 2002).	
Clathrin	is	recruited	to	endosomes	via	the	C-terminal	of	HRS	(Raiborg,	Gronvold	Bache	
et	al.	2001).	Interestingly,	though	HRS	is	required	for	proper	sorting	and	trafficking	to	
the	lysosome,	over-expression	of	HRS	leads	to	a	dominant	negative	effect,	disrupting	
correct	sorting	for	receptors	(Chin,	Raynor	et	al.	2001,	Urbé,	Sachse	et	al.	2003).	
	
As	mentioned	above,	HRS	was	first	identified	as	a	substrate	for	the	HGF	receptor,	c-
Met.	When	stimulating	cells	with	HGF	and	blotting	for	phospho-tyrosine,	apart	from	
the	receptor	itself,	HRS	is	the	most	intense	band	identified.	The	same	can	be	seen	with	
other	growth	factors	and	cytokines	(Komada	and	Kitamura	1995).	When	stimulating	
with	EGF,	ESCRT-0	subunits	are	highly	phosphorylated	(Bache,	Raiborg	et	al.	2002),	
and	this	is	blocked	with	the	inhibition	of	endocytosis	(Urbé,	Mills	et	al.	2000).	If	HRS	is	
so	highly	phosphorylated	by	these	growth	factors,	the	question	arises	as	to	what	the	
purpose	of	this	phosphorylation	is.	It	has	been	suggested	that	phosphorylation	alters	
the	 membrane	 binding	 dynamics	 of	 HRS.	 When	 stimulated	 with	 a	 growth	 factor,	
phosphorylated	HRS	 is	 predominantly	 present	 in	 the	 cytosol,	 despite	 the	 fact	 that	
endocytosis	 of	 growth	 factor	 receptors	 to	 the	 endosome	 is	 required	 for	 this	
phosphorylation	 in	 the	 first	 place	 (Urbé,	 Mills	 et	 al.	 2000).	 It	 could	 be	 that	
phosphorylation	 of	 HRS	 leads	 to	 it	 dropping	 off	 the	 endosome	 and	 allowing	 the	
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ubiquitylated	cargo	to	be	passed	off	to	the	other	ESCRT	complexes.	This	also	fits	with	
the	observation	that	HRS	over-expression	inhibits	protein	trafficking.		
	
	
	
Despite	this,	however,	when	examining	the	various	phosphorylation	sites	available	on	
HRS,	we	can	see	that	many	of	these	phosphorylation	sites	exist	outside	the	functional	
domains	 of	HRS	 (Figure	 1.5),	 and	 that	many	 of	 these	 sites	 have	 been	more	 highly	
observed	than	those	sites	 found	within	the	functional	domains	 (Urbé,	Sachse	et	al.	
2003).	 Furthermore,	 different	 growth	 factors	 induce	 different	 phosphorylation	
profiles	on	HRS	and	STAM	(Row,	Clague	et	al.	2005).	
	
	
	
Figure	 1.4	 Schematic	 diagram	 of	 HRS	 at	 endosomes.	 HRS	 is	 recruited	 to	 early	
endosomes	 through	 the	 interaction	 between	 its	 FYVE	 domain	 and	 PtdIns(3)P,	
where	 it	 forms	 the	 ESCRT-0	 complex	 with	 STAM.	 HRS	 can	 interact	 with	
ubiquitylated	 receptor	 via	 its	 multiple	 ubiquitin	 binding	 domains	 (UBDs).	 HRS	
recruits	Clathrin	to	endosomes,	forming	discreet	clathrin	microdomains.	
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1.2.12.	HRS	and	disease	
	
HRS	is	a	critical	component	of	the	machinery	involved	in	the	trafficking	and	sorting	of	
many	 receptors	 and	 cell	 surface	 proteins.	 It	 is	 therefore	 understandable	 that	
disruption	to	which	will	lead	to	serious	consequences	for	the	cell	and	its	intercellular	
function.		
	
Since	it	is	known	that	the	function	of	HRS	as	part	of	the	ESCRT	machinery	is	to	aid	in	
sorting	 ubiquitylated	 receptors	 into	 newly	 forming	 ILVs,	 thus	 targeting	 cargo	 for	
lysosomal	 degradation,	 it	 comes	 as	 no	 surprise	 that	 HRS	 has	 been	 shown	 to	 be	
involved	 in	 the	 down	 regulation	 of	 EGFR	 signalling	 (Lloyd,	 Atkinson	 et	 al.	 2002).	
Overexpression	of	HRS	paradoxically	displays	a	dominant	negative	effect	over	EGFR	
trafficking	and	accumulation	in	the	early	endosome	(Chin,	Raynor	et	al.	2001).	A	study	
from	Scoles	et	al.	however	showed	that	ectopic	expression	of	HRS	in	rat	schwannoma	
cells	led	to	a	reduction	of	EGFR	abundance,	contrary	to	preceding	studies	on	the	issue	
(Scoles,	Qin	et	al.	2005).	The	authors	suggest	a	cell	type-specific	effect	of	HRS	on	EGFR	
trafficking.	This	idea	is	strengthened	by	a	study	published	a	couple	of	years	later,	which	
suggests	that	knockdown	of	HRS	led	to	an	inhibition	of	proliferation	and	malignancy	
(Toyoshima,	Tanaka	et	al.	2007).	This	was	due	to	improper	degradation	of	E-cadherin,	
resulting	 in	 sequestering	 of	 beta-catenin	 in	 the	 cytoplasm	 and	 preventing	 it	 from	
entering	the	nucleus	to	exhibit	its	mitogenic	effects.	A	study	into	the	kinome	of	liver	
cancers	with	beta-catenin	mutations	showed	that	these	cells	also	relied	on	HRS	(Canal,	
Anthony	et	al.	2015).	Silencing	of	HRS	resulted	in	 inhibition	to	cell	growth.	HRS	has	
also	shown	to	be	 involved	 in	the	entry	of	Kaposi’s	Sarcoma-associated	herpes	virus	
into	the	cell	by	macropinocytosis	(Veettil,	Kumar	et	al.	2016).		
	
Classification	of	HRS	as	a	component	of	 the	ESCRT	machinery	came	about	 through	
studies	 examining	 the	 outward	 budding	 of	 HIV.	 Subsequent	 studies	 have	
demonstrated	 the	 involvement	 of	 HRS	 in	 the	 normal	 functioning	 of	 the	 immune	
system.	In	2011,	HRS	was	shown	to	actually	inhibit	HIV-1	virion	production	(Ding,	Su	
et	al.	2011).	This	effect	is	mediated	through	its	interaction	with	citron	kinase	via	its	
FYVE	 domain.	 Depletion	 of	 HRS	 led	 to	 increased	 virion	 production.	 Sorting	 of	 the	
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interleukin	receptor	(IL2)	has	also	been	shown	to	be	mediated	by	HRS,	in	a	manner	
that	 is	 independent	of	 its	ubiquitin	binding	(Yamashita,	Kojima	et	al.	2008).	A	study	
from	 Nagata	 et	 al.	 in	 2014	 provided	 evidence	 for	 the	 importance	 of	 HRS	 in	 the	
development	of	peripheral	B	lymphocytes	and	in	the	T-cell	dependent	production	of	
antibodies	 (Nagata,	 Murata	 et	 al.	 2014).	 In	 patients	 infected	 with	 Enterovirus	 71	
(EV71),	it	was	found	that	HRS	had	been	upregulated	and	is	an	important	regulatory	of	
Toll-like	 receptor	 7	 (TLR7).	 HRS	 recruits	 TLR7	 to	 endosomes	 in	 order	 to	 facilitate	
activation	of	NF-κB	signalling	pathways	(Luo,	Ge	et	al.	2017).		
	
A	growing	body	of	evidence	is	emerging	implicating	HRS	in	neurodegenerative	disease	
and	the	regular	functioning	of	neurons.	Neurons	rely	heavily	on	the	endocytic	system	
and	 disruption	 to	 degradative	 processes	 can	 lead	 to	 the	 accumulation	 of	 protein	
aggregates,	ultimately	leading	to	the	loss	of	neurons	and	neurodegenerative	disease.	
Conditional	knockdown	of	HRS	in	the	central	nervous	system	of	hrs(flox/flox);Synl-Cre	
mice	led	to	the	accumulation	of	ubiquitylated	proteins	and	loss	of	hippocampal	CA3	
pyramidal	 neurons	 (Tamai,	 Toyoshima	 et	 al.	 2008).	 HRS	 was	 further	 shown	 to	 be	
important	 for	the	normal	recycling	of	 full	 length	TrkB	receptor,	another	 interaction	
not	dependent	on	the	UIM	of	HRS	(Huang,	Zhao	et	al.	2009).	In	2016,	loss	of	HRS	was	
shown	 to	 lead	 to	 the	 disruption	 of	 the	 autophagic	 degradation	 of	 disease-related	
proteins,	such	as	Huntingtin.	This	leads	to	ER-stress	and	both	apoptosis	and	necrotopic	
cell	death	in	hippocampal	neuronal	cells	(Oshima,	Hasegawa	et	al.	2016).		Watson	et	
al.	 showed	 that	 neuronal	 deficits	 in	 teetering	 mice	 were	 a	 result	 of	 spontaneous	
mutation	 to	HRS.	 They	 show	 that	HRS	plays	 a	 role	 in	 the	maintenance	of	 synaptic	
transmission	and	that	the	expression	of	HRS	in	the	nervous	systems	is	developmentally	
regulated	(Watson,	Bhattacharyya	et	al.	2015).	Further	examples	demonstrating	the	
importance	 of	 HRS	 in	 development	 highlight	 the	 role	 it	 plays	 in	 developmental	
signalling	 pathways.	 Miura	 et	 al.	 show	 HRS	 is	 important	 for	 Bone	 morphogenetic	
proteins	(BMP)	signal	transduction,	by	localising	TAK1	to	early	endosomes,	leading	to	
its	activation	and	phosphorylation	(Miura	and	Mishina	2011).	Additionally,	as	well	as	
BMP	signalling,	HRS	was	also	implicated	in	Hedgehog	(Hh)	signalling	via	interactions	
with	cell	surface	protein	Smoothened	(Smo).	Loss	of	HRS	led	to	accumulation	of	Smo	
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in	endosomes	and	enhancement	of	the	wing	defect	caused	by	the	dominant-negative	
Smo	mutation	(Fan,	Jiang	et	al.	2013).	
	
A	 study	 from	 Hasseine	 et	 al.	 in	 2007	 suggests	 that	 HRS	 plays	 a	 protective	 role	 in	
diabetic	retinopathies,	by	preventing	the	degradation	of	the	VEGF	insulin	receptors	
(Hasseine,	Murdaca	et	al.	2007).	The	authors	come	to	this	conclusion	by	introducing	
ectopic	expression	of	HRS	in	HEK293	cells,	which	leads	to	increased	levels	of	the	two	
receptors.	However,	this	effect	is	more	like	due	to	the	dominant-negative	effects	of	
HRS	overexpression.	Another	study	from	2012	shows	that	HRS,	but	not	other	ESCRT	
proteins,	is	required	for	the	transport	of	cholesterol	from	endosomes	to	the	ER	(Du,	
Kazim	et	al.	2012).	HRS	depletions	has	also	been	shown	to	decrease	contractility	 in	
smooth	muscle	cells	(SMCs)	leading	to	oesophagus	dilation	(Chen,	Hou	et	al.	2015).	
This	study	also	showed	that	SMCs	exhibited	an	excessive	production	of	cytokines	and	
chemokines.	 More	 recently,	 HRS	 was	 identified	 in	 an	 epigenetic	 meta-analysis	 of	
studies	on	post-traumatic	stress	disorder	(PTSD).	Methylation	of	HRS	was	significantly	
associated	with	those	suffering	from	PTSD	(Uddin,	Ratanatharathorn	et	al.	2018).	
	
1.2.13.	STAM	
	
STAM	is	a	70kDa	protein	and	was	initially	identified	in	1996	as	a	downstream	effector	
of	JAK	tyrosine	kinases	(Takeshita,	Arita	et	al.	1996).	This	interaction	is	mediated	by	
the	immunoreceptor	tyrosine-based	activation	motif	(ITAM)	on	STAM,	which	serves	
as	a	docking	site	for	Src	homology	2	(SH2)	domain-containing	proteins.	STAM	is	thus,	
phosphorylated	 by	 JAK	 kinases	 in	 response	 to	 cytokine	 receptor	 stimulation	
(Takeshita,	Arita	et	al.	1997).	Due	to	its	role	in	cytokine	signalling,	STAM	was	expected	
to	be	an	essential	gene	in	lymphocyte	development,	however	this	was	not	the	case	
(Yamada,	Takeshita	et	al.	2001).		
	
STAM	 became	 associated	 with	 endocytic	 trafficking	 when	 a	 second	 STAM	 gene,	
STAM2/HRS-binding-partner	(Hbp),	was	identified	and	shown	to	interact	with	HRS	via	
coiled-coil	regions	in	both	proteins	(Asao,	Sasaki	et	al.	1997,	Takata,	Kato	et	al.	2000).	
The	role	of	STAM	in	endocytic	trafficking	was	corroborated	by	sub	cellular	localization	
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on	endosomes	(Lohi	and	Lehto	2001).	Further	to	this,	STAM	contains	a	VHS	domain	
and	a	UIM	domain,	which	allows	STAM	to	interact	with	ubiquitylated	receptors	(Bache,	
Raiborg	et	al.	2003).	STAM	also	contains	an	Src	homology	3	(SH3)	domain,	which	allows	
it	to	recruit	the	deubiquitylases	USP8	and	AMSH	to	endosomes	(Tanaka,	Kaneko	et	al.	
1999,	Kato,	Miyazawa	et	al.	2000).	They	also	interact	with	later	ESCRT	complexes	in	
order	 to	 deubiquitylate	 proteins,	 which	 have	 been	 targeted	 for	 degradation	
(McCullough,	Row	et	al.	2006).	This	serves	to	maintain	the	pool	of	ubiquitin	within	the	
cell.		
	
It	has	also	been	suggested	that	STAM	may	be	responsible	for	the	dissociation	of	the	
ESCRT-0	complex	from	endosomal	membranes.	Over-expression	of	STAM	leads	to	a	
diffuse	distribution	of	HRS	(Kojima,	Amano	et	al.	2014).	This	is	believed	to	aid	in	the	
function	of	ESCRT-0	by	allowing	 the	complex	 to	pass	ubiquitylated	cargo	on	 to	 the	
subsequent	ESCRT	complexes.	
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1.3.	Recycling	
	
Recycling	 of	 internalised	 cell	 surface	 proteins	 is	 important	 to	maintain	 the	 cellular	
pool.	When	the	sorting	endosome	was	first	described,	termed	CURL	(compartment	for	
uncoupling	 receptor	 from	 ligand),	 it	 was	 believed	 that	 recycling	 predominantly	
Figure	1.5	Schematic	of	the	functional	domains,	phosphorylation	sites	and	binding	
partners	of	HRS	and	STAM.	(A)	The	functional	domains	and	phosphorylation	sites	
of	HRS	and	STAM.	Both	HRS	and	STAM	are	highly	phosphorylated	in	response	to	
growth	 factor	 stimulation.	 Shown	 are	 commonly	 seen	 tyrosine	 phosphorylation	
sites.	Sites	indicated	in	red	have	been	seen	more	than	50	times	by	high	throughput	
mass	spectrometry,	whereas	sites	indicated	in	pink	have	been	seen	fewer	than	50	
times.	(Data	obtained	through	phosphosite).	Tyrosine	residues	329	and	334	have	
been	highlighted	due	to	the	fact	that	they	are	of	high	interest	in	this	thesis.	(B)	A	
network	of	the	known	interactors	of	HRS	according	to	the	STRING	database.	
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occurred	by	a	bulk	flow	mechanism.	This	was	driven	by	the	morphology	of	the	sorting	
endosome,	with	the	majority	of	the	compartments	membrane	existing	in	the	tubular	
regions,	 encouraging	 transmembrane	proteins	 to	be	 recycled.	As	with	degradation	
and	the	ESCRT	machinery,	there	is	a	collection	of	complexes	that	are	involved	in	the	
efficient	sorting	of	recycling	proteins	(Figure	1.6).	
	
1.3.1.	The	Retromer	
	
Initially	identified	in	yeast,	the	retromer	complex	is	a	highly	conserved	complex	and	
an	 integral	 component	 of	 the	 endosomal	 recycling	machinery	 (Seaman	2012).	 The	
complex	 is	 comprised	 of	 5	 proteins,	 Vps35p,	 Vps29p,	 Vps26p,	 Vps5p	 and	 Vps17p	
(Horazdovsky,	 Davies	 et	 al.	 1997,	 Seaman,	 Marcusson	 et	 al.	 1997).	 The	 retromer	
mediates	many	elements	of	transport	from	the	endosome	and	is	implicated	in	many	
important	biological	 processes,	 such	as	Wnt	 signalling,	 iron	 transport,	 cell	 polarity,	
direct	mediation	of	GPCR	signalling,	as	well	as	retrieval	to	the	Golgi	and	recycling	to	
the	plasma	membrane	of	various	receptors	and	membrane	associated	proteins	e.g.	
the	cation	independent	mannose	6-phosphate	receptor	(CIMPR),	Sortilin	and	Amyloid	
precursor	protein	(APP)	(Arighi,	Hartnell	et	al.	2004,	Seaman	2004,	Nielsen,	Gustafsen	
et	al.	2007,	Eaton	2008,	Tabuchi,	Yanatori	et	al.	2010,	Fjorback,	Seaman	et	al.	2012).	
Defects	in	the	retromer	are	implicated	in	some	cases	of	Alzheimer	disease	(AD)	(Small,	
Kent	et	al.	2005).	
	
When	first	discovered	in	yeast,	the	retromer	was	described	as	a	pentamer.	However,	
opinion	over	the	years	has	shifted	to	view	the	complex	more	as	two	sub-complexes	
that	 transiently	 interact	 with	 each	 other.	 Particularly	 when	 you	 consider	 that	 the	
traditional	 pentamer	 is	 not	 as	 stable	 in	 mammalian	 cells	 as	 was	 seen	 in	 yeast	
(Swarbrick,	 Shaw	et	 al.	 2011).	 The	 retromer	 can	 therefore	 be	 divided	 into	 a	 cargo	
selective	trimer	consisting	of	Vps35p,	Vps29p	and	Vps26p;	and	a	dimer	made	from	the	
dimerization	 of	 the	 Sorting	 nexin	 (Snx)	 family	 members,	 Vps5p	 and	 VPS17p	
(Horazdovsky,	 Davies	 et	 al.	 1997,	Nothwehr	 and	Hindes	 1997).	 These	 proteins	 are	
often	 described	 as	 Snx-BAR	 proteins	 to	 differentiate	 them	 from	 other	 Snx	 family	
members,	 due	 to	 the	 inclusion	 of	 a	 Bin	Amphiphysin-Rvs	 (BAR)	 domain	 in	 their	 C-
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terminus.	In	mammalian	cells,	Snx1	and	Snx2	are	orthologues	of	Vps5p	with	Snx5	and	
Snx6	being	orthologues	of	Vps17p	 (Wassmer,	Attar	et	al.	2007).	 From	here	on	out	
these	proteins	will	be	referred	to	by	their	mammalian	names	(table	1.3).		
	
Yeast	protein	name	 Metazoan	protein	name	
Vps35p	 VPS35	
Vps29p	 VPS29	
Vps26p	 VPS26	
Vps5p	
Snx1	
Snx2	
Vps17p	
Snx5	
Snx6	
	
Recruitment	 of	 the	 Snx-BAR	 dimers	 to	 membranes	 occurs	 through	 their	 Phox	
homology	(PX)	domains,	common	amongst	the	Snx	family	of	proteins	(Cozier,	Carlton	
et	 al.	 2002).	 The	 PX	 domains	 of	 the	 Snx-BAR	 proteins	 bind	 with	 high	 affinity	 to	
PtdIns(3)P	(Yu	and	Lemmon	2001)	present	on	early	endosomes	and	do	not	rely	on	the	
cargo	selective	complex	(CSC)	for	recruitment	(Arighi,	Hartnell	et	al.	2004).	The	CSC	
trimer	is	recruited	to	endosomes	however,	via	its	interaction	with	the	GTPase	Rab7a	
(Rojas,	van	Vlijmen	et	al.	2008,	Seaman,	Harbour	et	al.	2009).	This	interaction	was	first	
shown	 in	 amoeba	 (Nakada-Tsukui,	 Saito-Nakano	 et	 al.	 2005).	 Interestingly,	 the	
retromer	CSC	requires	both	Snx3	and	Rab7a	for	efficient	recruitment	to	endosomes,	
suggesting	that	 the	recruitment	of	 the	whole	complex	 is	 temporally	controlled	and	
occurs	 during	 the	 Rab5/7	 switch	 of	 the	maturing	 endosome	 (Harterink,	 Port	 et	 al.	
2011).	Further	regulation	of	the	retromer	CSC	is	also	evident	from	the	fact	that	Rab7a	
is	also	present	on	lysosomes	but	the	CSC	is	not.	Moreover,	proteins	implicated	in	the	
regulation	 of	 Rab7a	 activity	 will	 also	 be	 indirectly	 involved	 in	 the	 regulation	 of	
retromer	 CSC	 recruitment.	 TBC1D5,	 a	 Rab-GAP	 that	 can	 displace	 the	 CSC	 from	
endosomes	 if	overexpressed	(Seaman,	Harbour	et	al.	2009).	Whereas,	mutations	 in	
CLN5	 can	 lead	 to	 a	 reduction	 in	 Rab7a	 activity	 and	 the	 degradation	 of	 proteins	
Table	1.3	Yeast	and	mammalian	homologues	of	the	Retromer	complex	
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normally	transported	out	of	the	endosomal	compartments,	such	as	sortilin	and	CIMPR	
(Mamo,	Jules	et	al.	2012).		
	
More	recently,	evidence	has	emerged	that	suggests	a	redundancy	in	the	roles	of	the	
retromer	with	 other	 endosomal	 sorting	 components.	 Firstly,	 it	 isn’t	 clear	 how	 the	
retromer	CSC	recognises	cargo	or	how	the	retromer	can	distinguish	between	which	
proteins	are	to	be	trafficked	to	the	Golgi	and	which	are	to	be	trafficked	to	the	plasma	
membrane	(Seaman	2012).	Some	studies	in	yeast	suggest	that	Vps35	can	directly	bind	
to	cargo,	such	as	Vps10p	(Nothwehr,	Ha	et	al.	2000,	Arighi,	Hartnell	et	al.	2004),	while	
others	have	suggested	Vps26	may	be	responsible	due	to	the	fact	that	it	has	a	similar	
structure	to	that	of	β-arrestin	and	can	recognise	the	cytoplasmic	tail	of	SorL1/SorLA	
(Shi,	 Rojas	 et	 al.	 2006).	 Furthermore,	 CIMPR	 requires	 Vps26a	 for	 appropriate	
endosomal	 sorting,	 but	 does	 not	 require	 Vps26b	 (Bugarcic,	 Zhe	 et	 al.	 2011).	 In	
conjunction	 with	 this,	 although	 early	 studies	 indicated	 that	 cargo	 sorting	 by	 the	
retromer	required	both	the	CSC	timer	and	the	Snx-BAR	dimer,	instances	where	this	
rule	 does	 not	 apply	 have	 begun	 to	 be	 reported.	 For	 example,	 the	 P2Y1	 receptor	
requires	the	Snx-BAR	dimer	for	correct	sorting,	and	not	the	retromer	CSC	(Nisar,	Kelly	
et	al.	2010).	The	opposite	observation	was	shown	with	Wntless/MIG-14	trafficking	in	
C.	elegans,	where	Snx1	and	the	Snx-BAR	component	of	the	retromer	was	not	required	
for	Wntless/MIG-14	retrieval	(Harterink,	Port	et	al.	2011,	Zhang,	Wu	et	al.	2011).		
	
In	 2017,	 a	 second	 complex,	 which	 is	 functionally	 similar	 to	 the	 retromer,	 was	
discovered	 and	 named	 retriever	 (McNally,	 Faulkner	 et	 al.	 2017).	 This	 study	
investigated	the	retromer	independent	recycling	of	integrin	α5β1,	which	is	mediated	
by	the	cargo	adaptor	Snx17	(Steinberg,	Heesom	et	al.	2012).	Two	GFP-tagged	Snx17	
proteins	were	generated	with	GFP	tagged	to	either	the	N-terminus	or	the	C-terminus.	
When	GFP	is	tagged	to	the	C-terminus,	Snx17	is	unable	to	rescue	α5β1	recycling	after	
Snx17	knockdown.	These	two	fusion	proteins	were	used	as	bait	to	identify	candidates	
responsible	for	the	recycling	of	the	integrin.	This	identified	many	components	of	the	
CCC	complex,	along	with	C16orf62,	DSCR3	and	Vps29.	The	complex	produced	from	
C16orf62,	DSCR3	and	Vps29	form	a	structurally	similar	complex	to	that	of	the	retromer	
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(Gershlick	and	Lucas	2017),	which	was	shown	to	mediate	the	recycling	of	over	120	cell	
surface	proteins	(McNally,	Faulkner	et	al.	2017).		
	
1.3.2.	The	WASH	complex	
	
Endosomal	sorting	of	proteins	and	endosomal	maturation	both	require	localised	actin	
polymerisation	(Ohashi,	Tanabe	et	al.	2011)(Figure	1.6).	Generation	of	branch	actin	
filaments	 involves	 the	 Arp2/3	 complex,	 which	 acts	 as	 a	 nucleation	 point	 for	 actin	
polymerisation	(Machesky,	Atkinson	et	al.	1994,	Rotty,	Wu	et	al.	2013).	Activation	of	
this	complex,	however,	requires	the	activity	of	a	nucleation-promoting	factor	(NPF)	
(Higgs	and	Pollard	1999).	The	major	actin	NPF	at	endosomes	is	Wash1,	a	member	of	
the	Wiskott-Aldrich	syndrome	protein	(WASP)	family	of	actin	NPFs	(Derivery,	Sousa	et	
al.	2009).		
	
Wash1	is	a	component	of	the	WASH	complex,	which	was	identified	through	affinity	
isolation	of	Wash1	(Derivery,	Sousa	et	al.	2009).	This	complex	consists	of	5	proteins,	
the	interactions	between	which	were	resolved	using	biochemical	and	yeast	two	hybrid	
techniques	(Jia,	Gomez	et	al.	2010,	Harbour,	Breusegem	et	al.	2012).	These	proteins	
are:	Wash1,	Strumpellin,	Fam21,	CCDC53	and	KIAA1033/SWIP	(hereafter	referred	to	
as	KIAA1033).	Knockdown	of	any	of	these	components	leads	to	complex	instability	and	
degradation	of	the	other	subunits.	The	WASH	complex	is	ubiquitously	expressed	and	
evolutionarily	conserved	(Derivery	and	Gautreau	2010).	It	also	shares	functional	and	
structural	analogy	with	the	WAVE	complex,	which	mediates	actin	polymerisation	at	
the	leading	edge	of	migrating	cells	(Jia,	Gomez	et	al.	2010).		
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Recruitment	of	the	WASH	complex	to	endosomes	is	mediated	through	an	interaction	
with	the	retromer	CSC,	since	RNAi	silencing	of	the	CSC	leads	to	disassociation	of	the	
WASH	complex	 from	endosomal	membranes,	but	not	 to	other	endosomal	proteins	
such	as	Snx1	and	EEA1	(Harbour,	Breusegem	et	al.	2010).	This	interaction	occurs	via	
Figure	 1.6	 Overview	 of	 the	 complexes	 involved	 in	 recycling	 from	 sorting	
endosomes.	Recycling	of	receptors	occurs	at	tubular	regions	of	sorting	endosomes.	
(i)	The	WASH	complex	is	recruited	to	endosomes	in	part	by	its	interaction	with	the	
retromer	complex.	Wash	is	responsible	for	generating	actin	rich	microdomains	at	
endosomes.	 These	 domains	 help	 to	 sort	 actin-binding	 domain	 (ABD)	 containing	
proteins	 for	 recycling.	 (ii)	 The	 retromer	 CSC	 is	 comprised	 of	 VPS26,	 VPS35	 and	
VPS29.	This	complex	interacts	with	Snx-BAR	dimers	formed	from	the	dimerization	
of	Snx1	or	Snx2	with	Snx5	or	Snx6.	(iii)	The	retriever	complex	is	structurally	similar	
to	the	retromer	complex	and	mediates	the	recycling	of	cargo	dependent	on	Snx17.	
It	is	comprised	of	C16orf62,	DSCR3	and	VPS29.		
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the	unstructured	tail	of	Fam21.	Fam21	contains	a	globular	head,	which	is	responsible	
for	 its	 interactions	 with	 Wash1	 and	 KIAA1033,	 and	 an	 unstructured	 tail.	 The	
unstructured	tail	alone	is	enough	to	localise	Fam21	to	membranes.	The	tail	contains	
multiple	 Leu-Phe	and	acidic	 residue	 repeated	motifs	 (LFa	motifs)	 (Jia,	Gomez	et	al.	
2012).	Through	these	repeated	motifs	it	is	believed	that	Fam21	binds	to	Vps35,	with	
the	more	distal	repeats	being	more	important	for	this	interaction	than	the	proximal	
repeats.	 In	vivo,	Fam21	will	only	 interact	with	Vps35	 if	 it	 is	 in	complex	with	Vps29,	
therefore	 only	 interacting	with	 an	 intact	 and	 functional	 retromer	 complex	 (Helfer,	
Harbour	et	al.	2013).	Further	to	being	responsible	for	the	 localisation	of	the	WASH	
complex,	the	unstructured	tail	also	contains	a	short	motif	that	binds	to	actin	uncapping	
proteins	(Hernandez-Valladares,	Kim	et	al.	2010).		
	
The	link	between	the	retromer	and	the	WASH	complex	has	been	further	strengthened	
by	studies	 looking	 into	which	proteins	rely	on	the	respective	complexes	for	correct	
trafficking.	A	study	with	transgenic	mice,	which	generated	Wash1	knockout	cells	used	
cre-mediated	excision	of	the	gene	to	conditionally	knock	down	the	protein	in	certain	
cells,	termed	WASHout	(Piotrowski,	Gomez	et	al.	2013).	This	study	showed	defects	in	
the	 recycling	 of	 certain	 proteins	 back	 to	 the	 PM,	 e.g.	 the	 EGFR,	 Glut-1	 and	 CD28.	
Parallel	 studies	 have	 also	 highlighted	 the	 importance	 of	 the	 retromer	 in	 Glut-1	
transport	(Steinberg,	Gallon	et	al.	2013).	Another	example	would	be	that	of	CIMPR.	
Linking	WASH	to	endosome-to-Golgi	retrieval,	the	WASH	complex	has	been	shown	to	
be	involved	with	CIMPR	trafficking	to	the	Golgi,	a	process	that	also	relies	on	the	Snx	
component	of	the	retromer	(Arighi,	Hartnell	et	al.	2004,	Gomez	and	Billadeau	2009).	
Much	 like	 other	 members	 of	 the	WASP	 complex	 superfamily,	WASH	 is	 inherently	
inactive	by	itself.	The	activity	of	this	complex	is	regulated	by	the	E3	ubiquitin	 ligase	
TRIM27.	Moreover,	the	activity	of	this	enzyme	is	increased	by	another	protein	called	
MAGE-L2	 (Hao,	 Doyle	 et	 al.	 2013).	 This	 protein	 is	 recruited	 to	 endosomes	 via	
interactions	with	Vps35.		
	
The	WASH	complex	has	also	been	 linked	with	the	trafficking	and	recycling	of	other	
membrane	bound	proteins	and	receptors	back	to	the	PM.	Notable	examples	include:	
the	 transferrin	 receptor,	 α5β1	 integrin	 and,	 along	 with	 Snx-27,	 the	 β-adrenergic	
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receptor	(Derivery,	Sousa	et	al.	2009,	Temkin,	Lauffer	et	al.	2011,	Zech,	Calaminus	et	
al.	2011).		
	
It	has	been	proposed	that	the	WASH	complex	aids	the	sorting	of	endosomal	proteins	
through	the	generation	of	discrete	actin	micro-domains	(Puthenveedu,	Lauffer	et	al.	
2010).	Furthermore,	Wash1	domains	have	been	shown	to	coalesce	with	the	inhibition	
of	actin	polymerisation	(Derivery,	Helfer	et	al.	2012).	As	with	the	retromer	CSC,	it	is	
not	clear	how	specificity	for	certain	proteins	to	be	sorted	for	either	retrieval	to	the	
Golgi	or	 recycled	back	 to	 the	PM	 is	 regulated.	Current	opinion	believes	 that	 this	 is	
achieved	via	associated	proteins	to	the	complex,	such	as	Snx27	(Temkin,	Lauffer	et	al.	
2011).	 Further	 to	 this,	 the	WASH	 complex	 has	 also	 been	 associated	 with	 BLOC-1	
(biogenesis	 of	 lysosomal-related	 organelles	 complex	 1)	 and	 may	 be	 involved	 with	
lysosome	 related	 organelles	 such	 as	 melanosomes	 (Monfregola,	 Napolitano	 et	 al.	
2010,	Ryder,	Vistein	et	al.	2013).		
	
RNAi	knockdown	of	components	of	the	WASH	complex	leads	to	marked	increase	in	
tubulation	of	endosomes,	which	is	believed	to	be	due	to	a	defect	in	membrane	scission	
(Derivery,	Sousa	et	al.	2009,	Gomez	and	Billadeau	2009).	 It	 is	noteworthy	 that	 this	
increased	tubulation	phenotype	of	endosomes	was	not	observed	with	the	WASHout	
system	and	only	with	RNA	interference	(Seaman,	Gautreau	et	al.	2013).	Mutations	in	
components	of	the	WASH	complex	have	been	shown	to	lead	to	particular	neurological	
disorders.	 Mutations	 in	 strumpellin,	 for	 example,	 can	 lead	 to	 Hereditary	 spastic	
paraplegia	 (Valdmanis,	 Meijer	 et	 al.	 2007,	 de	 Bot,	 Vermeer	 et	 al.	 2013),	 while	
mutations	to	KIAA1033	can	lead	to	destabilisation	of	the	whole	complex	and	can	lead	
to	late	onset	AD	(Ropers,	Derivery	et	al.	2011,	Vardarajan,	Bruesegem	et	al.	2012).	
	
1.4.	Receptor	signalling	
	
Cells	express	receptors	on	their	cell	surface	as	a	method	for	sensing	the	extracellular	
environment.	 These	 receptors	 can	 then	 trigger	 a	 cascade	 of	 signalling	 events	 that	
allow	the	cell	to	respond	to	changes	in	their	environment.	
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1.4.1.	Growth	factors	
	
The	discovery	of	growth	factors	was	first	reported	in	the	1950’s	by	Levi-Montalcini	and	
Cohen,	the	two	would	later	receive	a	Nobel	prize	for	much	of	the	work	they	did	around	
this	 period.	 Levi-Montalcini	 showed	 that	 a	 mouse	 sarcoma	 had	 an	 impact	 on	 the	
growth	of	a	 chick	embryo’s	nervous	 system	 (Levi-Montalcini	 and	Hamburger	1951,	
Levi-Montalcini	1952,	Levi-Montalcini,	Meyer	et	al.	1954).	A	few	years	later,	the	factor	
responsible	for	this	observation	was	isolated	from	mouse	sarcomas	and	then	isolated	
again	 from	 snake	 venom	 (Cohen,	 Levi-Montalcini	 et	 al.	 1954,	 Cohen	 and	 Levi-
Montalcini	1956,	Levi-Montalcini	and	Cohen	1956).	This	molecule	was	the	first	growth	
factor	identified	and	is	now	known	as	Nerve	growth	factor	(NGF)	and	over	the	next	
few	years	was	followed	by	the	subsequent	identification	of	epidermal	growth	factor	
(EGF)	by	Cohen	 in	 the	1960’s.	Extracts	 from	mice	submaxillary	glands	could	 induce	
precocious	 eyelid	 opening	 and	 incisor	 eruption	 (Cohen	 1962).	 These	 observations	
were	reported	to	be	due	to	increased	keratinisation	and	epidermis	growth,	eventually	
leading	to	the	isolation	of	the	factor	responsible	for	epidermal	growth,	EGF	(Cohen	
and	Elliott	1963,	Cohen	1965).	It	was	almost	a	decade	later	before	human	EGF	was	
finally	identified	and	isolated	from	human	urine	by	Cohen	(Cohen	and	Carpenter	1975,	
Starkey,	Cohen	et	al.	1975).	 In	the	mid	1970’s,	EGF	was	shown	to	bind	to	cells	and	
membranes.	This	observation	was	taken	further,	when	125I-labelled	EGF	was	shown	to	
bind	 to	 fibroblasts	 before	 being	 degraded	 by	 the	 cells	 (Carpenter,	 Lembach	 et	 al.	
1975).	By	the	end	of	the	decade,	EGF	had	been	shown	to	induce	phosphorylation	of	
endogenous	 proteins	 in	 A-432	 tumour	 cells,	 providing	 insights	 into	 the	 molecular	
mechanisms	by	which	cells	would	translate	the	growth	factor	signal	into	a	biological	
response	 (Carpenter,	King	et	al.	1978).	The	 receptor	 for	EGF	 (EGFR,	also	known	as	
ErbB1)	 wasn’t	 fully	 sequenced	 until	 1984	 (Ullrich,	 Coussens	 et	 al.	 1984).	 Other	
members	of	the	EGF	receptor	family	(ErbB2-4)	would	be	identified	over	the	next	few	
years	 (Stern,	 Heffernan	 et	 al.	 1986,	 Plowman,	 Whitney	 et	 al.	 1990,	 Plowman,	
Culouscou	et	al.	1993).	
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1.4.2.	Receptor	tyrosine	kinases	(RTKs)	
	
The	principal	mechanism	of	action	and	main	components	of	RTK	signalling	are	highly	
conserved	 from	C.	 elegans	 to	 humans	 (Lemmon	 and	 Schlessinger	 2010).	With	 the	
exception	 of	 the	 insulin	 receptor	 and	 insulin-like	 growth	 factor-1	 (IGF-1)	 receptor,	
which	exist	as	a	disulphide	bound	inactive	dimer	(Ward,	Lawrence	et	al.	2007),	growth	
factors	 lead	to	the	activation	of	RTKs	by	 inducing	dimerization	of	the	receptor	with	
another	ligand	bound	receptor	(Ullrich	and	Schlessinger	1990).	The	RTKs	then	trans-
phosphorylate	each	other	with	the	resulting	phosphorylated	tyrosine	residue	acting	
as	an	assembly	site	for	downstream	signalling	molecules.	By	the	end	of	the	1990’s	and	
early	2000’s,	crystal	structures	of	RTK	fragments	began	to	emerge	for	many	receptors	
such	as:	the	VEGFR,	TrkA,	Eph	receptor,	Axl,	Tie2	and	the	stem	cell	factor	receptor	KIT	
(Wiesmann,	Fuh	et	al.	1997,	Wiesmann,	Ultsch	et	al.	1999,	Himanen	and	Nikolov	2003,	
Barton,	Tzvetkova-Robev	et	al.	2006,	Sasaki,	Knyazev	et	al.	2006,	Liu,	Chen	et	al.	2007).		
	
There	are	4	main	types	of	dimerization	that	essentially	all	RTKS	will	fall	into.	These	are	
dimerization	 mediated	 either:	 entirely	 by	 the	 ligand,	 entirely	 by	 the	 receptor,	 a	
mixture	of	both	the	receptor	and	the	ligand	or	with	the	aid	of	an	accessory	molecule,	
e.g.	heparin.	With	the	example	of	the	NGFR,	dimerization	is	mediated	entirely	by	the	
ligand,	with	no	direct	interaction	between	the	receptors	(Wehrman,	He	et	al.	2007).	
Whereas	 with	 the	 EGFR,	 ligand	 binding	 results	 in	 a	 conformational	 change	 in	 the	
extracellular	portion	of	the	receptor.	This	leads	to	the	region	that	is	responsible	for	
the	 dimerization	 being	 available	 to	 interact	with	 a	 neighbouring	 receptor	 (Garrett,	
McKern	et	al.	2002,	Ogiso,	Ishitani	et	al.	2002).	Stem	cell	factor	ligand	is	able	to	form	
a	dimer	with	itself.	This	allows	it	to	essentially	crosslink	2	KIT	receptors	that	contains	
2	Ig-like	domains	(D4	and	D5),	which	also	interact	and	strengthen	the	bond	between	
the	dimerising	receptors	(Yuzawa,	Opatowsky	et	al.	2007).	Finally,	with	the	fibroblast	
growth	factor	receptor	(FGFR)	ligand,	heparin	and	dimerised	receptor	all	bind	at	the	
same	 region	 (the	 D2	 domain)	 and	 cooperate	 to	 stabilise	 the	 dimer	 (Plotnikov,	
Schlessinger	et	al.	1999,	Stauber,	DiGabriele	et	al.	2000,	 Ibrahimi,	Yeh	et	al.	2005).	
Once	the	RTKs	have	dimerised,	trans-phosphorylation	and	activation	of	the	receptors	
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tyrosine	 kinase	 domain	 (TKD)	 can	 occur,	 leading	 to	 downstream	 signalling	 events	
(Honegger,	Kris	et	al.	1989).	
	
Auto-phosphorylation	of	RTKs	occurs	 in	distinct	phases.	The	first	of	 these	phases	 is	
responsible	for	relieving	the	auto-inhibition	placed	on	the	receptor	and	increasing	the	
kinase	 activity	 of	 the	 intrinsic	 TKD	 (Lemmon	 and	 Schlessinger	 2010).	 Despite	 the	
inactive	form	of	TKDs	varying	substantially	between	different	RTKs	,	the	active	form	of	
these	domains	 is	actually	very	similar	 (Huse	and	Kuriyan	2002).	This	 is	because	key	
regulatory	components	of	TKDs	need	to	adopt	a	specific	configuration	in	order	to	allow	
for	 efficient	 transfer	 of	 phosphate	 groups,	 and	 therefore,	 increased	 kinase	 activity	
(Nolen,	 Taylor	 et	 al.	 2004).	 Due	 to	 the	 differences	 in	 the	 inactive	 form,	 however,	
different	regulatory	mechanisms	are	exhibited	between	RTKs.	The	TKD	can	be	auto-
inhibited	by	its	own	activation	loop,	as	seen	with	the	insulin	receptor	and	the	FGFR	
(Hubbard	2004).	A	tyrosine	in	the	activation	loop	of	these	RTKS	sterically	blocks	the	
active	site	of	the	TKD.	This	tyrosine	is	trans-phosphorylated	when	the	receptors	bind	
their	ligands,	preventing	it	from	sitting	in	the	active	site,	providing	access	for	ATP	and	
substrates	(Chen,	Ma	et	al.	2007,	Bae,	Lew	et	al.	2009).		
	
TKDs	can	also	be	auto-inhibited	by	regions	outside	of	the	TKD	itself.	As	seen	with	the	
Musk	 receptor,	 Flt3	 receptor,	 KIT	 receptor	 and	 the	 Eph	 family	 of	 receptors,	 the	
juxtamembrane	region	of	the	receptor	can	make	extensive	contacts	with	the	TKD,	e.g.	
in	the	activation	 loop,	and	therefore	helps	to	stabilise	the	 inactive	form	of	the	TKD	
(Till,	Becerra	et	al.	2002,	Griffith,	Black	et	al.	2004,	Mol,	Dougan	et	al.	2004).	Further	
phosphorylation	of	 the	 TKD	 can	 lead	 to	 greater	 increases	 in	 its	 kinase	 activity.	 For	
example,	 Phosphorylation	 of	 Y553	 in	 the	 juxtamembrane	 region	 precedes	
phosphorylation	of	Y754	in	the	activation	loop	of	the	Musk	receptor	(Till,	Becerra	et	
al.	2002).	Mutations	to	RTKs	that	prevent	the	juxtamembrane	regions	interacting	with	
the	TKD	are	found	in	many	cancers,	as	these	 lead	to	constitutively	active	receptors	
(Dibb,	Dilworth	et	al.	2004).	Another	region	of	the	receptors,	that	can	provide	auto-
inhibition	of	the	TKDs,	is	the	C-terminal	tail.	This	region	contains	a	tyrosine	that	inhibits	
the	TKD	by	also	providing	a	steric	block	on	the	active	site	of	the	TKD	that	prevents	
substrate	access	(Shewchuk,	Hassell	et	al.	2000,	Niu,	Peters	et	al.	2002).		
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The	EGFR/ErbB	family	of	receptors	are	unusual	in	their	mode	of	activation,	due	to	the	
fact	that	the	activation	 loop	doesn’t	require	trans-phosphorylation	for	activation	of	
the	TKD	(Zhang,	Gureasko	et	al.	2006).	Activation	occurs	when	the	C-lobe	of	one	TKD	
interacts	with	the	N-lobe	of	another	TKD.	This	causes	a	conformational	change	in	the	
second	TKD	that	disrupts	the	auto-inhibition	placed	on	it	and	allows	it	to	adopt	the	
active	 conformation	 (Boyer,	 Turchi	 et	 al.	 2006,	 Qiu,	 Tarrant	 et	 al.	 2008).	 The	
juxtamembrane	 region	of	 these	 receptors	 is	 also	 important	 for	 TKD	activation,	but	
instead	of	helping	to	stabilise	the	inactive	TKD	form,	it	provides	a	pocket	for	the	C-lobe	
of	the	activating	TKD	to	sit	in,	aiding	it	to	interact	with	the	N-lobe	of	the	receiving	TKD	
(Jura,	Endres	et	al.	2009,	Red	Brewer,	Choi	et	al.	2009).		
	
The	 second	 phase	 of	 auto-phosphorylation	 is	 responsible	 for	 creating	 phospho-
tyrosine	 binding	 sites.	 Phosphorylation	 events	 within	 this	 phase	 occur	 in	 specific	
orders,	e.g.	Y583	in	the	kinase	insert	of	the	FGFR	is	phosphorylated	first,	followed	by	
Y463	in	the	Juxtamembrane	region	and	Y585	also	in	the	kinase	insert	(Furdui,	Lew	et	
al.	2006).	Phospho-tyrosines	generated	in	this	phase	of	auto-phosphorylation,	provide	
binding	sites	on	the	receptor	for	the	recruitment	of	SH2	domain	and	phospho-tyrosine	
binding	 (PTB)	 domain	 containing	 signalling	 adaptors	 (Mohammadi,	Honegger	 et	 al.	
1991,	 Pawson	 2004).	 These	 proteins	 are	 recruited	 either	 directly	 to	 the	 RTK	 or	 to	
already	docked	accessory	proteins,	e.g.	 insulin	 receptor	substrate	1	 (IRS1)	with	 the	
insulin	 receptor	 that	 becomes	hyper-phosphorylated	 in	 response	 to	RTK	 activation	
(Sun,	Crimmins	et	al.	1993).	From	here,	the	RTK	can	activate	a	number	of	signalling	
pathways,	 such	 as	 the	MAPK	or	 Akt	 signalling	 pathways.	 Although	 these	 pathways	
were	 thought	 to	 be	 linear	 and	 operate	 in	 isolation	 of	 each	 other,	 it	 has	 become	
increasingly	evident	that	they	in	fact	form	intertwined	networks.	
	
1.4.3.	ErbB	receptor	family	
	
The	EGFR	was	the	first	RTK	to	be	identified	and,	therefore,	is	the	most	heavily	studied	
out	 of	 the	 RTK	 family	 of	 receptors	 (Wang	 2017).	 The	 EGFR	 is	 a	 part	 of	 the	 ErbB	
subfamily	of	 receptors,	which	 includes,	EGFR/ErbB1/Her1,	ErbB2/Her2,	ErbB3/Her3	
and	ErbB4/Her4	(Yarden	and	Sliwkowski	2001).	These	receptors	can	form	both	hetero-	
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and	 homodimers	 (Citri	 and	 Yarden	 2006).	 Heterodimerisation	 is	 important	 for	
activation	of	all	the	ErbB	receptors,	due	to	the	fact	that	ErbB2	has	no	direct	ligand	and	
ErbB3	has	impaired	kinase	function	(Carraway	and	Cantley	1994).	Aberrant	activation	
of	ErbB	receptors	leads	to	tumourgenesis	in	many	cancers,	such	as	non-small	cell	lung	
cancer	 (NSCLC),	 breast,	 pancreatic,	 ovarian,	 head	 and	 neck,	 etc.	 (Arteaga	 and	
Engelman	 2014).	 The	 ErbB2	 receptor	 is	 highly	 implicated	 in	 breast	 and	 ovarian	
cancers.	In	these	cancers,	the	receptor	is	associated	with	gene	amplification	leading	
to	overexpression	of	the	receptor.	This	occurs	in	approximately	20-25%	of	breast	and	
ovarian	cancers	and	is	linked	with	poor	prognosis	(Slamon,	Clark	et	al.	1987,	Reese	and	
Slamon	 1997).	 The	 ErbB3	 receptor	 exhibits	 a	 1/1000th	 the	 autophosphorylation	
activity	of	the	EGFR.	It	has	been	linked	to	cancer,	mainly	due	to	its	ability	to	promote	
oncogenic	EGFR	and	ErbB2	receptor	signalling	(Gullick	1996).	ErbB4	differs	from	the	
other	members	of	the	ErbB	family	as	the	receptor	becomes	cleaved	after	binding	to	
its	ligand.	The	full	length	receptor	is	180kDa.	After	activation	the	80kDa	intracellular	
domain	 is	 cleaved	 and	 translocates	 to	 the	 nucleus	 in	 order	 to	 regulate	 gene	
transcription.	 This	 receptor	 is	 required	 for	 the	development	of	 the	CNS,	heart	 and	
mammary	glands	(Sardi,	Murtie	et	al.	2006).		
	
1.4.4.	Endosomal	RTK	signalling	
	
In	1979,	Haigler,	et	al.	showed	that,	when	treated	with	epidermal	growth	factor	(EGF),	
the	number	of	EGF	receptors	(EGFR)	present	on	the	cell	surface	was	reduced	by	99%,	
and	 subsequently	 redistributed	 to	 internal	 compartments	within	 the	 cells	 (Haigler,	
McKanna	 et	 al.	 1979).	 Endocytosis	 in	 turn,	 became	 viewed	 as	 a	 down	 regulatory	
mechanism,	by	which	the	cell	could	attenuate	growth	factor	signals	in	order	to	prevent	
aberrant	 cell	 growth	 (Beguinot,	 Lyall	 et	 al.	 1984,	 Sorkin	 and	 von	 Zastrow	 2002).	
However,	insights	indicating	that	this	wasn’t	the	full	picture,	in	terms	of	the	roles	of	
the	endosome,	came	in	1985	when	Wiley,	et	al.	observed	that	the	rate	of	degradation	
of	internalised	EGFRs	was	slower	than	the	rate	of	internalisation	(Wiley,	VanNostrand	
et	 al.	 1985).	 Further	 studies	 by	 Sorkin	 et	 al.,	 in	 1988,	 showed	 that	 EGF	 did	 not	
dissociate	from	the	EGFR	in	early	endosomes,	suggesting	that	the	EGFR	was	still	active	
after	endocytosis	(Sorkin,	Teslenko	et	al.	1988).		
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In	1994,	fractionation	studies	looked	into	EGFR	and	insulin	receptor	signalling.	Both	
the	EGFR	and	insulin	receptor	had	been	linked	to	the	recruitment	of	Grb2,	Sos	and	
Shc,	but	the	two	receptors	give	different	physiological	responses,	despite	containing	
converging	 signalling	 pathways.	 Separation	 of	 plasma	 membrane	 and	 endosomal	
compartments	 after	 stimulation	 with	 either	 EGF	 or	 insulin,	 showed	 greater	
internalisation	of	 the	EGFR	compared	 to	 the	 insulin	 receptor,	and	greater	 levels	of	
tyrosine	 phosphorylation	 in	 endosomal	 compartments	 when	 stimulated	 with	 EGF,	
compared	 to	 stimulation	 with	 insulin	 (Di	 Guglielmo,	 Baass	 et	 al.	 1994).	 These	
experiments	 indicated	 that	 internalisation	 of	 the	 EGFR	 to	 the	 endosome	 could	 be	
responsible	for	different	physiological	outcomes	observed	between	the	EGFR	and	the	
insulin	receptor	(Murphy,	Padilla	et	al.	2009,	Omerovic	and	Prior	2009).	
	
In	1996,	Vieira,	et	al.	showed	that	inhibition	of	endocytosis	increased	EGF-dependent	
cell	 growth,	and	 this	was	due	 to	changes	within	 the	phosphorylation	profile	of	 the	
EGFR	and	its	associated	proteins.	Interestingly,	both	hyper-	and	hypo-phosphorylation	
of	EGFR	associated	proteins	in	the	K44A	dynamin	mutant	cells,	compared	to	wild	type	
(WT)	cells	was	observed	(Vieira,	Lamaze	et	al.	1996).	 In	2001,	Burke,	et	al.	used	an	
anti-EGFR	antibody	tagged	with	biotin	via	a	disulphide	bond.	The	biotin	tag	could	then	
be	 removed	 from	 the	 cell	 surface	 with	 the	 addition	 of	 glutathione,	 while	 the	
internalised	antibody	would	retain	its	tag	(Burke,	Schooler	et	al.	2001).	This	allowed	
them	to	analyse	the	differences	in	signalling	within	the	normal	physiological	context	
of	 the	 cell.	 The	 results	 from	 the	 experiment	 show	 differential	 activation	 of	 EGFR	
associated	proteins,	at	internal	and	cell	surface	locations.	
	
	At	the	same	time,	Wu,	et	al.	was	working	on	both	EGF	and	NGF.	While	both	growth	
factors	induced	transient	Ras	activation,	only	NGF	caused	prolonged	Rap1	activation	
(Wu,	Lai	et	al.	2001).	Furthermore,	activated	Rap1,	along	with	associated	signalling	
complexes,	 was	 shown	 to	 be	 present	 at	 endosomes.	 Additionally,	 disruption	 of	
internal	membranes	within	the	cell	resulted	in	Rap1	signalling	being	abolished,	while	
having	little	to	no	effect	on	Ras	activity	(Wu,	Lai	et	al.	2001).	Later,	in	2002	and	2004,	
studies	by	Wang	et	al.	examined	endosomal	signalling	of	both	EGFR	and	PDGFR.	These	
studies	used	specific	RTK	inhibitors,	along	with	blocking	of	recycling	to	deliver	inactive	
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growth	factor-receptor	complexes	to	the	endosome.	From	here,	the	inhibitors	were	
washed	out	and	endosomal	signalling	could	be	observed	(Wang,	Pennock	et	al.	2002,	
Wang,	 Pennock	 et	 al.	 2004).	 These	 studies	 show	 that	 signal	 transduction	 can	 be	
initiated	 from	 endosomes	 and	 that	 this	 signal	 is	 sufficient	 to	 provide	 a	 biological	
response.	They	also	expand	the	concept	of	endosomal	signalling	to	RTKs	other	than	
the	EGFR.	
	
In	2012,	the	pioneering	study	by	Vieira,	et	al.	(Vieira,	Lamaze	et	al.	1996)	was	revisited	
using	more	modern	techniques.	Endocytosis	was	inhibited	using	a	dynamin	inhibitor,	
Dynasore,	 instead	 of	 expression	 of	 the	 K44A	 mutant	 dynamin.	 Protein	
phosphorylation	was	then	examined	by	phosphoproteomics	to	provide	an	unbiased	
global	view	of	EGF	and	endocytosis	dependent	phosphorylation	(Omerovic,	Hammond	
et	al.	2012).	The	results	validate	the	general	principle	established	by	Vieira	et	al.	but	
indicate	some	finding	may	be	due	to	compensatory	mechanisms	caused	by	long	term	
dynamin	 inhibition.	 This	 study	 also	 showed	 that	 phosphorylation	 of	 the	 ESCRT-0	
complex	 by	 EGF	 is	 highly	 dependent	 on	 endocytosis.	 The	 studies	 described	 above	
introduce	the	concept	of	spatial	regulation	of	RTKs,	whereby,	signals	generated	at	the	
plasma	 membrane	 and	 the	 endosome	 will	 result	 in	 different	 signalling	 outcomes	
(Figure	1.7).	
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1.4.5.	G-protein	coupled	receptors	(GPCRs)	
	
The	GPCR	family	of	the	receptors	makes	up	the	largest	group	of	receptors	with	almost	
a	1000	members	(Fredriksson	and	Schioth	2005).	Clinically,	these	receptors	are	very	
important	with	34%	of	all	FDA	approved	drugs	targeting	a	GPCR.	These	receptors	all	
share	 a	 7	 transmembrane	 (7TM)	 structure	 and	 are	 linked	 to	 second	 messenger	
generating	enzymes	via	the	action	of	heterotrimeric	G-proteins	(Gilman	1987).	Much	
of	 what	 we	 know	 about	 these	 receptors	 was	 pioneered	 by	 research	 into	 the	 β-
adrenergic	 receptor.	 This	work	 done	 in	 the	 1970’s	 and	 1980’s	 by	 Lefkowitz	would	
ultimately	 lead	 him	 to	 win	 the	 Nobel	 Prize	 in	 chemistry	 in	 2012	 for	 his	 efforts	
(Lefkowitz	2007).			
	
Figure	1.7	Spatial	 regulation	of	Receptor	tyrosine	kinases	 (RTKs).	The	receptor	 is	
activated	 at	 the	 plasma	membrane,	 where	 it	 exposed	 to	 an	 array	 of	 signalling	
adaptors	 and	 effectors	 to	 elicit	 a	 biological	 response.	 Later,	 trafficking	 of	 the	
receptor	to	the	endosome	will	result	in	the	receptor	being	exposed	to	a	different	
environment	of	adaptors	and	effectors,	resulting	in	a	distinct	biologically	response.	
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Studies	into	the	β-adrenergic	receptor	began	before	the	GPCR	class	of	receptors	had	
even	been	described,	and	also	before	it	was	even	known	if	the	β-adrenergic	receptor	
was	 even	 an	 individual	molecule	 (Lefkowitz	 2007).	 The	 biochemist	 Earl	 Sutherland	
even	said	at	the	time	that	it	was	possible	the	β-adrenergic	receptor	could	be	a	binding	
site	 on	 Adenylate	 cyclase	 (AC)	 (Robison,	 Butcher	 et	 al.	 1967).	 In	 the	 early-to-mid	
1970’s	radio-ligands	were	generated	for	the	β-	and	α-adrenergic	receptor	(Mukherjee,	
Caron	et	al.	1975),	as	well	as	for	a	number	of	other	receptors	such	as	glucagon,	opioid	
and	 muscarinic	 cholinergic	 receptors	 (Rodbell,	 Birnbaumer	 et	 al.	 1971,	 Pert	 and	
Snyder	 1973,	 Yamamura	 and	 Snyder	 1974).	 These	 tools	 helped	 to	 build	 on	 our	
understanding	 of	 the	 physiological	 outputs	 governed	 by	 the	 receptors	 they	 were	
targeted	 against.	 This	 work	 would	 be	 built	 upon	 further	 with	 these	 tools	 by	 the	
purification	of	many	targeted	receptors.	Affinity	chromatography,	along	with	the	radio	
ligands,	would	allow	for	the	purification	of	the	relatively	sparse	β-adrenergic	receptor	
in	1972	(Lefkowitz,	Haber	et	al.	1972).	By	the	end	of	the	decade,	the	‘ternary	complex	
model’	had	been	developed	(De	Lean,	Stadel	et	al.	1980).		
	
It	was	not	until	mid	1980’s	that	the	β-adrenergic	receptor	as	a	single	molecule	was	
finally	 accepted	 as	 a	 receptor.	 Reconstitution	 of	 the	 β-adrenergic	 receptor	 into	
xenopus	 erythrocytes	 allowed	 the	 previously	 unresponsive	 cells	 to	 respond	 to	
catecholamines	(Cerione,	Strulovici	et	al.	1983).	A	year	later	this	experiment	was	taken	
a	 step	 further	 by	 also	 reconstituting	 G-proteins	 with	 the	 β-adrenergic	 receptor,	
creating	a	hormone	responsive	AC	signalling	system	(Cerione,	Sibley	et	al.	1984).		
	
In	1986,	the	β-adrenergic	receptor	was	cloned,	a	task	only	possible	at	the	time	due	to	
the	fact	that	the	receptor	 is	 ‘intron-less’	 (Dixon,	Kobilka	et	al.	1986).	The	sequence	
revealed	the	receptor	to	have	7	membrane	spanning	regions	with	sequence	homology	
to	the	7TM	structure	of	Rhodopsin.	Until	this	point,	Rhodopsin	had	not	been	thought	
of	as	a	receptor	and	this	finding	changed	the	view	that	the	7TM	structure	was	specific	
to	 light	 sensitive	 proteins	 (Ovchinnikov	 Yu	 1982).	 Further	 sequencing	 of	 the	 other	
adrenergic	 receptors	 strengthened	 this	 argument	 (Kobilka,	 Matsui	 et	 al.	 1987,	
Dohlman,	Thorner	et	al.	1991).	Over	the	next	few	years	the	7TM	class	of	receptors	
began	 to	 grow	 rapidly	 as	 more	 receptors	 were	 cloned,	 including	 the	 muscarinic	
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cholinergic	 receptor	 and	 substance	 K	 receptors	 (Kubo,	 Fukuda	 et	 al.	 1986,	 Masu,	
Nakayama	et	al.	1987).	By	the	beginning	of	the	1990’s,	a	 large	number	of	olfactory	
receptors	had	been	cloned	(almost	500)	with	all	of	them	turning	out	to	be	GPCRs	(Buck	
and	Axel	1991).	By	the	end	of	the	decade,	many	taste	receptors	had	been	given	the	
same	treatment	(Hoon,	Adler	et	al.	1999).	
	
The	α2-	and	β2-	adrenergic	 receptors	are	an	 interesting	pair	of	 receptors	and	 their	
study	 has	 given	 great	 insight	 into	 the	 structural	 function	 of	 GPCRs.	 These	 two	
receptors	 share	a	 reasonably	high	degree	of	 sequence	homology,	and	 interestingly	
both	bind	the	same	adrenergic	ligands,	but	with	opposite	downstream	effects.	While	
the	β2	receptor	will	increase	the	activity	of	AC,	the	α2	receptor	will,	in	contrast,	inhibit	
AC	activity	due	 to	 the	binding	of	Gs	and	Gi	 respectively.	A	 series	of	 chimeras	were	
generated	 in	order	 to	determine	which	 regions	of	 the	 receptor	would	 translate	 to	
which	 function	 and	where	 specificity	 for	G-proteins	 could	 be	 determined	 (Kobilka,	
Kobilka	et	al.	1988).	From	these	experiments	performed	in	the	late	1980’s	and	early	
1990’s,	it	was	determined	that	the	third	intracellular	loop	was	responsible	for	Gs	and	
Gi	 specificity,	 while	 ligand	 binding	 was	 determined	 by	 the	 membrane	 spanning	
domains	(Ostrowski,	Kjelsberg	et	al.	1992).	It	was	also	shown	that	residues	in	the	distal	
region	 of	 the	 third	 intra	 cellular	 loop	 would	 provide	 important	 intra-receptor	
interactions	that	hold	the	receptor	in	an	inactive	state	at	rest.	Binding	of	a	ligand	would	
lead	to	a	conformational	change	allowing	the	receptor	to	‘relax’	into	its	active	state	
(Cotecchia,	Exum	et	al.	1990).	Mutations	to	these	residues	can	be	found	 in	thyroid	
adenomas.			
	
In	 the	 mid	 1970’s,	 it	 was	 first	 observed	 that	 repeated	 exposures	 to	 β-adrenergic	
receptor	agonists	would	lead	to	reduced	cellular	responses.	This	desensitization	is	a	
key	homeostasis	process	regulating	GPCR	function,	but	it	was	unclear	at	the	time	what	
was	responsible	for	the	phenomenon.	A	few	years	later	it	was	shown	that	cells	which	
had	been	desensitized	to	isoproterenol,	exhibited	receptors	that	migrated	slower	on	
polyacrylamide	gels	 (Stadel,	Nambi	et	al.	1982).	Suggesting	the	presence	of	a	post-
translational	modification	 (PTM)	such	as	phosphorylation.	This	was	 later	 confirmed	
with	 the	 use	 of	 32Pi	 labelled	 phosphate	 (Stadel,	 Nambi	 et	 al.	 1983).	 The	 enzyme	
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responsible	for	phosphorylating	the	β-adrenergic	receptor	wouldn’t	be	identified	until	
the	end	of	the	1986	and	was	named	β-adrenergic	receptor	kinase	(βARK)	but	has	since	
been	 renamed	 GRK2	 (Benovic,	 Strasser	 et	 al.	 1986).	 This	 enzyme	 appeared	 to	 be	
similar	 to	 an	 enzyme	 identified	 in	 rod	 cells,	 which	 was	 responsible	 for	 the	
phosphorylation	of	Rhodopsin	 (Wilden	and	Kuhn	1982).	 This	 family	of	 kinases	now	
contains	7	members	(GRK1-7)	(Pitcher,	Freedman	et	al.	1998).		
	
β-ARK	was	purified	from	bovine	brain	tissue	and,	interestingly,	would	lose	its	ability	to	
desensitize	the	β-adrenergic	receptor	the	further	it	was	purified.	An	explanation	for	
this	would	come	from	studies	into	Rhodopsin.	A	48kDa	protein	(now	called	arrestin1)	
was	shown	to	work	with	Rhodopsin	kinase	in	order	to	deactivate	Rhodopsin	(Kuhn	and	
Wilden	1987).	This	protein	was	able	to	restore	the	desensitizing	effects	of	purified	β-
ARK	(Benovic,	Kuhn	et	al.	1987).	β-arrestin1	and	β-arrestin2	(also	known	as	arrestin2	
and	3	respectively)	would	soon	be	identified	(Lohse,	Benovic	et	al.	1990,	Attramadal,	
Arriza	et	al.	1992).		
	
GPCR	phosphorylation	by	GRKs	does	not	convey	receptor	desensitization	per	se,	but	
rather	generates	high	affinity	binding	sites	for	the	arrestins	(Lohse,	Benovic	et	al.	1990,	
Gurevich,	Dion	et	al.	1995).	This	series	of	events	was	first	visualized	in	1999	by	Barak	
et	al.	(Barak,	Warabi	et	al.	1999).	Arrestins	downregulate	GPCR	signal	by	reducing	Gαs	
activation,	thus	hampering	the	production	of	further	cAMP,	and	the	recruitment	of	
phosphodiesterase’s	 to	 increase	 the	 rate	 of	 cAMP	degradation	 (Perry,	 Baillie	 et	 al.	
2002).	Arrestins	can	also	act	as	adaptors	 for	proteins	 involved	 in	clathrin	mediated	
endocytosis	 in	 order	 to	 aid	 in	 the	 internalization	 of	 activated	 GPCRs	 (Ferguson,	
Menard	 et	 al.	 1995,	 Laporte,	 Oakley	 et	 al.	 1999).	 Once	 internalized	 to	 endosomal	
membranes,	 the	GPCR	 is	 uncoupled	 from	 its	 ligand	 and	 re-sensitized	 before	 being	
recycled	back	to	the	plasma	membrane	(Yu,	Lefkowitz	et	al.	1993,	Krueger,	Daaka	et	
al.	1997).	Arrestins	are	also	responsible	for	the	G-protein	independent	activation	of	
MAP	kinase	pathways	(Luttrell,	Ferguson	et	al.	1999).	
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1.4.6.	Endosomal	GPCR	signalling	
	
Much	like	with	RTKs,	internalization	of	GPCRs	was	viewed	as	a	mechanism	to	attenuate	
receptor	 signaling,	 with	 activation	 of	 heterotrimeric	 G	 proteins	 occurring	 at	 the	
plasma	membrane	(Figure	1.8).	However,	during	the	1990’s,	multiple	studies	observed	
G	proteins	present	at	endo-membranes	(Stow,	de	Almeida	et	al.	1991,	de	Almeida,	
Holtzman	et	al.	1994,	Brand,	Holtzman	et	al.	1996,	Weiss,	White	et	al.	1997),	indicating	
that	GPCR	signaling	may	not	be	restricted	to	the	plasma	membrane	(Irannejad	and	
von	Zastrow	2014).	The	first	example	of	an	endosomally	derived	GPCR	signal	came	
from	 study	 of	 Ste2	 in	 2006.	 When	 activated,	 Ste2	 catalyzes	 guanine	 nucleotide	
exchange	of	the	Gα	subunit,	allowing	the	βγ	subunits	to	dissociate	and	transduce	the	
receptors	 signal	 by	 activation	 of	 the	MAP	 kinase	 pathway	 (Slessareva,	 Routt	 et	 al.	
2006).	This	study	showed	that	the	Gα	subunit	conveyed	part	of	the	receptors	signalling	
activity	and	that	this	took	place	at	endosomes.		
	
A	few	years	later,	in	2009,	an	immunotherapy	study	showed	that	the	S1P1R	receptor	
displayed	sustained	receptor	activity	at	endosomes	when	the	cells	were	treated	with	
the	drug;	FTY720	(Mullershausen,	Zecri	et	al.	2009).	Another	group	investigating	the	
thyroid-stimulating	 hormone	 (TSH)	 receptor	 show	 that	 receptor	 activity	 is	 poorly	
reversed	after	the	hormone	is	washed	out	(Calebiro,	Nikolaev	et	al.	2009).	However,	
upon	inhibition	of	endocytosis	with	the	dynamin	inhibitor,	Dynasore,	they	were	able	
to	 attenuate	 the	 persistent	 signal	 with	 removal	 of	 the	 TSH.	 Interestingly,	 this	
persistent	signal	produced	by	the	TSHR	continues	after	TSH	has	dissociated	from	the	
receptor	 (Werthmann,	Volpe	et	 al.	 2012).	 Sustained	 cAMP	 signalling	was	observed	
with	Parathyroid	hormone	(PTH)	receptor	in	HEK293	cells	adding	further	support	for	
the	notion	of	sustained	GPCR	activation	occurring	at	endosomes	(Ferrandon,	Feinstein	
et	al.	2009).	Overexpression	of	Arrestins	was	also	shown	to	prolong	the	PTHR	signal,	
leading	to	the	proposed	mechanism	by	which	Arrestins	were	responsible	for	sustained	
endosomal	signalling	of	GPCRs	(Feinstein,	Wehbi	et	al.	2011).		
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Figure	1.8	Classical	and	endosomal	GPCR	signalling.	In	both	circumstances,	binding	
of	the	ligand	to	the	GPCR	results	in	a	conformational	change	in	the	receptor.	This	
now	allows	the	receptor	to	bind	to	the	α	subunit	of	the	heterotrimeric	G-proteins,	
causing	it	to	displace	GDP	for	GTP	and	become	active.	The	α	subunit	dissociates	
from	 the	 βγ	 subunits	 and	 activates	 various	 effectors.	 The	 GPCR	 is	 then	
phosphorylated	 by	 GRK,	 allowing	 it	 to	 bind	 Arrestins.	 This	 results	 in	 the	
internalisation	of	the	receptor.	In	the	classical	model,	trafficking	of	the	receptor	to	
the	endosome	results	in	the	attenuation	of	the	signal	and	resetting	of	the	receptor	
to	be	recycled	back	to	the	PM.	However,	in	the	alternative	model,	the	GPCR	can	
further	activate	heterotrimeric	G-proteins	at	the	endosome,	resulting	in	a	2nd	and	
more	sustained	wave	of	activation.	
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Further	studies	would	report	persistent	GPCR	signalling	with	the	Vasopressin	receptor,	
V2R,	 as	 well	 as	 an	 acute	 endosomal	 signal	 from	 the	 dopamine	 receptor,	 DRD1	
(Kotowski,	Hopf	et	al.	2011,	Feinstein,	Yui	et	al.	2013).	Resulting	in	a	revision	of	the	
proposed	model	that	suggested	the	sustained	endosomal	signal	resulted	from	a	GPCR-
Arrestin-Gβγ	complex	(Wehbi,	Stevenson	et	al.	2013).		
	
Sustained	 cAMP	 signalling	 had	 previously	 been	 ruled	 out	 for	 the	 β-adrenergic	
receptor,	 however,	 in	 2013,	 an	 elegant	 study	 using	 conformational	 biosensors	 of	
active	G-proteins	found	that	isoproterenol	was	able	to	induce	endosomally	active	G-
proteins	 (Irannejad,	 Tomshine	 et	 al.	 2013).	 The	 same	 group	 also	 showed	 that	 the	
endosomal	derived	portion	of	the	β-adrenergic	receptor	signal	is	responsible	for	the	
cells	transcriptional	response	(Tsvetanova	and	von	Zastrow	2014).		
	
1.4.7.	Crosstalk	between	GPCRs	and	RTKs	
	
Traditionally,	studies	on	GPCRs	and	RTKs	have	been	performed	in	isolation.		While	this	
has	been	important	for	understanding	the	basic	signalling	of	each	family	of	receptors,	
rarely	in	nature	will	cells	experience	a	growth	factor	or	other	ligand	in	isolation.	In	the	
mid	 1990’s	 it	 began	 to	 emerge	 that	 RTKs	 could	 be	 activated	 independent	 of	 their	
ligands,	e.g.	by	various	stress	factors	such	as	UV	radiation	(Knebel,	Rahmsdorf	et	al.	
1996,	Goldkorn,	Balaban	et	al.	1997).	The	term	transactivation	was	coined	in	1996	by	
Ullrich’s	lab	when	they	showed	that	stimulation	with	endothelin-I,	lysophosphatic	acid	
(LPA)	and	thrombin,	all	 lead	to	the	phosphorylation	of	the	EGFR	(Daub,	Weiss	et	al.	
1996).	This	added	to	the	observation	that	the	PDGFR	can	be	activated	by	angiotensin	
II	(Linseman,	Benjamin	et	al.	1995).	By	the	end	of	the	decade	a	number	of	GPCR	ligands	
had	been	shown	to	activate	RTKs	but	the	mechanism	for	how	this	occurs	had	not	been	
elucidated	(Daub,	Wallasch	et	al.	1997,	Lee	and	Chao	2001,	Peng,	Myers	et	al.	2002).		
	
In	 1999,	 it	 was	 suggested	 that	 GPCR	 stimulation	 led	 to	 the	 activation	 of	
metalloproteinases	 and	 cleavage	 of,	 for	 example,	 heparin-binding	 EGF	 (HB-EGF)	
(Prenzel,	 Zwick	et	 al.	 1999).	 Further	examples	of	metalloproteinase	 involvement	 in	
GPCR-RTK	crosstalk	were	observed	over	the	next	few	years	in	cardiac	cells	with	the	
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angiotensin	 receptors,	and	 in	 response	 to	other	 factors	 such	as	Helicobactor	pylori	
infection	 (Uchiyama-Tanaka,	Matsubara	 et	 al.	 2001,	 Asakura,	 Kitakaze	 et	 al.	 2002,	
Wallasch,	 Crabtree	 et	 al.	 2002).	 This	 gave	 rise	 to	 the	 ‘triple	 membrane	 passing	
signalling’	 (TMPS)	model,	whereby	 the	 signal	 crosses	 the	 plasma	membrane	 three	
times.	Other	mechanisms	for	the	transactivation	of	RTKs	have	also	been	suggested.	
Src	 and	 Pyk	 were	 shown	 to	 interact	 with	 the	 EGFR	 in	 response	 to	 LPA	 receptor	
activation	(Luttrell,	Hawes	et	al.	1996,	Keely,	Calandrella	et	al.	2000).	Src	is	capable	of	
directly	 phsophorylating	 the	 EGFR	 (Biscardi,	 Maa	 et	 al.	 1999).	 Another	 possible	
mechanism	 for	 the	 transactivation	 of	 RTKs	 is	 via	 the	 inhibition	 of	 protein	 tyrosine	
phosphatases	(PTPs).	H2O2	has	been	shown	to	inhibit	PTPs	(Sundaresan,	Yu	et	al.	1995)	
and	stimulation	of	some	GPCRs	can	lead	to	H2O2	generation	(Rhee,	Bae	et	al.	2000).		
	
Transactivation	 of	 RTKs	 by	 GPCRs	 has	 been	more	 commonly	 observed	 throughout	
recent	years	as	opposed	to	RTK	activation	of	GPCRs.	However	there	a	few	examples	of	
evidence	to	suggest	that	RTKs	are	capable	of	GPCR	transactivation	(Delcourt,	Bockaert	
et	al.	2007).	Pertussis	toxin	has	been	shown	to	mediate	some	of	the	actions	of	insulin	
via	G	proteins	(Luttrell,	Kilgour	et	al.	1990),	suggesting	the	insulin	receptors	mitogenic	
effects	are	mediated	by	Gβγ	subunits	(Luttrell,	van	Biesen	et	al.	1995,	Dalle,	Ricketts	et	
al.	2001).	A	similar	observation	was	also	seen	with	FGF	(Fedorov,	Jones	et	al.	1998).	In	
1996,	 EGF	 was	 observed	 to	 activate	 adenylate	 cyclase	 via	 phosphorylation	 of	 Gαs	
subunit	(Poppleton,	Sun	et	al.	1996).	Phosphorylation	of	Gαi	prevents	its	reassociation	
with	the	βγ	subunits	and	prolongs	G	protein	activation	(Alderton,	Rakhit	et	al.	2001).	
The	S1P	receptor	has	also	been	shown	to	be	activated	in	response	to	various	RTKs,	e.g.	
IGF-1,	NGF	and	PDGF,	via	 synthesis	and	secretion	of	 the	 receptor	 ligands	 (Hobson,	
Rosenfeldt	et	al.	2001,	Toman,	Payne	et	al.	2004,	El-Shewy,	Johnson	et	al.	2006).	The	
PDGFR	has	also	been	observed	to	transactivate	S1P	recetors	in	a	ligand	independent	
way	(Waters,	Sambi	et	al.	2003).	Further	to	this,	stimulation	of	Gαi	has	been	shown	to	
be	important	for	both	EGFR	and	PDGFR	dependent	migration	(Shan,	Chen	et	al.	2006)	
and	inhibition	of	a	S1P	receptor	blocks	PDGF	induced	cell	migration	(Waters,	Long	et	
al.	2006).	
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1.5.	Objectives	
	
A	 major	 aim	 of	 the	 work	 described	 in	 this	 thesis	 is	 to	 expand	 upon	 our	 current	
knowledge	 surrounding	 the	 role	 of	 HRS	 in	 endosomal	 signalling	 and	 trafficking.	 In	
particular,	 I	 hoped	 to	 advance	 our	 understanding	 of	 the	 function	 of	 HRS	
phosphorylation.	HRS	is	a	prominent	target	of	RTK	activity,	but	despite	this,	the	role	
of	 HRS	 phosphorylation	 is	 still	 up	 for	 contention.	 Furthermore,	 the	 profile	 of	 HRS	
phsophorylation	changes	when	stimulating	with	different	growth	factors	(Row,	Clague	
et	 al.	 2005).	 Here	 I	 attempt	 to	 bring	 clarity	 to	 the	 issue	 by	 assessing	 the	
phosphorylation	dependent	interactors	of	HRS	and	investigate	the	dynamics	of	HRS	
recruitment.	
	
Work	preceeding	this	project	from	our	laboratory	indicates	that	HRS	may	have	a	role	
as	a	signalling	adaptor	(Han	liu,	unpublished	data;	described	in	chapter	three).	I	aimed	
to	evaluate	this	hypothesis	by	examining	the	EGF	dependent	binding	partners	of	HRS	
by	 mass	 spectrometry	 and	 to	 also	 establish	 proximity	 labelling	 techniques	 in	 the	
laboratory.	Secondly,	 I	aimed	to	build	upon	the	existing	tools	and	methodologies	in	
order	 to	 investigate	specific	endosomally	derived	cAMP	and	protein	kinase	A	 (PKA)	
signalling.	The	purpose	of	this	is	to	progress	the	field	by	developing	a	method	for	the	
direct	visualisation	of	cAMP	generation	and	PKA	signalling	at	endosomes.	 I	hope	to	
introduce	new	tools	for	examining	crosstalk	between	RTKs	and	GPCRs	that	in	principle	
could	be	governed	by	HRS.	
	
There	 is	 evidence	 that	 suggests	 phosphorylation	 of	 HRS	 may	 alter	 its	 binding	
properties	with	membranes	(Urbé,	Mills	et	al.	2000).	I	therefore	aimed	to	visualise	the	
dynamics	of	HRS	recruitment	to	endosomes	in	response	to	growth	factor	stimulation.	
Tyrosine	 residues	 329	 and	 334	 of	 HRS	 have	 been	 identified	 as	 principal	
phosphorylation	 sites	 in	 response	 to	 EGFR	 activation	 (Urbé,	 Sachse	 et	 al.	 2003).	 I	
utilised	a	HRS	mutant	lacking	in	these	tyrosine	residues	to	investigate	the	function	of	
phosphorylation	at	these	sites.		
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Chapter	two:	Materials	and	methods	
2.1.	Cell	biology	
	
2.1.1.	Materials	and	Reagents	
	
Dulbecco’s	 Modified	 Eagle’s	 Medium	 (DMEM)	 +	 GlutaMAX-I	 (#31966-021),	 Fetal	
bovine	serum	(FBS)	(#10270),	Penicillin	and	Streptomycin	antibiotic	mixture	(#15140-
122)	 and	 Minimum	 Essential	 Medium/Non-Essential	 Amino	 Acids	 (MEM/NEAA)	
(#11140-035)	were	purchased	from	Thermo	Fisher	Scientific.	Trypsin-EDTA	(#15400)	
and	 Opti-MEM	 (#409864),	 and	 Hygromycin	 B	 (#10687010)	 were	 from	 Invitrogen	
(Paisley,	UK).	GeneJuice®	Transfection	reagent	(#70967-3)	came	from	EMD	Millipore	
(Darmstadt,	Germany).	Geneticin	(G418)	(#04727878001)	was	purchased	from	Roche	
Diagnostics.	Wortmannin	 (#W1628),	 Forskolin	 (#F6886)	 and	 Isoproterenol	 (#I6504)	
were	all	supplied	from	Sigma-Aldrich	(Dorset,	UK).	EGF	(#AF100-15),	TGFα	(#100-16A)	
were	purchased	from	Peprotech	(London,	UK)	and	EGF-AlexaFluor555	(#E35350)	was	
from	 Fisher	 Scientific.	 SAR405	 (#AOB6007)	 came	 from	 Aobious	 (MA,	 USA),	 Dyngo	
(#ab120689)	was	from	Abcam	(Cambridge,	UK)	and	IBMX	(#410957)	was	bought	from	
EMD	Millipore	 (Darmstadt,	Germany).	All	 cell	 culture	plastics	were	purchased	 from	
Corning	(NY,	USA).		
	
2.1.2.	Cell	culture	
	
HeLa	S3	Flp-In	cells	and	HEK293	Flp-In	cells	were	cultured	in	Dulbecco’s	Modified	Eagle	
Medium	 supplemented	 with	 10%	 Fetal	 bovine	 serum	 (FBS),	 0.1mM	 MEM/Non-
Essential	Amino	Acids	(MEM/NEAA)	and	100units/ml	of	Penicillin	and	Streptomycin.	
All	cells	were	cultured	at	37°C	and	in	a	humidified	5%	CO2	atmosphere.	Confluent	cells	
were	split	for	maintenance	at	1:4-1:6	dilutions	every	2-3	days.		
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2.1.3.	DNA	transfection	
	
Transient	DNA	transfections	were	performed	using	GeneJuice®	in	all	cell	lines.	For	a	
35mm	dish,	cells	were	seeded	into	each	dish	and	incubated	overnight	at	37°C.	The	
following	day,	the	culture	medium	was	exchanged	for	1ml	of	fresh	full	DMEM.	3µl	of	
GeneJuice	was	then	added	to	100µl	of	Opti-MEM	and	mixed	gently.	After	a	5-minute	
incubation	at	room	temperature,	1µg	of	DNA	was	added	to	the	Opti-MEM	and	mixed	
gently.	The	mixture	was	then	incubated	for	20	minutes	at	room	temperature	before	
being	added	to	cells	 in	a	drop	wise	manner.	Cells	were	fixed,	harvested	or	used	for	
live-cell	imaging	24	hours	after	transfection.	
	
2.1.4.	Drug	treatments	
	
Generation	of	 PtdIns(3)P	was	 inhibited	with	 either	 a	 15-minute	 treatment	of	 1µM	
Wortmannin	 or	 a	 2	 hour	 treatment	 with	 1µM	 SAR405.	 Dynamin	 inhibition	 was	
achieved	from	a	15-minute	pre-treatment	with	30µM	Dyngo.	The	same	concentration	
of	Dyngo	was	maintained	for	the	duration	of	the	experiment.	β-adrenergic	receptors	
were	 stimulated	 with	 10nM	 Isoproterenol	 for	 the	 indicated	 time	 periods.	 EGF	
receptors	were	stimulated	with	20ng/ml	of	EGF	or	TGFα,	unless	otherwise	stated.	For	
experiments	using	fluorescent	EGF,	1µg/ml	of	EGF-AlexaFluor555	was	used.	Where	
indicated,	cells	were	serum	starved	6	hours	prior	to	growth	factor	stimulation.	
	
2.2.	Molecular	biology	
	
2.2.1.	Reagents	
	
Pfu	Ultra	II	DNA	polymerase	(#600670)	and	Deoxynucleotide	mix	(#200415-51)	were	
purchased	from	Agilent	Technologies	(Cheshire,	UK).	Agarose	powder	(#15510-019),	
DH5α	competent	cells	(#18265017)	and	S.O.C	medium	(#S1797)	were	from	Invitrogen	
(Paisley,	 UK).	 Rosetta™	 (DE3)	 competent	 cells	 (#70954)	 were	 bought	 from	Merck	
Millipore.	 Miniprep	 (#27106),	 HiSpeed	 Midiprep	 (#12643)	 and	 HiSpeed	 Maxiprep	
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(#12663),	 Gel	 extraction	 (#28704)	 kits	 and	 RNAase-free	DNAase	 (#79254)	were	 all	
purchased	 from	 Qiagen	 (Crawley,	 UK).	 All	 restriction	 endonucleases	 (RE),	 Quick	
Ligation	kit	(#M22000S),	Purple	Gel	loading	dye	(#B7025S),	100bp	(#N3231)	and	1kb	
(#N3232)	ladders	were	bought	from	New	England	Biolabs	(Herts,	UK).	TAE	buffer	(#EC-
872)	was	obtained	from	National	Diagnostics	(Hull,	UK).	All	primers	were	purchased	
from	Eurofins	MWG	Operon	(Ebersberg,	Germany).	Zero	Blunt™	TOPO™	PCR	Cloning	
Kit	 (#450031),	 pEF5/FRT/V5	 Directional	 TOPO™	 Cloning	 Kit	 (#K603501),	 TOP10	
competent	 cells	 (#C404003),	 One	 Shot®	 ccdB	 Survival™	 2	 T1R	 Competent	 Cells	
(#A10460)	 and	 Snakeskin®	 pleated	 dialysis	 tubing	 (3,500MWCO)	 (#68035)	 were	
bought	from	Fisher	Scientific	(Loughborough,	UK).	Gateway™	BP	Clonase™	II	Enzyme	
mix	 (#11789020)	 and	 Gateway™	 LR	 Clonase™	 II	 Enzyme	 mix	 (#11791020)	 were	
purchased	 from	 Life	 Technologies	 (Paisley,	 UK).	 Isopropyl	 β-D-1-
thiogalactopyranoside	(IPTG)	(#MB1008)	was	from	Melford	biolaboratories	(Suffolk,	
UK).	 Ethidium	 Bromide	 (EtBr)	 (#E1510),	 Lysozyme	 (#L6876)	 and	 Imidazole	 (#I202-
100G)	were	all	from	Sigma-Aldrich	(Dorset,	UK).	5ml	HisTrap	HP	column	(#17524801)	
and	 AKTA	 chromatography	 system	 are	 both	 from	 GE	 Healthcare	 Life	 Sciences	
(Buckinghamshire,	UK).	 pcDNA-APEX2-NES	 (#49386)	 (Lam,	Martell	 et	 al.	 2015)	 and	
pCSDEST-APEX2-GBP	 (#67651)	 (Ariotti,	 Hall	 et	 al.	 2015)	 were	 purchased	 from	
Addgene.	pcDNA3.1-AKAR4-NES	and	pcDNA3.1-ICUE3	plasmids	were	a	gift	from	Oliver	
Rocks	 (Max	Delbrück	Centre),	and	 the	pGFP-C1-Epac1-RA2	plasmid	was	a	gift	 from	
Philip	Stork	(Oregon	Health	and	Science	University).	A	summary	of	all	primers	used	can	
be	found	in	table	2.1.	
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Name	 Sequence	(5'->3')	 Length	 Tm	 GC	
content	
DG-FFYVE-
HinDIII-F	
AGAAGCTTGGCACCATGGATGTTAGCAGAGA
AGAGGCTCC		
40	 74.6	 52.5%	
DG-FFYVE-
BamHI-R	
AAGGATCCCCAGACCCAGATCCAGAAGTCCG
ATCTTCATC		
40	 74.6	 53%	
DG-ICUE3-3231F	 GGGAGGTACCTGAGGATCTATGG	 23	 64.2	 56%	
DG-ICUE3-3253R	 CCATAGATCCTCAGGTACCTCCC	 23	 64.2	 56%	
DG-ICUE3-2217F	 TGTTGTCAACCCACAGGAAG	 20	 57.3	 50%	
DG-AKAR4-1107F	 ACTAGGAGAAGACGGTAACC	 20	 57.3	 50%	
DG-APEX2-397F	 GACCTAAGGTTCCATTCCAC	 20	 57.3	 50%	
DG-CFP-NES-R	 CCTCAGGTTACAGGGTCAGGCGCTCCAGGGG
GGGCAGGGTACCTCCCTTGTACAGCTC	
58	 >75	 65.5%	
DG-HRS-N-
attB1F	
GGGGACAAGTTTGTACAAAAAAGCAGGCTGG
GGATCCACCATGGGGCGAGGCAGCGGCAC	
60	 >75	 60%	
DG-HRS-N-
attB2R	
GGGGACCACTTTGTACAAGAAAGCTGGGTGG
TCGACTCAGTCAAAGGAGATGAGC	
55	 >75	 52.7%	
DG-RfB-Fwd	 GCCTGACCCTGGACTCAACAAGTTTGTACAAA
AAAGC	
37	 75	 35.2%	
DG-RfB-Rev	 CTCGAGTTATATCAACCACTTTGTACAAG	 29	 65	 38%	
DG-APEX2-RfB-R	 GTACAAACTTGTTGAGTCCAGGGTCAGGCGC
TCCAG	
36	 >75	 56%	
	
2.2.2.	Polymerase	chain	reaction	(PCR)	
	
PCR	 was	 used	 for	 DNA	 amplification	 in	 order	 to	 clone	 the	 FYVE	 domain	 from	
pcDNA3.1-GFP-FENSFYVE	vector	and	add	a	Kozak	sequence,	a	linker	and	BamHI	and	
HindIII	restriction	sites.	This	PCR	fragment	was	 later	used	to	add	a	FYVE	domain	to	
both	cAMP	and	PKA	FRET	biosensors.	PCR	was	also	used	for	site-directed	mutagenesis	
(SDM).	The	nuclear	export	sequence	(NES)	was	re-introduced	to	pcDNA3.1-FF-AKAR4	
CFP-only	vector,	after	the	SDM	removed	the	sequence	from	the	open	reading	frame	
(ORF).	The	RA2	domain	from	the	Epac1-RA2	vector	was	also	cloned	by	PCR	in	order	to	
be	introduced	into	the	pcDNA3.1-FF-ICUE3	vector.		
Table	2.1	Summary	of	the	primers	used	for	cloning	
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A	 two-step	 PCR	was	 also	 used	 to	 create	 an	APEX2	 destination	 vector	 for	Gateway	
cloning.	 Primers	 were	 designed	 to	 amplify	 the	 enzyme	 from	 the	 pcDNA3-APEX2	
vector,	without	the	constructs	STOP	codon.	More	primers	were	designed	to	amplify	
the	RfB	cassette	such	that	the	forward	primer	had	an	over	lapping	sequence	to	the	
reverse	primer	used	to	amplify	the	APEX2	enzyme.	The	second	PCR	step	took	the	two	
PCR	fragments	along	with	the	end	primers	to	create	the	final	DNA	sequence,	which	
was	used	to	generate	the	destination	vector.	AttB	sites	were	added	to	amplified	HRS	
and	mutant	HRS	(YYFF)	to	create	gateway	compatible	PCR	fragments.	These	fragments	
were	amplified	from	pcDNA3-GFP-HRS	and	pcDNA3-GFP-HRS	(YYFF)	vectors.	
	
Finally,	 PCR	 was	 used	 to	 add	 FRT	 sites	 to	 the	 APEX2	 tagged	 HRS	 constructs	 from	
pcEXP221-APEX2-HRS	 and	 pcEXP221-APEX2-YYFF	 vectors,	 along	 with	 a	 cytosolic	
version	 of	 the	 enzyme	 from	 pcDNA3-APEX2-NES,	 to	 generate	 Flp-In	 compatible	
vectors.	 Examples	of	 the	PCR	 reactions	 and	 temperature	 cycles	used	are	 shown	 in	
tables	2.2	and	2.3	respectively.	
	
		 FFYVE	 Control	 	
Water	 Up	to	38.5µl	 38.5μl	 	
Plasmid	 -μl	 0μl	 (50ng)	
pfu	buffer	 5μl	 5μl	 	
Primer	1	 2.5μl	 2.5μl	
(0.5μM)	
Primer	2	 2.5μl	 2.5μl	
dNTPs	 0.5μl	 0.5μl	 	
HS	pfu	ultra	 1μl	 1μl	 	
Total	 50μl	 50μl	 	
	
Stage	 No.	Cycles	 Temp	 Duration	
1	 1	 95	 2	mins	
		 	 95	 30	sec	
2	 30	 55	 30	sec	
		 	 68	 1	min/kb	
3	 1	 68	 10	mins	
	
Table	2.2	Example	PCR	reaction	setup	
Table	2.3	Example	PCR	temperature	cycles	
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2.2.3.	TOPO	cloning	
	
TOPO	Blunt-end	cloning	was	used	to	generate	sub-cloning	vector	 intermediates	for	
many	of	the	DNA	fragments	that	had	been	amplified	by	PCR.	The	blunt-end	ligation	is	
catalysed	by	the	topoisomerase	I	enzyme,	which	is	covalently	ligated	to	a	phosphate	
group	at	each	end	of	a	linearized	PCR4®Blunt-TOPO	vector.	After	PCR	amplification,	
the	PCR	fragments	were	resolved	on	an	agarose	gel	and	visualised	under	UV	light.	The	
DNA	band	was	then	cut	out	from	the	gel	and	eluted	using	a	Qiagen	Gel	Extraction	kit.	
The	eluted	PCR	product	was	ligated	with	the	PCR4®Blunt-TOPO	vector	for	5	minutes	
at	room	temperature.	Resulting	cloning	vectors	were	transformed	into	TOP10	cells	as	
described	in	section	2.2.8.	
	
2.2.4.	Quick	ligation	
	
Quick	ligation	was	used	for	the	ligation	of	DNA	fragments	generated	from	RE	digestion.	
These	DNA	 fragments	were	 then	 resolved	 in	 an	 agarose	 gel	 and	 visualised	 by	UV.	
Bands	corresponding	to	the	correct	fragment	size	would	be	cut	out	and	eluted	in	the	
same	manner	described	in	the	above	section.	The	eluted	DNA	fragments	were	ligated	
at	room	temperature	for	5	minutes.	The	ligated	vectors	were	used	to	transform	DH5α	
competent	cells	as	described	in	section	2.2.8.	
	
2.2.5.	Gateway	cloning	
	
Gateway	cloning	was	performed	according	to	the	manufacturer’s	instructions.	Briefly,	
wild	type	and	mutant	HRS	were	flanked	by	attB	sites	using	PCR	as	described	in	section	
2.2.2.	This	PCR	product	was	combined	with	150ng	of	pDONR	vector	in	a	1:1	ratio.	The	
solution	was	made	up	to	8µl	with	TE	buffer	before	2µl	of	Gateway®	BP	Clonase®	 II	
enzyme	mix	was	added	to	the	mixture.	The	reaction	was	incubated	at	25°C	for	1	hour.	
2µg	of	Proteinase	K	was	added	and	the	mixture	was	incubated	for	a	further	10	minutes	
at	37°C.	The	reaction	was	then	used	to	transform	DH5α	as	described	in	section	2.2.8.	
This	recombination	reaction	resulted	in	the	generation	of	pENTR	vectors	containing	
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the	wild	 type	 and	mutant	HRS	 sequences.	 These	 vectors	were	 then	used	with	 the	
APEX2	destination	vector	to	generate	the	final	expression	vectors.	pENTR	vectors	were	
mixed	with	150ng	of	the	destination	vector	in	a	1:1	ratio	and	made	up	to	8µl	with	TE	
buffer.	2µl	of	Gateway®	LR	Clonase®	 II	enzyme	mix	was	added	to	 the	mixture.	The	
reaction	was	 incubated	for	1	hour	at	25°C.	2µg	of	proteinase	K	was	added	and	the	
mixture	was	 incubated	 for	a	 further	10	minutes	at	37°C.	DH5α	bacterial	cells	were	
transformed	with	the	LR	reaction	mixture	as	described	in	section	2.2.8.	
	
2.2.6.	Restriction	endonuclease	(RE)	digestion	
	
Generally,	 500ng	 of	 DNA	 was	 used	 for	 test	 digests	 and	 4-5µg	 was	 used	 when	
generating	 DNA	 fragments	 for	 cloning.	 Reaction	 mixtures	 were	 incubated	 for	 1-4	
hours	at	the	optimal	temperature	dictated	by	the	RE	used,	typically	this	was	37°C.		
	
2.2.7.	Agarose	gel	electrophoresis	
	
Electrophoresis	grade	agarose	powder	was	added	to	TAE	buffer	(40mM	Tris-acetate,	
1mM	 Na2-EDTA)	 and	 heated	 in	 a	 microwave	 until	 the	 agarose	 was	 completely	
dissolved.	 Prepared	 agarose	 gels	 were	 typically	 0.8-1.0%	 agarose	 (w/v).	 Ethidium	
Bromide	 (EtBr)	 was	 then	 added	 to	 a	 final	 concentration	 of	 0.5µg/ml	 to	 allow	 for	
visualisation	by	UV	light.	The	agarose	was	then	poured	and	allowed	to	cool	at	room	
temperature.	Samples	were	mixed	with	6x	sample	buffer	and	loaded	alongside	100bp	
or	 1kb	 ladders.	 DNA	 gels	 were	 resolved	 in	 a	 horizontal	 midi	 electrophoresis	 tank	
(Fisher	Scientific,	Loughborough,	UK)	using	TAE	buffer.	Gels	were	typically	run	for	40-
60	minutes	at	120V.		
	
2.2.8.	Bacteria	transformation	
	
Bacterial	transformations	were	performed	using	either	DH5α	or	TOP10	cells,	unless	
otherwise	stated.	For	each	transformation,	50µl	of	bacteria	was	thawed	on	ice	before	
having	2-3µl	of	DNA	from	a	ligation	reaction	mixture	added	to	the	cells.	The	bacteria	
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were	then	heat	shocked	by	incubation	on	ice	for	20	minutes,	1-minute	incubation	in	a	
water	bath	at	42°C,	followed	by	a	further	2	minutes	on	ice.	200µl	of	S.O.C.	medium	
was	then	added	and	the	bacteria	were	incubated	at	225	rpm	and	37°C	for	1	hour.	The	
bacterial	culture	was	then	spread	onto	LB	agar	plates	with	the	appropriate	antibiotic	
(Ampicillin:	100mg/ml	or	Kanamycin:	10mg/ml)	and	incubated	at	37°C	for	overnight.		
	
Between	4-6	colonies	were	selected	per	transformation.	Each	colony	would	be	used	
to	inoculate	5ml	of	LB	broth	with	the	appropriate	antibiotic	(Ampicillin:	100mg/ml	or	
Kanamycin:	10mg/ml)	and	incubated	for	16-18	hours	at	37°C	and	225rpm.	DNA	was	
then	purified	from	the	overnight	bacterial	culture	using	a	Qiagen	Miniprep	kit,	and	
tested	 using	 RE	 digestion.	 Positive	 colonies	were	 further	 expanded	 in	 150ml	 of	 LB	
broth	with	the	appropriate	antibiotic	and	 incubated	at	37°C	and	225rpm	for	16-18	
hours.	DNA	was	 then	purified	using	either	a	Qiagen	Midiprep	or	Maxiprep	kit.	 The	
purified	DNA	was	then	sent	for	sequencing	at	the	DNA	Sequencing	Service	(University	
of	 Dundee,	 UK).	 A	 glycerol	 stock	was	 also	made	 at	 this	 point,	 as	 described	 in	 the	
following	section.	
	
2.2.9.	Glycerol	stock	
	
5ml	 of	 overnight	 bacterial	 culture	 was	 centrifuged	 at	 3000g	 for	 5	 minutes.	 After	
discarding	the	supernatant,	the	pellet	was	re-suspended	in	2ml	of	40%	glycerol	in	LB	
broth	and	stored	at	-80°C.	
	
2.2.10.	Nanotrap	purification	
	
Rosetta	 cells	 were	 transformed	 with	 the	 vector	 containing	 the	 GFP-nanotrap	
sequence	as	described	in	section	2.2.8.	5ml	bacterial	cultures	were	added	to	500ml	LB	
broth	with	the	appropriate	antibiotic	and	were	incubated	at	37°C	and	225rpm	for	2	
hours.	Samples	were	removed	from	the	broth,	and	the	OD600	was	measured.	 If	 the	
measurement	was	below	0.6,	the	bacterial	broth	was	returned	to	the	incubator	and	
re-measured	every	30	minutes	until	 the	OD600	 reached	between	0.6	and	0.8.	1mM	
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IPTG	was	added	to	the	broth	and	incubated	for	a	further	4	hours	at	225rpm	and	37°C	
to	induce	protein	expression.	The	broth	was	then	centrifuged	for	15	minutes	at	3000g.	
The	 Supernatant	was	 removed	 and	 the	 remaining	 pellet	was	 flash	 frozen	 in	 liquid	
nitrogen	and	stored	at	-20°C	until	ready	to	be	lysed.		
	
Frozen	 pellets	were	 thawed	 on	 ice.	 The	 bacteria	were	 then	 lysed	 on	 ice	 in	 a	 lysis	
solution	 [5mM	 imidazole	 in	 IMAC	 buffer	 (20mM	 Tris	 pH	 8,	 300mM	 NaCl)	
supplemented	with	0.5mg/ml	lysozyme	and	DNAase]	and	sonicated	on	full	speed	for	
5	x	20	seconds.	The	lysates	were	then	ultra-centrifuged	at	100,000g	for	20	minutes.	
The	supernatant	was	collected	for	further	purification.	The	GFP-nanotrap	was	purified	
by	affinity	chromatography	using	a	HisTrap	column	and	increasing	concentrations	of	
imidazole	to	elute	His-tagged	proteins	from	the	column.	The	eluate	was	collected	in	1	
ml	fractions	and	analysed	by	SDS-PAGE.	The	purified	GFP-nanotrap	was	then	dialysed	
overnight	 in	 3,500	MWCO	dialysis	 tubing	 and	 dialysis	 buffer	 (25mM	HEPES	 pH7.2,	
150mM	NaCl,	0.5mM	DTT).	The	purified	protein	was	flash	frozen	in	liquid	nitrogen	and	
stored	 at	 -80°C.	 The	 nanobody	 was	 conjugated	 to	 sepharose	 beads	 according	 to	
manufactures	instructions.		
	
2.2.11.	Generation	of	Flp-In	stable	cell	lines	
	
FRT-containing	PCR	product	of	APEX2-HRS,	APEX2-YYFF	and	APEX2-NES	were	cloned	
into	 a	 pEF5/FRT/V5	 TOPO	 vector	 to	 generate	 pEF5/FRT/V5-TOPO-APEX2-NES,	
pEF5/FRT/V5-TOPO-APEX2-HRS	 and	 pEF5/FRT/V5-TOPO-APEX2-YYFF	 Flp-In	
compatible	vectors.	These	vectors	were	transfected	into	HeLa	S3	Flp-In	host	cells	along	
with	pOG44	plasmid,	to	express	the	Flp	recombinase	in	a	9:1	ratio.	Expressing	cells	
were	selected	and	maintained	using	150µg/ml	Hygromycin	B.		
	
2.2.12.	Generation	of	FRET	biosensor	expressing	cell	lines	
	
HEK293	cells	were	transfected	with	pcDNA3.1-AKAR4-NES,	pcDNA3.1-AKAR4-FF-NES,	
pcDNA3.1-ICUE4	and	pcDNA3.1-ICUE4-FF	constructs	as	described	in	section	2.1.3.	24	
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hours	after	transfection,	the	cells	were	treated	with	G418	(0.4mg/ml)	antibiotic.	They	
were	 maintained	 in	 the	 antibiotic	 for	 approximately	 two	 weeks,	 with	 the	 media	
exchanged	every	3-4	days.	Once	single	colonies	were	visible,	they	were	 individually	
picked	into	separate	wells	of	a	24-well	plate.	The	cells	were	maintained	in	antibiotic	
media.	
	
2.3.	Imaging	
	
2.3.1.	Materials	and	Reagents	
	
For	 Live-cell	 imaging,	 µ-Dish	 35mm	 (#81156)	was	 purchased	 from	Thistle	 scientific	
(Glasgow,	UK).	Hank’s	balanced	salt	solution	(HBSS)	(#14065-049)	and	HEPES	(#15630-
056)	 were	 purchased	 form	 Life	 technologies.	 4ʹ,6-diamidino-2-phenylindole	 (DAPI)	
stain	 (#D1306)	 was	 bought	 from	 Invitrogen	 (Paisley,	 UK).	 Mowiol	 (#475904)	 was	
purchased	 from	 Merck	 Millipore.	 Glutaraldehyde	 (#AGR1020),	 Osmium	 (OsO4)	
(#75632),	200	mesh	copper	grids	(#AGG2450C)	and	pioloform	(#AGR1275)	were	all	
purchased	from	Agar	Scientific	(Essex,	UK).	Uranyl	acetate	(UA)	(#U007),	Lead	citrate	
(#L018)	and	resin	(#T031)	were	from	TAAB	Laboratory	equipment	(Berkshire,	UK).	The	
dEYEmond	 Ultra	 3mm	 45°	 diamond	 knife	 (#A2013213)	 was	 bought	 from	 Scimed	
GmbH	 (Germany).	 3,3’-Diaminobenzidine	 (DAB)	 (#D5905),	 Ethanol	 (#270741),	
Chloroform	 (#288306)	 and	hydrogen	peroxide	 (H2O2)	 (#H1009)	were	 all	 purchased	
from	Sigma-Aldrich	(Dorset,	UK).	All	solutions	were	made	up	in	PBS	unless	otherwise	
stated.	
	
2.3.2.	Immunofluorescence	staining	(IF)	
	
For	immunofluorescence,	cells	were	cultured	on	glass	coverslips.	The	coverslips	were	
washed	twice	with	room	temperature	PBS,	before	being	fixed	in	4%	paraformaldehyde	
(PFA)	for	10	minutes.	The	coverslips	were	washed	twice	in	PBS	again	and	quenched	by	
a	20-minute	 incubation	 in	50mM	ammonium	chloride	 (NH4Cl).	The	cells	were	 then	
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permeabilised	with	0.2%	Triton-X	100	 in	PBS	for	4	minutes	before	being	blocked	 in	
10%	 goat	 serum	 for	 30	 minutes.	 The	 coverslips	 were	 then	 incubated	 in	 primary	
antibody	in	5%	goat	serum	for	20	minutes,	and	then	washed	in	PBS	three	times	for	5	
minutes.	 The	 secondary	 antibody	 in	 5%	 goat	 serum	 was	 then	 incubated	 with	 the	
coverslips	for	20	minutes,	followed	by	another	three	washes	in	PBS	for	5	minutes.	The	
coverslips	were	then	rinsed	in	water	and	mounted	onto	Mowiol	with	or	without	the	
addition	of	4’,6-diamidino-2-phenylindole	 (DAPI)	 stain.	All	 IF	 images	were	 taken	on	
either	a	Ziess	scanning	line	or	a	3i	Marianas	spinning	disk	confocal	microscope,	using	
a	x63	objectives	(Ziess).	A	summary	of	the	antibodies	used	for	immunofluorescence	
are	shown	in	tables	2.4	and	2.5.	
	
Target	 Species	 Source/Catalog	No.	 Incubation	conditions	
EEA-1	 mouse	 BD	Transduction	(#610456)	 PFA,	1:500,	5%	GS,	20	mins	
HRS	 rabbit	 Home	made	
(Sachse,	Urbé	et	al.	2002)	
PFA,	1:1000,	3%	BSA,	2	hrs	
Flag	 mouse	 Sigma	(#F1804)	 PFA,	1:1000,	3%	BSA,	2	hrs	
	
Sceondary	antibody	 Source/Catalog	No.	 Incubation	conditions	
Donkey	anti-mouse	AF350	 Invitrogen	(#A10035)	 1:1000,	5%	GS,	20	mins,	RT	
Donkey	anti-rabbit	AF350		 Invitrogen	(#A10039)	 1:1000,	5%	GS,	20	mins,	RT	
Donkey	anti-rabbit	AF488		 Invitrogen	(#A21206)	 1:1000,	5%	GS,	20	mins,	RT	
Donkey	anti-rabbit	AF594		 Invitrogen	(#A21207)	 1:1000,	5%	GS,	20	mins,	RT	
Donkey	anti-mouse	AF488		 Invitrogen	(#A21202)	 1:1000,	5%	GS,	20	mins,	RT	
Donkey	anti-mouse	AF594		 Invitrogen	(#A21203)		 1:1000,	5%	GS,	20	mins,	RT	
	
2.3.3.	Live-cell	imaging	
	
Live	 cell	 experiments	 were	 performed	 with	 a	 3i	 Marianas	 spinning	 disk	 confocal	
microscope	 (3i	 intelligent	 imaging	 innovations,	 Germany)	 or	 a	 Ziess	 scanning	 line	
Table	2.4	Summary	of	the	primary	antibodies	used	for	immunofluorescence	
Table	2.5	Summary	of	the	secondary	antibodies	used	for	immunofluorescence	
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confocal	microscope	where	indicated.	Cells	were	imaged	in	a	humidified	chamber	at	
37°C	and	5%	CO2,	unless	otherwise	stated.	All	cells	were	seeded	in	35mm	Ibidi	dishes	
for	imaging	on	both	the	spinning	disk	and	scanning	line	confocal	microscopes.	Images	
were	taken	with	a	x63	objective	(Ziess).	Endosome	numbers	were	counted	using	the	
Trackmate	 plug-in	 on	 ImageJ.	 Fluorescent	 intensities	 of	 endosomes	were	 analysed	
using	the	slidebook6	software	(3i).	
	
2.3.4.	FRET	imaging	
	
Cells	 were	maintained	 in	 Hank’s	 balanced	 salt	 solution	 and	 buffered	 using	 25mM	
HEPES.	Cells	were	imaged	in	a	CO2-independent,	humidified	chamber	at	37°C.	Cells	
were	treated	with	Forskolin,	IBMX,	isoproterenol,	Dyngo,	and	EGF	as	indicated	by	the	
respective	figure	legends	and	section	2.1.4.	Images	were	all	taken	on	a	3i	Marianas	
spinning	 disk	 confocal	microscope.	 For	 each	 image,	 three	 channels	were	 captured	
denoted	‘Donor’	(447-517nm	detection	range,	445nm	excitation),	‘Acceptor’	(515-569	
detection	 range,	 514nnm	 excitation)	 and	 ‘Transfer’	 (515-569nm	 detection	 range,	
445nm	excitation)	channels.	For	the	FRET	experiments,	three	fields	of	view	were	taken	
to	generate	an	average	 for	each	biological	 repeat.	The	 images	were	 then	analysed	
using	the	Slidebook	6	software	(3i).	For	endosomal	FRET	sensor	cell	lines,	a	laplacian	
filter	was	applied	to	the	acceptor	channel,	in	order	to	generate	an	endosomal	mask	
for	 analysis.	 The	 intensities	 were	 measured	 and	 background	 and	 bleed	 through	
corrected.	FRET	was	calculated	from	the	intensities	using	the	following	equation:	
	
𝐹𝑅𝐸𝑇 = 𝐼'()*+,-( − (𝐼'()*+,-((01234*56) 𝐼84*4((01234*56) 	𝑋	𝐼84*4()𝐼84*4( 	
	
‘I’	represents	intensity	for	the	indicated	channel	(Miyawaki,	Llopis	et	al.	1997).	Bleed	
through	correction	factor	calculated	from	cells	expressing	CFP-only	versions	of	each	
biosensor.		
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2.3.5.	Electron	Microscopy	(EM)	
	
HeLa	S3	Flp-In	APEX2-HRS	cells	were	fixed	in	2.5%	glutaraldehyde	in	0.1M	PB	buffer	
pH7.4	for	a	total	2	minutes	in	a	PELCO	BioWave	Pro	(Ted	Pella,	USA)	at	100W	and	20Hg	
chamber	pressure.	The	cells	were	then	incubated	in	1mg/ml	DAB	and	10mM	H2O2	for	
30	minutes	at	room	temperature.	The	cells	were	then	washed	in	1M	Cacodylate	buffer	
and	stained	using	1%	OsO4	for	a	total	of	one	minute	in	a	PELCO	BioWave	Pro	at	100W	
and	20Hg	chamber	pressure.	The	cells	were	further	stained	in	1%	UA	at	4°C	overnight.	
The	samples	were	dehydrated	 in	 increasing	concentrations	of	ethanol	before	being	
embedded	in	TAAB	medium	resin	and	cured	at	60°C	for	48	hours.	Thin	sections	(60-
70nm)	were	cut	with	a	Leica	UC6	ultramicrotome	using	a	dEYEmond	Ultra	3mm	45°	
diamond	knife,	relaxed	using	chloroform	and	mounted	on	200	mesh	copper	grids	that	
had	been	coated	with	0.3%	pioloform	in	chloroform.	Samples	were	post	stained	with	
lead	citrate	and	2%	UA.	Images	were	taken	using	a	FEI	120kV	tecnai	G2	Spirit	BioTwin	
transmission	electron	microscope	(TEM)	and	AnaySIS	software	(Olympus,	Germany).	
	
2.4.	Protein	biochemistry	
	
2.4.1.	Reagents		
	
Ponceau-S	stain	(#P7170),	Hydrogen	peroxide	(H2O2)	(#H1009),	(±)-6-Hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic	 acid	 (Trolox)	 (#238813),	Ascorbic	 acid	 (#A-7631)	
and	mammalian	protease	 inhibitor	 (MPI)	 (#P8340)	were	all	purchased	 from	Sigma-
Aldrich	(Dorset,	UK).	PhosSTOP	Phosphatase	inhibitor	cocktail	tablets	(#4906845001)	
were	purchased	from	Roche	(Sussex,	UK).	Marvel	skimmed	milk	powder	was	obtained	
from	 Premier	 Brands,	 UK.	 Pierce	 660-nm	 protein	 assay	 reagent	 (#22662)	 and	
Streptavidin	magnetic	beads	 (#88817)	were	bought	 from	Life	 technologies	 (Paisley,	
UK).	NHS-activated	Sepharose	4	Fast	Flow	beads	(#17-0906-01),	Amersham	ECL	full	
range	 rainbow	 marker	 (#RPN800E)	 and	 Amersham	 Protran	 0.45µm	 nitrocellulose	
membrane	(#10600002)	were	purchased	from	GE	healthcare	(Buckinghamshire,	UK).	
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Biotin-phenol	 (#LS-3500-0250)	 was	 from	 Iris	 Biotech	 GMBH	 and	 Sodium	 Azide	
(#AA14314-22)	 was	 from	 VWR	 (Leicestershire,	 UK).	 NuPAGE	 Bis-Tris	 4-12%	 gels	
(1.5mm	10-well:	#NP0303BOX,	1mm	20-well:	#W61402A),	NuPAGE	MOPS	(#NP0001-
02)	and	NuPAGE	MES	(#NP0002-02)	buffers	were	all	obtained	from	Invitrogen	(Paisley,	
UK).	A	summary	of	the	antibodies	used	are	shown	in	tables	2.4	and	2.5.	
	
2.4.2.	Cell	lysis	
	
Near	confluent	cells	were	washed	three	times	on	ice	with	PBS	that	had	been	chilled	to	
4°C.	The	cells	were	then	lysed	for	10	minutes	on	ice,	using	either	nonidet	P-40	(NP-40)	
lysis	buffer	(0.5%	NP-40,	25mM	Tris	pH	7.5,	100mM	NaCl,	50mM	NaF)	or	RIPA	lysis	
buffer	 (10mM	 Tris	 pH	 7.5,	 150mM	 NaCl,	 1%	 Triton-X	 100,	 0.1%	 SDS,	 1%	 sodium	
deoxycholate).	 Both	 NP-40	 and	 RIPA	 buffer	 were	 supplemented	 with	 mammalian	
protease	 inhibitor	 cocktail	 (MPI).	 For	 experiments	 looking	 at	 phosphorylation,	 a	
phosphatase	 inhibitor	 was	 also	 added	 to	 the	 lysis	 buffer.	 Lysates	 were	 then	
centrifuged	at	14,000g	for	10	minutes,	with	the	supernatant	being	collected.	Samples	
were	then	stored	at	-20°C.	
	
2.4.3.	Protein	assay	
	
The	 protein	 concentration	 of	 cell	 lysates	 was	 measured	 using	 the	 Pierce	 660-nm	
protein	 assay	 reagent.	 Protein	 assays	 were	 carried	 out	 as	 per	 the	 manufactures	
instructions.	 125µg-2,000µg	 protein	 standards	 were	 used	 to	 establish	 a	 standard	
curve.	For	very	concentrated	samples,	the	lysate	used	for	the	protein	assay	was	diluted	
1:2.	After	a	5-minute	incubation	at	room	temperature,	samples	were	read	at	OD660.	
	
2.4.4.	Proximity	labelling	
	
For	proximity	labelling,	the	APEX2	peroxidase	enzyme	was	used	in	order	to	tag	nearby	
proteins	with	Biotin-phenol	in	the	presence	of	H2O2	(Hung,	Udeshi	et	al.	2016).	When	
cells	were	 ready	 to	harvest,	 the	cell	medium	was	exchanged	 for	 fresh	 full	medium	
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containing	 500µM	 Biotin-phenol	 and	 incubated	 for	 30	 minutes	 at	 37°C.	 Unless	
otherwise	stated,	labelling	would	be	initiated	by	a	1-minute	incubation	of	1mM	H2O2	
at	room	temperature.	Immediately	afterwards,	cells	were	placed	on	ice	and	washed	
three	times	with	ice	cold	quenching	solution	(PBS	supplemented	with	10mM	sodium	
ascorbate,	5mM	Trolox	and	10mM	sodium	azide).	The	cells	were	then	lysed	using	NP-
40	 lysis	buffer	supplemented	with	MPI,	1mM	PMSF	and	quenchers	 (10mM	sodium	
ascorbate,	5mM	Trolox	and	10mM	sodium	azide).		
	
2.4.5.	Immunoprecipitation	(IP)	
	
Immunoprecipitation	 with	 GFP-nanotrap	 cross-linked	 to	 sepharose	 beads	 was	
performed	 immediately	 after	 cell	 lysis	 to	 avoid	 losing	 potential	 interactions	 from	
freeze-thaw	 cycles.	 Prior	 to	 immunoprecipitation,	 GFP-nanotrap	 sepharose	 beads	
were	pre-washed	in	whichever	lysis	buffer	was	used	to	generate	the	cell	lysates.	With	
the	 exception	 of	 titration	 experiments,	 the	 sepharose	 beads	were	 added	 to	 lysate	
samples	in	a	ratio	of	400µg	protein	sample	per	10µl	of	beads.	For	Mass	spectrometry	
experiments,	3-4mg	of	lysate	was	typically	used	per	condition.	Lysate	samples	were	
incubated	on	a	rotating	wheel	at	4°C	for	30	minutes.	The	beads	were	centrifuged	at	
1000g	 for	1	minute	at	4°C	and	washed	 three	 times	with	YP-IP	buffer	 (0.1%	NP-40,	
25mM	Tris	pH	7.5,	150mM	NaCl)	and	once	with	10mM	Tris/HCl,	pH7.5.	The	final	pellet	
was	then	re-suspended	in	1.5x	SDS-PAGE	sample	buffer	to	elute	the	proteins	bound	
to	the	beads.	
	
For	biotin	IPs,	streptavidin	magnetic	beads	were	pre-washed	in	the	same	lysis	buffer	
used	 to	generate	 lysates.	Unless	otherwise	stated,	 the	beads	were	added	 to	 lysate	
samples	 in	a	 ratio	of	360µg	of	protein	 lysate	 for	30µl	of	magnetic	beads.	For	Mass	
spectrometry	experiments,	2-3mg	of	lysate	was	typically	used	per	condition,	which	are	
combined	prior	 to	 the	streptavidin	pulldown.	Lysates	were	 incubated	on	a	 rotating	
wheel	at	room	temperature	for	1	hour.	The	beads	were	then	pelleted	on	a	magnetic	
rack	for	1	minute.	For	each	wash	step,	the	wash	buffer	was	added	to	the	beads,	the	
tubes	were	vortexed	and	incubated	for	1	minute	before	being	pelleted	again	on	the	
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magnetic	rack.	The	beads	were	washed	twice	with	RIPA	buffer,	once	with	1M	KCl,	once	
with	0.1M	Na2CO3,	once	with	8M	Urea	in	10mM	Tris-HCl	pH	8.0	and	finally	twice	again	
with	RIPA	buffer.	 The	proteins	were	eluted	 from	 the	beads	with	3x	 sample	buffer,	
2mM	biotin	and	20mM	DTT	for	10	minutes	at	98°C.	
	
2.4.6.	Sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)	
	
Proteins	were	resolved	by	SDS-PAGE	using	precast	NUPAGE	4-12%	Bis-Tris	gels.	Prior	
to	loading,	protein	samples	were	standardised	to	the	same	concentration	and	mixed	
with	5x	sample	buffer	and	heated	to	98°C	for	10	minutes.	In	general,	20µg	of	boiled	
protein	samples	were	loaded	in	each	well,	depending	on	the	abundance	of	the	protein	
of	 interest.	 For	 IP’s	 all	 of	 the	 eluted	 protein	 sample	 would	 be	 loaded	 for	 each	
condition.	Rainbow	protein	ladder	would	be	loaded	alongside	protein	samples.	Protein	
separation	was	typically	performed	at	200V	for	55-60	minutes	in	MOPS	running	buffer,	
for	small	molecular	weight	proteins,	MES	running	buffer	would	be	used	instead.	
	
2.4.7.	Western	blotting	
	
For	 Western	 blotting,	 proteins	 were	 transferred	 from	 polyacrylamide	 gels	 onto	
0.45µm	 Protran	 nitrocellulose	 membranes.	 This	 was	 performed	 in	 transfer	 buffer	
(200ml	ethanol,	800ml	water,	14.4g	Glycine	and	3.03g	Tris)	ran	at	a	constant	current	
of	0.9A	and	24V	for	1	hour	in	a	genie	blotter.	After	being	transferred,	the	nitrocellulose	
membrane	was	stained	with	Ponceau-S	stain	to	check	the	transfer	efficiency,	equal	
loading	of	wells	and	DNA	contamination.	The	Ponceau-S	stain	was	washed	off	with	
either	PBS	or	TBS	before	being	blocked	in	5%	Marvel	milk	powder	in	either	PBS	or	TBS	
containing	0.1%	tween-20	(w/v)	 (PBS-T	or	TBS-T),	unless	otherwise	stated,	at	 room	
temperature	 for	 1	 hour.	 The	 membrane	 was	 then	 incubated	 in	 primary	 antibody	
according	 to	 the	 conditions	 described	 in	 table	 2.6.	 Unused	 primary	 antibody	 was	
removed	by	 three	5-minute	washes	 in	PBS-T	or	TBS-T,	 followed	by	 incubation	with	
IRDye	 conjugate-secondary	 antibodies	 (LI-COR	 Biosciences)	 for	 1	 hour.	 The	
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membranes	 were	 washed	 as	 above	 and	 visualised	 on	 a	 LI-COR	 Odessey	 imaging	
system.	A	summary	of	the	antibodies	used	are	shown	in	tables	2.6	and	2.7.	
	
Target	 Species	 Source/Catalog	No.	 Incubation	conditions	
EEA-1	 Mouse	 BD	Transduction	
(#610456)	
1:1000,	5%	milk	in	PBS-T,	o/n,	
4°C	
EEA-1	 Rabbit	 Home	made	(MILLS,	
JONES	et	al.	1998)	
1:1000,	5%	milk	in	PBS-T,	o/n,	
4°C	
HRS	 Goat	 Everest	Biotech	
(#EB07211)	
1:2000,	5%	milk	in	PBS-T,	o/n,	
4°C	
STAM2	 Rabbit	 Home	made	(Row,	
Clague	et	al.	2005)	
1:1000,	5%	milk	in	PBS-T,	o/n,	
4°C	
PY334-HRS	 Rabbit	 Home	made	(Urbé,	
Sachse	et	al.	2003)	
1:1000,	5%	milk	in	TBS-T,	o/n,	
4°C,	(blocked	5%	BSA	in	TBS-T)	
Actin	 Rabbit	 Sigma	(#A2266)	 1:10,000,	5%	milk	in	PBS-T,	1	hr,	
RT	
Actin	 Mouse	 Abcam	(#Ab6276)	 1:10,000,	5%	milk	in	PBS-T,	1	hr,	
RT	
GFP	 Sheep	 Home	made	(Prior,	
Harding	et	al.	2001)	
1:5000,	5%	milk	in	PBS-T,	1	hr,	
RT	
Flag	 Rabbit	 Sigma	(#F4725)	 1:1000,	5%	milk	in	PBS-T,	o/n,	
4°C	
	
Sceondary	antibody	 Source/Catalog	No.	 Incubation	conditions	
Donkey	anti-mouse	IRDye	800CW	 LICOR	(#926-32212)	 1:10,000,	5%	milk	in	
PBS-T,	1h,	RT	
Donkey	anti-mouse	IRDye	680CW	 LICOR	(#926-32222)	 1:10,000,	5%	milk	in		
PBS-T,	1h,	RT	
Donkey	anti-rabbit	IRDye	800CW	 LICOR	(#926-32213)	 1:10,000,	5%	milk	in	
PBS-T,	1h,	RT	
Donkey	anti-rabbit	IRDye	680CW	 LICOR	(#926-32223)	 1:10,000,	5%	milk	in	
PBS-T,	1h,	RT	
Donkey	anti-sheep	IRDye	800CW	 LICOR	(#926-32214)	 1:10,000,	5%	milk	in	
PBS-T,	1h,	RT	
Donkey	anti-sheep	IRDye	680CW	 LICOR	(#926-32224)	 1:10,000,	5%	milk	in	
PBS-T,	1h,	RT	
Table	2.7	Summary	of	the	secondary	antibodies	used	for	western	blotting	
Table	2.6	Summary	of	the	primary	antibodies	used	for	western	blotting	
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2.5.	Mass	spectrometry	(MS)	
	
2.5.1.	Reagents	
	
L-Lysine	and	L-Arginine	free	DMEM	(#D633)	were	purchased	from	DC	biosciences	and	
the	FBS	(#FB-1001D/500)	was	from	Biosera	(France).	All	amino	acids	used	for	SILAC	
labelled	 media	 (Lys,	 #L8662;	 Arg,	 #A-8094;	 Pro,	 #P5607;	 Lys4,	 #616192;	 Arg6,	
#643440;	Lys8,	#608041;	Arg10,	#609033)	and	Iodoacetamide	(IAA)	(#T-6125)	were	
purchased	 from	 Sigma-Aldrich,	 (Dorset,	 UK).	 Dithiothreitol	 (DTT)	 (#MB1015)	 was	
purchased	 from	Melford	 biolaboratories	 (Suffolk,	 UK).	 Coomassie	 stain	 (#46-5034)	
was	 obtained	 from	 Invitrogen.	 LoBind	 Eppendorf	 tubes	 (#022431081)	 are	 from	
Eppendorf	(Hamburg,	Germany).	HPLC	grade	water	(#23595328),	HPLC	grade	formic	
acid	 (#20318.297)	and	HPLC	grade	acetonitrile	 (ACN)	 (#20060320)	were	all	bought	
from	VWR	(Leicestershire,	UK).	Mass	spectrometry	grade	Trypsin	Gold	(#V5280)	was	
purchased	from	Promega	(WI,	USA).	
	
2.5.2.	Stable	isotope	labelling	by	amino	acids	in	cell	culture	(SILAC)	
	
HeLa	 S3	 Flp-In	 cell	 lines	were	 cultured	 in	 either	 ‘Light’,	 ‘Medium’	 or	 ‘Heavy’	 SILAC	
medium	 for	 at	 least	 two	 weeks	 (6	 passages)	 prior	 to	 experimentation	 to	 ensure	
optimal	isotope	labelling.	SILAC	medium	was	made	up	of	DMEM	supplemented	with	
10%	 dialysed	 FBS	 and	 amino	 acids	 to	 generate	 the	 ‘Light’,	 ‘Medium’	 or	 ‘Heavy’	
labelling.	These	amino	acids	are:	‘Light’	(L-Lysine,	Lys-0;	L-Arginine,	Arg-0;	L-Proline,	
Pro-0),	 ‘Medium’	 (L-Lysine-2H4,	 Lys-4;	 L-Arginine-13C6,	 Arg-6;	 L-Proline,	 Pro-0)	 and	
‘Heavy’	(L-Lysine-2H6-15N2,	Lys-8;	L-Arginine-13C6-15N2,	Arg-10;	L-Proline,	Pro-0).		
	
2.5.3.	In-gel	digest	
	
Lysates	were	prepared	as	indicated	in	the	relevant	chapter,	according	to	the	methods	
outlined	 in	 sections	 2.4.2,	 2.4.3,	 2.4.4	 and	 2.4.5.	 Protein	 samples	 were	 run	 on	 a	
NUPAGE	4-12%	gel,	as	described	in	section	2.4.6.	The	gel	was	then	fixed	and	stained	
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by	using	a	coomassie	stain	as	per	the	manufactures	instructions.	The	gel	was	washed	
in	water	overnight	to	remove	the	excess	stain.	The	loaded	lane	was	then	cut	into	bands	
and	diced	 into	 small	 pieces	using	a	 stainless	 steel	blade.	 The	gel	pieces	were	 then	
transferred	 to	 LoBind	 Eppendorf	 tubes	 and	 de-stained	 using	 a	 solution	 of	 50mM	
ammonium	bicarbonate	and	50%	acetonitrile	(ACN)	for	10	minutes	at	37°C.	The	de-
staining	step	was	repeated	until	all	the	stain	was	removed	from	the	gel	pieces.	The	gel	
pieces	 were	 then	 dehydrated	 in	 100%	 ACN	 for	 5	 minutes.	 The	 supernatant	 was	
discarded	and	the	gel	pieces	were	placed	in	a	speed	vacuum	for	a	further	5	minutes.	
10mM	DTT	in	100mM	ammonium	bicarbonate	was	added	to	the	gel	pieces	in	order	to	
reduce	 the	 protein	 samples.	 The	 gel	 pieces	 were	 incubated	 at	 56°C	 for	 1	 hour,	
followed	by	a	30-minute	incubation	in	50mM	iodoacetamide	in	100mM	ammonium	
bicarbonate	 at	 room	 temperature.	 Band	 pieces	 were	 then	 washed	 with	 100mM	
ammonium	bicarbonate	 for	15	minutes,	before	being	dehydrated	again	with	100%	
ACN	for	5	minutes	and	5	minutes	in	a	speed	vacuum.	The	proteins	within	the	gel	pieces	
were	digested	by	 incubation	with	 trypsin	diluted	 in	40mM	ammonium	bicarbonate	
and	9%	ACN	at	37°C	for	16	hours,	at	a	trypsin:	protein	ratio	of	1:25.		
	
2.5.4.	Peptide	extraction	
	
Once	the	trypsin	digestion	has	been	completed,	an	equal	volume	of	ACN	was	added	
to	each	tube	and	incubated	at	30°C	for	30	minutes.	The	supernatant	of	each	tube	was	
then	transferred	to	a	fresh	LoBind	Eppendorf	tube.	The	gel	pieces	were	then	incubated	
for	20	minutes	in	1%	formic	acid.	The	supernatant	was	transferred	to	the	collection	
tube.	 The	 formic	 acid	 incubation	was	 repeated	 once	more	 before	 100%	 ACN	was	
added	to	the	gel	pieces	for	10	minutes.	The	supernatant	was	once	again	transferred	
to	 the	 collection	 tube.	 The	 collection	 tubes	 containing	 the	 peptide	 samples	 were	
placed	in	the	speed	vacuum	until	all	the	liquid	had	evaporated.	Peptide	samples	were	
re-suspended	in	25μl	of	1%	formic	acid	prior	to	mass	spectrometry	analysis.	
	
2.5.5.	Detection	and	identification	
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Peptides	were	separated	using	a	nanoACQUITY	UPLC	system	(Waters)	coupled	to	a	
Proxeon	nanoelectrospray	source	and	LTQ-Orbitrap	XL	mass	spectrometer	(Thermo	
Fisher).	4µl	of	each	sample	was	loaded	onto	a	180µm	x	20mm,	5µm	C18	symmetry	
trapping	 column	 (Waters)	 in	 0.1%	 formic	 acid	 at	 10-15µl/min.	 Peptides	were	 then	
resolved	 on	 a	 25cm	 x	 75µm	BEH-C18	 column	 (Waters)	 on	 an	 ACN	 gradient	 and	 a	
300nl/min	flow	rate.	Mass	spectrometry	spectra	(m/z	300-2000)	were	obtained	at	a	
resolution	 of	 30,000	 and	 collision	 energy	 at	 35%,	 30ms.	 The	 top	 five	 ions	 were	
subjected	to	MS/MS	in	the	linear	quadrapole	ion	trap.	All	spectra	were	acquired	using	
the	Xcalibur	 software	 (Thermo	Fisher).	MS	 spectra	were	 analysed	using	MaxQuant	
(version	 1.5.3.8)	 using	 default	 settings,	 with	 additional	 SILAC	 labelling	 and	 biotin	
variable	modification.	 	
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Chapter	 three:	 Analysis	 of	 the	 HRS	
interactome	 in	 response	 to	growth	 factor	
stimulation	
	
The	 purpose	 of	HRS	 phosphorylation	 in	 response	 to	 growth	 factor	 stimulation	 has	
remained	elusive,	despite	being	a	topic	that	has	been	studied	on	numerous	occasions	
(Urbé,	Mills	et	al.	2000,	Row,	Clague	et	al.	2005,	Stern,	Visser	Smit	et	al.	2007,	Meijer,	
van	 Rotterdam	 et	 al.	 2012).	 HRS	 is	 highly	 phosphorylated	 in	 response	 to	 EGF	
stimulation	(Bache,	Raiborg	et	al.	2002,	Omerovic,	Hammond	et	al.	2012),	but	previous	
work	 from	 my	 laboratory	 has	 shown	 this	 to	 have	 little,	 to	 no,	 effect	 on	 EGFR	
degradation	kinetics.	One	alternative	function	could	be	that	HRS	acts	as	a	signalling	
adaptor	and	that	phosphorylation	of	the	protein	could	change	the	suite	of	proteins	
present	at	the	endosome.		
	
Preliminary	 results	 from	 our	 laboratory	 investigated	 this	 idea	 by	 examining	 the	
differences	in	binding	partners	between	GFP-tagged,	HRS	(WT)	and	a	phosphorylation	
mutant	(YYFF),	which	has	had	tyrosine	residues	329	and	334	mutated	to	phenylalanine	
residues.	The	approached	used	stable	cell	 lines	generated	with	the	Flp-In	system	to	
express	the	GFP-tagged	proteins	at	near	endogenous	levels.	Previous	studies	looking	
into	the	role	of	these	phosphorylation	sites	have	often	used	over-expression	in	their	
studies,	which	can	lead	to	misinterpretation.	The	binding	partners	were	then	assessed	
by	 performing	 immunoprecipitation	 (IP)	 using	 a	 polyclonal	 anti-GFP	 antibody	 with	
SILAC	labelled	cells	and	analysed	by	mass	spectrometry.		
	
This	data	 indicated	a	 collection	of	hetero-trimeric	G-proteins,	 along	with	 the	 small	
GTPase	Rac1,	binding	to	HRS,	with	the	G-proteins	being	enriched	in	the	WT	condition	
compared	to	the	YYFF	mutant	(Liu,	unpublished	data).	A	follow-up	experiment	using	a	
HRS	antibody	against	the	endogenous	protein	found	Rac1	and	the	same	collection	of	
G-proteins	 enriched	 in	 the	 EGF	 stimulated	 condition	 compared	 to	 the	 starved	
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condition	 (Liu,	 unpublished	 data),	 suggesting	 that	 these	 interactions	 are	 EGF	
dependent.		
	
However,	inconsistencies	exist	between	the	individual	repeats	of	the	experiments	that	
needed	resolving.	It	may	be	possible	to	improve	reproducibility	by	using	a	less	variable	
antibody.	One	alternative,	 is	 to	use	the	GFP-nanotrap.	This	 is	a	 ‘nanobody’	derived	
from	the	hypervariable	region	of	a	Llama	antibody	(Rothbauer,	Zolghadr	et	al.	2008,	
Beghein	and	Gettemans	2017).	Antibodies	from	Camelidae	species	are	comprised	of	a	
single	 amino	 acid	 chain,	 in	 comparison	 to	 the	 two	 heavy	 and	 two	 light	 chains	 of	
conventional	 antibodies.	 The	nanobody	 is	 then	expressed	 from	a	bacterial	 plasmid	
enabling	it	to	be	purified	in	large	quantities,	whilst	experiencing	less	batch-to-batch	
variation.	Furthermore,	the	GFP-nanotrap	has	been	shown	to	identify	binding	partners	
by	proteomic	analysis	with	higher	efficiency	compared	to	conventional	GFP-antibodies	
(Galan,	Paris	et	al.	2011).	
	
One	of	the	larger	challenges	faced	with	this	experiment,	is	the	fact	that	it	is	pushing	
the	boundary	of	the	signal-to-noise	ratio.	This	is	likely	due	to	the	transient	nature	of	
the	interactions	we	are	trying	to	identify.	Previous	studies	into	the	binding	partners	of	
HRS	 have	 only	 identified	 a	 few	 strong	 interactors,	 namely	 STAM1/2	 and	 Eps15	
(Roxrud,	Raiborg	et	al.	2008,	Huttlin,	Ting	et	al.	2015).	However,	it	is	known	that	HRS	
interacts	 with	 many	 more	 proteins,	 for	 example,	 through	 Yeast	 two	 hybrid	 (Y2H)	
experiments,	HRS	has	been	shown	to	bind	to	TSG101	(Pornillos,	Higginson	et	al.	2003).	
HRS	also	contains	a	ubiquitin	interacting	motif	and	is	important	for	the	trafficking	of	
ubiquitylated	 receptors,	 yet	 no	 receptors	 have	 been	 shown	 to	 bind	 to	 HRS	 by	
traditional	 IP	 techniques.	 It	 is	possible	 that	 these	potential	 interacting	partners	are	
binding	only	very	weakly,	and	therefore	transiently,	to	HRS.		
	
APEX2	is	the	second	generation	of	a	modified	peroxidase	enzyme	from	the	soy	bean	
plant	(Martell,	Deerinck	et	al.	2012,	Lam,	Martell	et	al.	2015).	The	APEX2	enzyme	is	
able	to	create	phenoxyl	free	radicals	from	Biotin	phenol	in	the	presence	of	H2O2	and	
is	 used	 in	 proximity-labelling	 of	 proteins	 (Hwang	 and	 Espenshade	 2016).	 The	
advantage	of	using	this	enzyme	over	other	enzymes	used	for	proximity-labelling,	such	
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as	BirA,	 is	that	 it	has	a	much	higher	activity	 level	and	can	label	proteins	with	Biotin	
within	minutes,	as	opposed	to	hours	with	BirA	(Mehta	and	Trinkle-Mulcahy	2016).	This	
allows	for	greater	time	resolution	and	to	study	changes	to	interacting	partners	as	a	
result	of	an	acute	treatment.	Proximity-labelling	should	allow	for	better	identification	
of	transiently	interacting	proteins	as	these	proteins	can	now	be	enriched	through	a	
direct	interaction	between	the	biotin	modification	and	streptavidin	conjugated	beads	
(Hung,	Udeshi	et	al.	2016).		
	
3.1.	Objectives:	
	
The	primary	objective	of	 this	chapter	was	 to	 investigate	 the	potential	difference	 in	
interacting	 partners	 between	 wild	 type	 HRS	 and	 the	 tyrosine	 point	 mutant	 under	
conditions	 of	 EGF	 stimulation,	 in	 order	 to	 assess	 the	 role	 of	 phosphorylation	 at	
Y329/334.	 The	 secondary	 objective	 of	 this	 chapter	was	 to	 assess	 the	 suitability	 of	
proximity-ligation	techniques	for	use	with	mass	spectrometry.		
	
3.2.	Results	
	
3.2.1.	Purification	of	GFP-nanotrap	antibody	
	
I	 began	 by	 purifying	 the	 GFP-nanotrap	 in	 order	 to	 conjugate	 the	 nanobody	 to	
sepharose	beads.	The	GFP-nanotrap	plasmid	was	introduced	into	E.	coli	and	induced	
with	 IPTG.	After	 the	 cells	were	 lysed	by	 sonication,	 the	GFP-nanotrap	was	purified	
using	an	imidazole	gradient	on	a	His-Trap	column.	The	purification	of	the	nanobody	is	
shown	 in	 Figure	3.1.	A	 single	 large	peak	 is	 seen	on	 the	UV	 trace	 (blue	 line)	 as	 the	
concentration	 of	 imidazole	 increases.	 The	 flow-through	 was	 collected	 into	 1ml	
fractions,	indicated	by	the	red	strokes	on	Figure	3.1(A).	The	two	larger	strokes	indicate	
the	fractions	taken	from	the	purification.	Samples	of	these	fractions	were	taken	for	
analysis	by	SDS-PAGE	(Figure	3.1(B)).		
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Samples	 from	 every	 stage	 of	 the	 purification	 process	 have	 been	 taken	 to	 quality	
control	the	purification	process	(Figure	3.1(C)).	The	+/-	IPTG	conditions	represent	the	
protein	abundance	in	the	bacteria	before	and	after	induction	of	the	GFP-nanotrap	by	
IPTG.	The	nanobody	is	13KDa	in	size,	which	is	clearly	shown	to	be	induced	by	IPTG,	
along	 with	 several	 other	 large	 bands.	 After	 lysis,	 the	 bacterial	 solution	 was	
ultracentrifuged.	Samples	from	both	the	supernatant	and	pellet	from	this	step	were	
retained	for	analysis.	This	step	removes	one	of	the	large	unspecific	bands.	A	portion	
of	the	GFP-nanotrap	also	appears	to	be	removed	at	this	step.	The	bound	and	unbound	
fractions	represent	the	proteins	which	were	passed	through	the	His-Trap	column.	The	
fractions	analysed	in	Figure	3.1(B)	are	pooled	to	generate	the	bound	fraction	in	Figure	
3.1(C).	The	vast	majority	of	the	unspecific	bands	are	removed	by	the	His-Trap	column,	
leaving	a	relatively	pure	batch	of	the	GFP-nanotrap.		
	
After	conjugating	the	nanobody	to	sepharose	beads,	a	quality	control	experiment	was	
performed	to	optimise	the	ratio	of	lysate-to-beads	needed	to	obtain	the	best	results	
for	immunoprecipitation	(IP).	GFP-HRS	expressing	HeLa	cells	were	harvested	for	the	
IP,	 with	 varying	 amounts	 of	 the	 protein	 lysate	 added	 to	 10µl	 of	 sepharose	 beads	
(Figure	 3.1(D)).	 Similar	 amounts	 of	 GFP-tagged	 HRS	 are	 pulled	 down	 across	 all	
conditions.	In	the	unbound	fraction,	increasing	amounts	of	GFP-HRS	are	seen	as	the	
protein	amounts	increase.	Only	small	amounts	can	be	seen	in	the	unbound	fraction	of	
the	100µg	and	200µg	conditions.	The	intensity	of	the	800µg	and	1000µg	bands	are	
much	larger,	indicating	that	the	beads	are	saturated	with	material.	A	moderate	band	
can	be	seen	with	the	400µg	condition	and	as	such,	 it	was	decided	that	this	ratio	of	
lysate-to-beads	was	to	be	used	in	future	experiments.	This	condition	will	ensure	that	
the	beads	have	bound	to	as	much	material	as	possible.	
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Figure	3.1	Purification	of	GFP-nanotrap.	(A)	Affinity	chromatography	UV	trace	(blue	
line)	 taken	 during	 the	 elution	 of	 the	 GFP-nanotrap	 off	 a	 His-Trap	 column	 with	
increasing	 concentrations	 of	 imidazole	 (green	 line).	 Red	 ticks	 represent	 the	
collected	fractions.	(B)	SDS-PAGE	of	the	fractions	indicated	by	the	two	larger	red	
ticks	 in	 (A).	 (C)	SDS-PAGE	analysis	of	samples	 taken	at	various	points	during	the	
purification	process.	The	bound	fraction	represents	the	pooling	of	the	fractions	in	
(B).	(D)	GFP-HRS	cell	line	lysate	titration	for	the	GFP-nanotrap	after	conjugation	to	
sepharose	beads.	
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3.2.2.	Characterisation	of	GFP-cell	lines	
	
For	these	experiments,	the	GFP-tagged	cell	lines	described	above	were	used.	These	
cell	lines	include	a	GFP	only	control	and	GFP	tagged	to	both	the	wild	type	HRS	and	the	
phosphorylation	mutant	YYFF.	These	cell	lines	were	counter	stained	with	an	anti-EEA1	
antibody.	As	shown	in	Figure	3.2(A),	both	the	wild	type	and	the	mutant	HRS	localise	
to	endosomes	that	overlap	with	EEA1	positive	endosomes.	By	immunofluorescence,	
no	defects	or	differences	can	be	seen	in	the	localisation	in	the	mutant	HRS	compared	
to	the	wild	type.		
	
The	purpose	of	using	the	Flp-In	system	to	generate	the	GFP	cell-lines,	was	to	create	
isogenic	cell	lines	that	express	the	tagged	proteins	at	equal	levels,	which	are	at	near	
endogenous	 levels.	As	previously	mentioned,	over-expression	of	HRS	 can	 lead	 to	a	
dominant	negative	phenotype	in	the	normal	trafficking	and	degradation	of	receptors.	
The	levels	of	HRS	were	assessed	in	all	the	cell	lines	by	western	blotting.	The	GFP	tag	
on	 the	 proteins	 we	 have	 introduced	 increases	 their	 molecular	 weight	 and	 so	 the	
endogenous	and	GFP-tagged	proteins	can	be	differentiated	by	gel	electrophoresis.	As	
shown	by	the	blot	in	Figure	3.2(B),	the	total	levels	of	HRS	in	the	wild	type	cell	line	and	
the	mutant	cell	line	are	similar	to	the	levels	of	HRS	in	the	GFP	only	control.	Expression	
of	the	GFP-tagged	HRS	leads	to	a	reduction	in	the	endogenous	HRS	levels,	with	the	
majority	of	the	total	HRS	pool	in	these	cell	lines	made	up	of	the	tagged	proteins	that	
are	being	expressed.		
	
Next,	the	ability	of	the	GFP-tagged	HRS	proteins	to	be	phosphorylated	was	assessed.	
This	was	achieved	by	stimulating	the	cell	lines	with	20ng/ml	of	EGF	for	the	indicated	
time	points.	Phosphorylation	of	the	residual	endogenous	HRS	can	be	seen	in	all	the	
cell	 lines,	 with	 peak	 phosphorylation	 occurring	 at	 8	 minutes.	 The	 signal	 then	
diminishes	 after	 30	 minutes	 of	 stimulation.	 In	 addition	 to	 the	 endogenous	 HRS,	
phosphorylation	to	the	GFP-tagged	HRS	can	be	seen	in	the	wild	type	cell	line	but	not	
in	the	YYFF	mutant.	As	the	phospho-antibody	is	targeted	to	the	tyrosine	sites	that	have	
been	mutated	in	the	mutant	cell	line,	the	absence	of	the	phosphorylation	bands	in	the	
up-shifted	position	for	the	mutant	cell	line	was	expected	(Figure	3.2(C)).	
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Further	 optimisation	 was	 undertaken	 for	 the	 following	 experiments.	 The	
concentration	of	EGF	was	titrated	to	ensure	a	high	enough	concentration	was	being	
used	 to	obtain	 full	phosphorylation	without	over	saturating	 the	signalling	pathway.	
The	cell	lines	were	stimulated	with	the	indicated	concentrations	of	EGF	for	8	minutes	
and	then	blotted	for	with	an	anti-phospho-HRS	antibody.	As	seen	in	Figure	3.2(D),	peak	
phosphorylation	was	seen	with	20ng/ml	and	40ng/ml	concentrations.	Although	the	
40ng/ml	condition	appeared	to	exhibit	slightly	higher	levels	of	phosphorylation	than	
the	20ng/ml	condition,	the	increase	was	only	small	and	suggests	that	40ng/ml	would	
Figure	3.2	GFP-Cell	line	characterisation	and	optimisation.	(A)	HeLa	S3	Flp-In	cells	
stably	 expressing	GFP-tagged	 constructs	 co-stained	with	 an	 anti-EEA1	 antibody.	
Scale	bar	=	10µm	(B)	Western	blot	assessing	the	relative	levels	of	GFP-tagged	HRS	
constructs	compared	to	endogenous	levels.	Values	normalised	to	HRS	levels	of	GFP	
control.	 N	 =	 3.	 Error	 bars	 represent	 standard	 deviation.	 One-way	 ANOVA	 with	
Tukey’s	multiple	comparisons	test,	*	P	<	0.01,	**	P	<	0.0001.	(C&D)	HeLa	S3	GFP	
Flp-In	cells	were	serum	starved	for	6	hours	and	then	(C)	stimulated	with	20ng/ml	
EGF	 for	 the	 indicated	 time	 periods,	 or	 (D)	 stimulated	 for	 8	 minutes	 with	 the	
indicated	concentration	of	EGF.		
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be	an	over-saturating	concentration	of	EGF.	Hence,	 for	the	remaining	experiments,	
20ng/ml	of	EGF	will	be	used	whenever	the	cells	are	stimulated	with	the	growth	factor.	
	
3.2.3.	GFP	cell	line	mass	spectrometry	results	
	
To	analyse	the	differences	in	interacting	partners	between	wild	type	HRS	and	mutant	
HRS,	the	GFP-tagged	cell	lines	were	assessed	by	mass	spectrometry.	Each	cell	line	was	
grown	in	a	separate	SILAC	media	for	two	weeks,	with	the	GFP	only	control	 labelled	
with	‘light’	media	(Lys	0,	Arg	0),	the	wild	type	cell	line	labelled	with	‘medium’	media	
(Lys	4,	Arg	6),	and	the	mutant	cell	line	labelled	with	‘heavy’	media	(Lys	8,	Arg	10).	See	
section	2.5.2	for	more	details	on	the	SILAC	labelling.	After	stimulation	with	20ng/ml	of	
EGF	for	8	minutes,	the	cell	 lines	were	immunoprecipitated	(IP)	separately	using	the	
GFP-nanobody	conjugated	to	sepharose	beads.	The	elutions	were	then	mixed	1:1:1	
and	process	for	mass	spectrometry	(see	schematic	in	Figure	3.3(A)).	Cells	were	serum	
starved	for	6	hours	prior	to	stimulation.	
	
Comparing	the	wild	type	cell	lines	to	the	GFP	control	(Figure	3.3(B)),	we	can	see	the	
largest	enrichments	in	the	wild	type	cell	line	from	the	GFP	IP	are:	HRS,	STAM,	STAM2	
and	 the	 ribosomal	 protein,	 RPL14.	 Apart	 from	 these	 well-established	 interacting	
proteins,	no	other	proteins	(except	RPL14)	showed	any	significant	enrichment	outside	
the	 background	 signal	 seen	 around	 the	 baseline.	 The	 same	 can	 be	 seen	 with	 the	
mutant	cell	line,	when	compared	to	the	GFP	only	control	cells.	A	handful	of	proteins	
are	indicated	as	significantly	de-enriched	in	the	mutant	cell	line,	though	only	to	a	small	
degree.	These	are:	an	actin-like	protein	ACTL8,	an	uncharacterised	protein	and	the	
proteasome	complex	subunit	PSME1.	Both	of	these	de-enrichments	can	possibly	be	
explained	by	untagged	GFP	being	more	like	to	interact	with	these	proteins	due	to	its	
cytosolic	localisation.			
	
	Assessing	this	experiment	from	a	technical	standpoint,	we	have	to	conclude	that	 it	
was	successful.	HRS	and	STAM	give	the	experiment	an	internal	control.	These	proteins	
interact	together	strongly	and	are	well	established.	Since	these	proteins	are	enriched	
in	 both	 the	wild	 type	 and	mutant	 cell	 lines,	 the	 results	 cannot	 be	discounted	 as	 a	
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mistake	in	performing	the	experiment.	The	proteins	identified	in	this	experiment	to	
be	significantly	altered	between	conditions	appear	to	be	of	little	biological	relevance	
in	the	context	HRS	function.	
	
	
	
The	results	described	above	suggest	that	any	potential	interaction	with	the	G-proteins	
would	be	very	weak	and	transient.	It	may	be	that	these	interactions	are	too	transient	
to	 be	 reliably	 detected	 by	 traditional	 IP	 techniques.	 As	 a	 result,	 proximity-ligation	
Figure	 3.3	 GFP-HRS	 interactome	 in	 EGF	 stimulated	 HeLa	 S3	 Flp-In	 cells.	 (A)	
Workflow	of	the	SILAC	experiment	using	the	stable	GFP	cell	lines.	In	gel	digest	was	
carried	 out	 on	 the	 samples	 prior	 to	 analysis	 with	 LC-MS/MS.	 Log2	 transformed	
ratios	plotted	against	Log10	transformed	intensities	for	(B)	GFP-HRS	versus	GFP,	(C)	
GFP-YYFF	 versus	GFP	 and	 (D)	GFP-HRS	 versus	GFP-YYFF.	 Filled	 circles	 represent	
proteins	which	show	significant	ratio	changes.	Significance	B,	false	discovery	rate	
(FDR)	<	0.05.	
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techniques	were	employed	to	attempt	to	detect	these	transient	interactions.	Out	of	
the	various	methods	for	proximity-ligation,	the	APEX2	enzyme	was	chosen	over	the	
promiscuous	BirA	enzyme	used	in	the	BioID	system.	The	reason	for	this	is	because	the	
APEX2	enzyme	allows	for	greater	time	resolution	than	BioID,	since	APEX2	has	been	
shown	to	tag	proteins	with	biotin	within	minutes,	as	opposed	to	hours	with	the	BirA	
enzyme	(Trinkle-Mulcahy	2019).	
	
Further	to	this,	a	tool	has	been	developed	that	combines	the	APEX	enzyme	with	the	
GFP-nanotrap	for	faster	screening	of	any	GFP-tagged	protein	by	electron	microscopy	
(Ariotti,	Hall	et	al.	2015).	We	aimed	to	assess	whether	this	technique	can	be	used	for	
the	detection	of	protein-protein	interactions	via	mass	spectrometry.	Using	the	same	
GFP-tagged	cell	 lines	as	used	above,	the	APEX2-nanotrap	was	transfected	into	each	
cell	line	(Figure	3.4).	The	nanobody	portion	of	the	construct	should	direct	the	APEX2	
enzyme	to	the	GFP-tagged	proteins.		
	
Using	 this	 system	 for	 these	 experiments	 also	 offers	 another	 benefit	 over	 the	
traditional	 IP	 methodology.	 As	 labelling	 with	 biotin	 occurs	 prior	 to	 cell	 lysis,	 the	
samples	 can	 be	 combined	 prior	 to	 biotin-streptavidin	 IP	 (Figure	 3.4(C)).	 This	 will	
reduce	 the	 variation	 that	 may	 be	 introduced	 between	 samples	 when	 they	 are	
immunoprecipitated	 separately.	 The	 Biotin-streptavidin	 bond	 is	 a	 very	 strong	 and	
therefore	allows	for	much	harsher	washes	to	be	used	as	well.	
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Figure	3.4	Schematic	diagram	of	the	experimental	setup	for	using	APEX2-nanotrap.	
(A)	 Simplified	mechanism	of	 how	 the	APEX2	 enzyme	 tags	 nearby	 proteins	with	
biotin	phenol	in	the	presence	of	H2O2.	(B)	APEX2	enzyme	is	attached	to	the	GFP-
nanotrap	and	used	in	the	HeLa	S3	Flp-In	GFP-tagged	cell	lines.	(C)	Workflow	of	SILAC	
experiment	using	the	stable	cell	lines	and	APEX2-nanotrap.	Cells	were	stimulated	
with	 20ng/ml	 EGF	 following	 a	 6-hour	 serum	 starvation	 and	 30-minute	 pre-
treatment	with	Biotin-phenol.	Labelling	of	 interacting	proteins	 is	 induced	by	the	
addition	of	H2O2.	Cell	lysates	are	then	mixed	in	a	1:1:1	ratio	before	enrichment	by	
Streptavidin	pulldown.	
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3.2.4.	Enrichment	of	biotin-labelled	proteins	using	APEX2	
	
A	control	experiment	was	performed	to	assess	the	ability	of	APEX2	to	label	proteins	
with	biotin	and	determine	 if	an	enriched	pool	of	 these	proteins	could	be	obtained	
(Figure	 3.5).	 The	 GFP-tagged	 cell	 lines	 were	 transfected	 with	 the	 APEX2-nanotrap	
construct	24	hours	prior	to	labelling.	Labelling	was	activated	by	the	addition	of	H2O2	
for	1	minute.	The	cells	were	quickly	quenched	and	then	lysed.	A	control	condition	was	
set	up	for	each	cell	line,	which	was	not	transfected	with	the	APEX2	enzyme	and	did	
not	have	H2O2	added	to	induce	labelling.		
	
The	top	panel	of	Figure	3.5	shows	the	total	amount	of	protein	on	the	blot.	Samples	
are	 taken	 from	 all	 parts	 of	 the	 streptavidin	 IP.	 The	 Input	 and	 flow-through	 (first	
supernatant	 taken	 from	 the	 IP	 prior	 to	 washing)	 show	 no	 difference	 in	 the	 total	
amounts	of	protein	between	cell	lines	and	positive	and	negative	controls.	This	shows	
that	equal	concentrations	were	used	for	all	the	conditions	in	the	IP.	An	increase	in	the	
total	protein	is	seen	in	the	positive	controls	of	the	bound	fraction	compared	to	the	
non-labelled	negative	 control.	After	 looking	at	 the	 total	protein,	 the	blot	was	 then	
probed	for	biotin	using	a	streptavidin	antibody.	Stronger	staining	can	be	seen	in	the	
positive	controls	compared	to	 the	negative	controls,	 suggesting	 that	 the	enzyme	 is	
effectively	 labelling	 proteins	 with	 biotin.	 The	 bound	 fraction	 shows	 a	 massively	
increased	 enrichment	 of	 biotinylated	 proteins	 compared	 to	 the	 input	 and	 flow-
through	fractions,	showing	that	the	biotinylated	proteins	have	been	enriched	by	the	
streptavidin	IP.		
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Figure	3.5	Enrichment	of	biotin-labelled	proteins	by	APEX2-nanotrap.	HeLa	S3	Flp-
In	 GFP	 cell	 lines	 transfected	 with	 APEX2-nanotrap	 were	 incubated	 with	 biotin-
phenol.	Biotinylation	was	stimulated	in	the	cells	where	indicated	before	the	cells	
were	 lysed	and	a	 streptavidin	 IP	was	performed.	The	 top	panel	 shows	 the	 total	
proteins	present	 in	each	 lane.	The	second	panel	was	probed	with	a	streptavidin	
antibody	to	show	the	levels	of	biotinylation.	The	bottom	two	panels	were	probed	
for	HRS	and	STAM.		
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3.2.5.	APEX2-nanotrap	approach	for	mass	spectrometry	identifies	a	larger	pool	
of	proteins	
	
The	SILAC	labelled	cell	lines	were	transfected	with	the	APEX2-nanotrap	construct	24	
hours	 prior	 to	 labelling,	 as	mentioned	 above.	 The	 cells	were	 then	 stimulated	with	
20ng/ml	of	EGF	at	37°C	for	8	minutes	before	H2O2	was	added	for	1	minute	at	room	
temperature	to	activate	the	biotin	 labelling	by	the	APEX2	enzyme.	Cells	were	 lysed	
and	the	lysates	mixed	prior	to	immunoprecipitation.	The	samples	were	then	processed	
for	mass	spectrometry.	The	first	observation	from	the	data	obtained	using	the	APEX2-
nanotrap	approach	was	that	much	more	material	had	been	detected	compared	to	the	
previous	mass	spectrometry	experiment.		
	
From	the	graphs	generated	(Figure	3.6),	the	majority	of	proteins	fall	around	the	base	
line,	creating	a	large	background	signal.	I	was	encouraged	to	see	that	a	collection	of	
G-proteins,	and	Rac1,	had	been	identified	in	the	dataset.	These	proteins,	however,	fall	
within	the	large	background	‘cloud’	of	proteins,	and	thus,	we	have	to	conclude	that	
they	are	not	enriched	in	this	dataset.		
	
Further	problems	arise	in	the	dataset	when	looking	for	HRS	and	STAM	to	act	as	the	
internal	controls	for	the	experiment.	HRS	was	not	identified	at	all	in	the	dataset,	while	
STAM1	also	failed	to	make	it	out	of	the	background	‘cloud’.	This	casts	doubt	over	the	
validity	of	these	results	if	a	strong	enrichment	of	the	bait	protein,	or	its	most	common	
binding	partner,	hasn’t	been	obtained.		
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3.2.6.	Abundant	cytosolic	proteins	make	up	the	largest	intensities	in	the	dataset	
	
Upon	further	examination	of	the	results,	I	noticed	that	the	proteins	which	displayed	
the	largest	intensities,	tended	to	be	very	abundant	cytosolic	proteins.	For	example,	
tubulin	subunits	as	well	as	actin	subunits	had	some	of	the	highest	intensities	in	the	
dataset	 (Figure	 3.7(A)).	 Moreover,	 these	 proteins	 tended	 to	 have	 similar	 levels	
between	conditions,	meaning	that	there	was	no	enrichment	in	any	condition.	This	may	
Figure	3.6	GFP-HRS	interactome	in	EGF	stimulated	HeLa	S3	Flp-In	cells	transfected	
with	APEX2-nanotrap.	(A)	Workflow	of	SILAC	experiment	using	the	stable	cell	lines	
and	APEX2-nanotrap.	In	gel	digest	was	carried	out	on	the	samples	prior	to	analysis	
with	 LC-MS/MS.	 Log2	 transformed	 ratios	 plotted	 against	 Log10	 transformed	
intensities	for	(B)	GFP-HRS	versus	GFP,	(C)	GFP-YYFF	versus	GFP	and	(D)	GFP-HRS	
versus	 GFP-YYFF.	 Filled	 circles	 represent	 proteins	 which	 show	 significant	 ratio	
changes.	Significance	B,	false	discovery	rate	(FDR)	<	0.05.	
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have	 been	 due	 to	 the	 nature	 of	 this	 approach.	 The	 APEX2-nanotrap	 was	
overexpressed	via	transient	transfection	and	as	such	would	be	in	excess	of	the	GFP-
tagged	constructs.	This	would	mean	that	there	was	more	than	likely,	an	excess	of	the	
enzyme,	which	is	unable	to	bind	to	a	GFP	molecule.	The	excess	enzyme	would	then	
be	generating	biotin-phenoxyl	radicals	in	the	cytosol,	potentially	explaining	why	the	
proteins	with	the	highest	intensities	are	abundant	cytosolic	proteins.	
	
	
	 	
Figure	 3.7	 intensity	 analysis	 of	 HRS	 interactome	 generated	 with	 APEX2-tagged	
nanotrap.	 (A)	 intensity	 histogram	 of	 proteins	 identified	 using	 APEX2-nanotrap.	
Highlighted	are	the	ten	highest	intensity	proteins.	(B)	Intensities	from	the	APEX2-
nanotrap	mass	spectrometry	experiment	were	compared	to	the	HeLa	copy	number	
dataset	generated	from	(Nagaraj,	Wisniewski	et	al.	2011).	Pearson	r	=	0.4243,	P	<	
0.0001.	
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To	examine	this	further,	I	took	the	intensities	of	all	the	proteins	within	my	dataset	and	
compared	 them	 to	 the	 copy	 number	 for	 HeLa	 cells	 from	 a	 dataset	 published	 by	
Matthias	Mann	and	colleagues	(Nagaraj,	Wisniewski	et	al.	2011)	(Figure	3.7(B)).	There	
was	a	correlation	between	the	intensities	of	the	biotinylated	proteins	in	the	APEX2-
nanotrap	dataset	and	the	copy	number	dataset	from	Matthias	Mann.	This	suggests	
that	there	is	not	a	specific	enrichment	of	proteins	interacting	with	HRS	with	the	APEX2-
nanotrap.	
	
3.2.7.	Generation	of	APEX2-tagged	HRS	cell	lines	
	
Due	to	the	issues	brought	about	from	the	overexpression	of	the	APEX2	enzyme	in	the	
last	 approach.	 I	 decided	 to	 make	 cell	 lines	 using	 the	 same	 Flp-In	 system	 used	 to	
generate	the	GFP-tagged	cell	lines.	The	idea	is	that	all	of	the	APEX2	enzyme	will	now	
be	associated	with	HRS	as	 they	would	be	directly	 linked	 to	each	other.	This	would	
hopefully,	 reduce	 the	 background	 signal	 significantly	 and	 maybe	 eliminate	 the	
abundant	cytosolic	proteins	from	the	subsequent	datasets.	Using	the	Flp-In	system	
also	ensures	that	the	HRS	constructs	are	being	expressed	at	a	similar	level	to	what	is	
seen	under	normal	physiological	conditions.	A	schematic	of	the	experimental	setup	is	
shown	in	Figure	3.8.	This	set	up	mirrors	that	which	was	used	for	the	GFP-tagged	cell	
lines,	with	lysate	collection	and	IP	methodology	being	identical	to	the	APEX2-nanotrap	
approach.	Generation	of	the	cell	lines	is	described	in	section	2.2.11.		
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Figure	3.8	Schematic	diagram	of	the	experimental	setup	for	using	APEX2-tagged	
HRS.	(A)	APEX2	enzyme	is	attached	directly	to	HRS	and	stably	expressed	in	HeLa	S3	
Flp-In	cell	lines.	(B)	Workflow	of	SILAC	experiment	using	the	APEX2	cell	lines.	Cells	
were	stimulated	with	20ng/ml	EGF	following	a	6-hour	serum	starvation	and	30-
minute	 pre-treatment	 with	 Biotin-phenol.	 Labelling	 of	 interacting	 proteins	 is	
induced	by	the	addition	of	H2O2.	Cell	lysates	were	then	mixed	in	a	1:1:1	ratio	before	
enrichment	by	Streptavidin	pulldown.	
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3.2.8.	APEX2-tagged	cell	line	characterisation	and	IP	optimisation	
	
The	APEX2	enzyme	contains	a	Flag	tag.	In	order	to	visualise	the	localisation	of	APEX2	
in	the	three	cell	 lines,	APEX2	expressing	cell	 lines	were	co-stained	with	an	anti-HRS	
and	 an	 anti-Flag	 antibody	 (Figure	 3.9(A)).	 Both	 the	 APEX2-HRS	 and	 APEX2-YYFF	
expressing	cells	show	co-localisation	between	the	anti-HRS	and	anti-Flag	antibodies.	
No	co-localisation	is	seen	between	the	two	antibodies	in	the	APEX2	only	cells.		
	
By	Western	blot,	APEX2-HRS	and	APEX2-YYFF	constructs	are	expressed	at	similar	levels	
to	the	endogenous	HRS	in	the	APEX	only	cell	lines.	The	endogenous	HRS	levels	within	
the	WT	 and	mutant	HRS	 cell	 lines	 decreases	with	 the	 presence	 of	 the	APEX2-HRS	
constructs.	This	 is	a	similar	phenomenon	that	was	seen	with	the	GFP-HRS	cell	 lines	
used	above.	
	
The	APEX2	cell	lines	also	respond	to	20ng/ml	of	EGF	as	per	the	GFP	cell	lines.	APEX2-
HRS	 shows	a	P-HRS	band	appearing	 after	 8	minutes	of	 EGF	 stimulation,	which	has	
decreased	after	30	minutes	of	stimulation.	These	bands	are	not	seen	in	the	APEX2	only	
or	the	mutant	HRS	cell	lines.		
		
Since	the	previous	IP	was	optimised	for	cell	lines	expressing	higher	levels	of	the	APEX2	
enzyme,	the	amount	of	protein	lysate	would	need	to	be	titrated	for	a	given	amount	of	
streptavidin	 beads.	 Increasing	 amounts	 of	 protein	 lysate	 were	 used	 with	 30µl	 of	
magnetic	beads	to	assess	how	much	of	the	beads	will	be	used	in	the	MS	experiment.	
As	shown	in	the	bottom	panel	of	Figure	3.9(D),	as	the	protein	amount	used	increases,	
so	does	the	strength	of	the	biotinylated	bands.	Looking	at	the	unbound	fraction,	there	
does	not	seem	to	be	an	increase	of	biotinylated	bands	until	a	slight	increase	seen	in	
the	1000µg	condition.	This	suggests	that	at	1000µg	of	protein,	the	beads	are	reaching	
saturation.	
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Figure	3.9	APEX2	Cell	line	characterisation	and	optimisation.	(A)	HeLa	S3	Flp-In	cells	
stably	expressing	APEX2-tagged	constructs	co-stained	with	anti-Flag	and	anti-HRS	
antibodies.	 Scale	 bar	 =	 10µm	 (B)	 Western	 blot	 assessing	 the	 relative	 levels	 of	
APEX2-tagged	HRS	 constructs	 compared	 to	 endogenous	 levels.	 (C)	 APEX2	 Flp-In	
cells	were	serum	starved	for	6	hours	and	then	stimulated	with	20ng/ml	EGF	for	the	
indicated	 time	 periods.	 (D)	 APEX2	 cell	 line	 lysate	 titration	 against	 streptavidin	
beads.	Indicated	amounts	of	protein	lysate	were	loaded	onto	30µl	of	beads.	
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3.2.9.	APEX2	cell	line	mass	spectrometry	results	
	
The	first	observation	that	can	be	made	from	the	APEX2	cell	line	mass	spectrometry,	is	
that	 far	 fewer	biotin-labelled	proteins	have	been	 identified	 compared	 to	using	 the	
APEX2-nanotrap	 approach.	 This	 is	 due	 to	 a	 much	 lower	 expression	 of	 the	 APEX2	
enzyme.		
	
Looking	at	both	the	wild	type	and	mutant	HRS	compared	to	GFP,	several	proteins	are	
identified	 as	 up	 regulated	 in	 both	 conditions	 (Figure	3.10(B)).	 These	 are:	 the	 tRNA	
synthase	 LARS,	 the	 serine/threonine	 kinase	 STK10,	 the	 non-muscle	 myosin	 heavy	
chain	MYH14	and	the	E1	ubiquitin	enzyme	UBA1.	Enriched	in	the	mutant	cell	line	was	
several	proteins	involved	in	RNA	regulation:	RIOK2,	RPL3	and	RPL7;	as	well	as	a	couple	
of	metabolic	enzymes,	PMK2	and	GPI	(Figure	3.10(C)).	Perhaps	the	most	interesting	
enrichment	was	of	the	E3	ligase	deltex-3-like	(DTX3L),	which	was	enriched	in	the	wild	
type	HRS	condition	compared	to	both	the	APEX2	only	control	and	the	mutant	HRS	cell	
lines	(Figure	3.10(B&D)).	This	indicates	that	the	interaction	between	this	E3	ligase	and	
HRS	is	dependent	on	the	phosphorylation	of	tyrosine	residues	329	and	334.		
	
As	with	the	APEX2-nanotrap	approach,	I	looked	for	HRS	and	STAM	in	the	dataset	to	
use	as	an	 internal	control.	Despite	 the	APEX2	enzyme	being	directly	 linked	 to	HRS,	
neither	HRS	or	STAM	were	 identified	 in	the	dataset.	Furthermore,	the	collection	of	
heterotrimeric	G-proteins,	along	with	Rac1,	were	also	absent	from	this	dataset.	This	
lack	 of	 a	 positive	 internal	 control	 raises	 concern	 over	 the	 validity	 of	 the	 mass	
spectrometry	results.		
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Figure	 3.10	 APEX2-HRS	 interactome	 in	 EGF	 stimulated	 HeLa	 S3	 Flp-In	 cells.	 (A)	
Workflow	of	the	SILAC	experiment	using	the	stable	APEX2	cell	lines.	In	gel	digest	
was	carried	out	on	the	samples	prior	to	analysis	with	LC-MS/MS.	Log2	transformed	
ratios	plotted	against	Log10	transformed	intensites	for	(B)	APEX2-HRS	versus	APEX2,	
(C)	APEX2-YYFF	versus	APEX2	and	(D)	APEX2-HRS	versus	APEX2-YYFF.	Filled	circles	
represent	 proteins	 which	 show	 significant	 ratio	 changes.	 Significance	 B,	 false	
discovery	rate	(FDR)	<	0.05.	
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3.3.	Summary	of	results	
	
• Only	 strong,	 well	 established	 interaction	 partners	 were	 identified	 by	 mass	
spectrometry	from	the	traditional	GFP	IP	
• Over-expression	 of	 APEX2-nanotrap	 in	 the	 GFP	 cell	 lines	 lead	 to	 a	 high	
background	 signal,	 with	 predominantly	 abundant	 cytosolic	 proteins	 being	
identified.		
• Mass	spectrometry	analysis	of	biotin	labelled	proteins	from	the	APEX2	cell	lines	
identified	 proteins	 associated	 with	 range	 of	 biological	 processes.	 These	
include:	RNA	regulation,	components	of	the	ubiquitin	cascade	pathway	and	a	
couple	of	metabolic	enzymes.	
• The	 E3	 ligase	 DTX3L	 was	 enriched	 in	 the	 wild	 type	 APEX2-HRS	 cell	 lines	
compared	to	both	the	mutant	HRS	(APEX2-YYFF)	and	APEX2	only	cell	lines.	
• Neither	method	of	proximity	labelling	managed	to	identify	the	possible	HRS-
dependent	enrichment	of	heterotrimeric	G-proteins.	
	
3.4.	Discussion	
	
As	 mentioned	 in	 the	 introduction	 to	 this	 chapter,	 the	 transient	 nature	 of	 these	
potential	interactions	makes	them	very	difficult	to	measure.	Evident	by	the	initial	mass	
spectrometry	 experiment,	 where	 only	 STAM1	 and	 STAM2	 were	 identified	 as	
interacting	partners	of	HRS,	despite	the	literature	showing	many	other	proteins	are	
capable	of	interacting	with	HRS	(Huttlin,	Ting	et	al.	2015).		
	
APEX2-nanotrap	is	a	tool	used	in	electron	microscopy	to	create	a	modular	system	for	
the	 visualisation	 of	 GFP-labelled	 proteins	 (Ariotti,	 Hall	 et	 al.	 2015).	 The	 enzyme	 is	
linked	to	the	anti-GFP	nanobody	and	introduced	into	cells	via	a	transient	transfection.	
The	 GFP-nanotrap	 localises	 APEX2	 to	 GFP-tagged	 proteins.	 This	 method	 has	 been	
successfully	employed	in	electron	microscopy	studies.	In	this	chapter,	I	attempted	to	
determine	 if	 this	methodology	 could	 be	 used	 for	 the	 detection	 of	 protein-protein	
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interactions	via	mass	spectrometry.	Successfully	utilising	this	method	would	allow	for	
the	rapid	proximity-labelling	analysis	of	GFP-tagged	proteins.	Over-expression	of	the	
APEX2-nanotrap	led	to	a	huge	excess	of	the	probe	compared	to	GFP-tagged	HRS.	The	
result	of	this	was	a	high	background	noise	level.	The	largest	intensity	proteins	within	
the	dataset	were	predominantly	abundant	cytosolic	proteins	and	lacked	specificity	for	
HRS.		
	
To	 overcome	 these	 caveats,	 the	 APEX2	 enzyme	 was	 tagged	 directly	 to	 HRS	 and	
expressed	the	construct	in	cells	using	the	Flp-In	system.	This	should	avoid	the	issue	of	
the	 enzyme	 being	 expressed	 in	 excess	 and	 vastly	 improve	 the	 specificity	 of	 the	
method.	The	resulting	mass	spectrometry	dataset	using	the	APEX2	cell	lines	certainly	
contained	much	less	material	than	the	preceding	dataset	and	identified	a	completely	
different	set	of	proteins	(Figures	3.6	and	3.10).	However,	HRS	and	STAM	failed	to	be	
labelled	by	APEX2,	despite	the	enzyme	being	directly	tagged	to	HRS.	It	is	possible	that	
the	 expression	 of	 APEX2	 is	 too	 low	 in	 these	 cell	 lines	 to	 obtain	 reliable	 mass	
spectrometry	 data.	 The	 amount	 of	 material	 identified	 in	 the	 APEX	 cell	 line	 mass	
spectrometry	 experiments	 was	 comparable	 to	 the	 traditional	 GFP	 IP	 experiments,	
however.		
	
It	 is	worth	considering	the	possibility	that	HRS	may	be	poorly	 labelled	by	the	biotin	
phenol	free	radicals	generated	by	the	APEX2	enzyme.	An	interesting	preprint	article	
studying	 the	 ‘biotinome’	 suggests	 that	 biotin	 modifications	 preferentially	 favour	
intrinsically	disordered	regions	(IDRs)	(Minde,	Ramakrisna	et	al.	2018).		This	provides	
a	possible	explanation	for	the	absence	of	HRS	in	both	proximity-labelling	experiments.	
It	may	then	be	difficult	to	use	HRS	and	STAM	as	internal	controls	when	using	proximity-
labelling	techniques.	
	
With	this	 in	mind,	the	results	of	 the	APEX2	cell	 line	experiment	can	be	considered,	
albeit	with	caution,	without	the	presence	of	HRS	and	STAM.	Two	metabolic	enzymes,	
pyruvate	kinase	isozyme	M2	(PKM2)	and	glucose-6-phosphate	isomerase	(GPI),	were	
identified	in	the	APEX2	cell	line	dataset.	PKM2	and	GPI	were	enriched	in	the	mutant	
cell	lines	compared	to	both	the	APEX2	only	control	and	wild	type	HRS	conditions.	This	
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suggests	 that	HRS	phosphorylation	 inhibits	 the	 interaction	between	HRS	and	 these	
enzymes.	 A	 study	 on	 CXCR4	 has	 shown	 that	 various	 components	 of	 the	 ESCRT	
machinery	mediate	the	CXCR4-induced	activation	of	Akt	(Verma	and	Marchese	2015).	
This	study	suggests	that	the	ESCRT	machinery	regulates	Akt	activity	by	mediating	the	
degradation	 of	 DEPTOR,	 an	 mTORC2	 complex	 antagonist.	 The	 mTORC2	 complex	
regulates	certain	aspects	of	cellular	metabolism,	providing	a	potential	 link	between	
the	two	identified	metabolic	enzymes	and	ESCRT-0.	
	
The	ubiquitin-activating	enzyme	UBA1	was	also	identified	in	both	the	wild	type	and	
mutant	HRS	cell	lines.	Along	with	it	was	the	E3	ligase,	deltex-3-like	(DTX3L),	which	was	
enriched	in	the	wild	type	condition	compared	to	both	the	APEX2	only	control	and	the	
mutant	HRS	cell	 lines.	 Interestingly,	DTX3L	has	been	shown	to	 regulate	another	E3	
ligase	atrophin-1	 interacting	protein	4	 (AIP4),	 independently	 from	 its	own	E3	 ligase	
activity	 (Holleman	 and	 Marchese	 2014).	 This	 prevents	 AIP4	 from	 ubiquitylating	
components	 of	 ESCRT-0,	 thus	 promoting	 the	 degradation	 of	 the	 cytokine	 receptor	
CXCR4.	DTX3L	 is	recruited	to	endosomes	upon	CXCR4	activation	and	knockdown	of	
the	 E3	 ligase	 by	 siRNA,	 leads	 to	 both	 HRS	 and	 STAM	 exhibiting	 a	 more	 cytosolic	
distribution	in	the	context	of	CXCL12	stimulation.		Furthermore,	the	authors	also	show	
that	DTX3L	interacts	with	both	HRS	and	STAM.	This	is	built	upon	by	the	data	described	
here,	which	suggests	that	this	interaction	is	dependent	on	phosphorylation	of	tyrosine	
residues	329	and	334	in	the	context	of	EGF	stimulation.		
	
The	 role	 of	 DTX3L	 in	 CXCR4	 signalling,	 according	 to	 the	 study	 by	 Holleman	 and	
Marchese,	is	to	aid	in	the	degradation	of	the	cytokine	receptor	by	attenuating	AIP4	
dependent	ubiquitylation	of	HRS	and	STAM.	The	mass	 spectrometry	data	obtained	
from	the	APEX2	cell	lines	suggests	that	this	concept	may	also	extend	to	RTK	signalling.	
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Chapter	four:	Development	of	endosomal	
biosensors	for	cAMP	and	PKA		
	
The	classical	model	of	GPCR	signalling	envisions	that	activation	of	the	receptor,	and	
subsequent	effectors,	occurs	at	the	plasma	membrane.	Binding	of	the	ligand	by	the	
receptor	leads	to	a	conformational	change	at	the	cytosolic	tail.	This	allows	it	to	activate	
the	α	subunit	of	hetero-trimeric	G-proteins	by	exchanging	GDP	for	GTP.	Later,	after	
binding	of	β-arrestin,	the	GPCR	is	internalised	to	the	endosome.	Here	the	signal	is	then	
down-regulated	 and	 the	 receptor	 reset	 before	 being	 recycled	 back	 to	 the	 plasma	
membrane.		
	
More	 recently,	 this	 view	has	 shifted.	 Increasing	evidence	has	 shown	 that	a	 second	
wave	of	activation	can	occur	at	endosomes	and	that	this	produces	a	more	prolonged	
cAMP	signal	compared	to	the	plasma	membrane	signal	(Irannejad	and	von	Zastrow	
2014).	This	phenotype	was	initially	identified	with	the	parathyroid	hormone	receptor	
and	 thyroid	 stimulating	 hormone	 (TSH)	 receptor	 (Calebiro,	 Nikolaev	 et	 al.	 2009,	
Ferrandon,	Feinstein	et	al.	2009),	but	has	subsequently	been	shown	to	be	exhibited	in	
various	other	GPCRs	including	the	β2-adrenergic	receptor	(Irannejad,	Tomshine	et	al.	
2013).	 Furthermore,	 work	 with	 the	 β2-adrenergic	 receptor	 also	 showed	 that	 the	
prolonged	 endosomal	 signal	 was	 responsible	 for	 the	 transcriptional	 response	
(Tsvetanova	and	von	Zastrow	2014).		
	
Despite	 the	 increasing	evidence	 to	 support	 this	model,	no	direct	measurements	of	
endosomally	produced	cAMP	have	been	recorded.	Current	methods	have	looked	at	
differences	 in	 the	 global	 cAMP	 population	 after	 various	manipulations	 to	 receptor	
trafficking.	 In	 order	 to	 measure	 endosomal	 cAMP	 production	 and	 signalling,	 I	
proposed	to	use	the	FRET	based	cAMP	and	PKA	biosensors,	 ICUE3	and	AKAR4,	and	
modify	their	location	to	endosomes.		
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The	indicator	of	cAMP	using	Epac	(ICUE)	FRET	based	biosensor	was	first	developed	in	
2004	 by	 sandwiching	 cyan	 and	 yellow	 fluorophores	 around	 a	 full	 length	 Epac1	
(DiPilato,	 Cheng	 et	 al.	 2004).	 Upon	 binding	 cAMP,	 Epac1	 undergoes	 a	 large	
conformational	change.	This	moves	the	fluorophores	further	apart	and	reduces	the	
FRET	between	them.	The	ICUE3	sensor	is	the	third	generation	for	the	biosensor	with	
an	improved	dynamic	range	over	previous	iterations	(DiPilato	and	Zhang	2009)(Figure	
4.1).		
	
	
	
A-kinase	 activity	 reporter	 (AKAR)	 developed	 in	 2001,	 is	 a	 FRET	 based	 biosensor	
containing	a	substrate	sequence	for	PKA	and	a	phosphorylation	recognition	domain	to	
induce	a	conformational	change	in	response	to	PKA	activity	(Zhang,	Ma	et	al.	2001).	In	
contrast	to	the	ICUE	biosensor,	AKAR	is	open	under	non-stimulated	conditions.	When	
PKA	 becomes	 active,	 it	 phosphorylates	 the	 pseudo-substrate.	 The	 phosphorylation	
recognition	 domain	 now	 binds	 to	 the	 phosphorylated	 amino	 acid,	 resulting	 in	 the	
Figure	4.1	Evolution	of	PKA	and	cAMP	biosensors.	Multiple	versions	of	the	cAMP,	
indicator	of	cAMP	using	Epac	(ICUE),	and	PKA,	A-kinase	activity	reporter	 (AKAR),	
biosensors	have	been	generated.	Different	fluorescent	protein	variants	have	been	
used	in	order	to	improve	the	intensity	and	dynamic	range	of	FRET	measurements.	
The	phosphoamino	acid	domain	has	also	been	changed	in	AKAR4	over	the	earlier	
iteration.	14-3-3τ	has	been	replaced	by	Forkhead	associated	domain	(FHA1).	
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sensor	folding	up	and	an	increase	in	FRET.	The	AKAR4	sensor	is	the	latest	iteration	of	
the	biosensor	(Depry,	Allen	et	al.	2011).		
	
Organelles	are	identified	by	the	GTPases	and	specific	lipids	present	on	the	cytosolic	
surface	 (Behnia	 and	 Munro	 2005).	 Early	 endosomes	 are	 in	 part	 identified	 by	 the	
phosphoinositide	 PtdIns(3)P	 (Di	 Paolo	 and	 De	 Camilli	 2006).	 This	 phosphoinositide	
species	is	generated	by	the	class	III	phosphoinositide	3-kinase,	Vps34	(Schu,	Takegawa	
et	al.	1993),	which	is	recruited	to	endosomes	by	the	GTPase,	Rab5.	Proteins	bind	to	
PtdIns(3)P	 through	an	 interaction	with	their	FYVE	domain	(Gaullier,	Simonsen	et	al.	
1998).	The	FYVE	domain	is	named	after	the	first	4	proteins	it	was	found	in	(Fab1,	YOTB,	
Vac1	and	EEA1)	when	it	was	shown	to	be	required	for	the	endosomal	localisation	of	
EEA1	(Stenmark,	Aasland	et	al.	1996).	The	FYVE	domain	has	since	been	identified	on	
numerous	endosomal	 proteins,	many	of	which	 are	 critical	 for	 endosomal	 function.	
Overexpression	 of	 FYVE	 domain	 containing	 proteins	 can	 therefore	 saturate	 the	
PtdIns(3)P	available	for	binding	and	disrupt	normal	endosome	function,	as	is	seen	with	
HRS	overexpression	(Chin,	Raynor	et	al.	2001).		
	
4.1.	Objectives	
	
My	aim	for	the	work	described	in	this	chapter	was	to	develop	FRET	based	biosensors	
for	the	study	of	endosomal	cAMP	generation	and	PKA	signalling.	The	resulting	FRET	
sensors	will	then	be	used	to	determine	if	manipulation	of	HRS	will	lead	to	altered	cAMP	
and	PKA	signalling.	
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4.2.	Results	
	
4.2.1.	GFP-FENSFYVE	construct	localises	to	endosomes	
	
In	order	to	 localise	the	AKAR4	and	ICUE3	constructs	to	endosomes,	a	FYVE	domain	
was	added	to	the	N-terminus	of	each	construct.	The	FYVE	domain	can	localise	GFP	to	
PtdIns(3)P	containing	membranes.	This	has	been	achieved	previously	through	the	use	
of	a	double	FYVE	domain	from	HRS	(Gillooly,	Morrow	et	al.	2000).	However,	a	single	
FYVE	domain	from	FENS	has	been	found	to	be	sufficient	to	localise	GFP	to	endosomes.	
GFP-FENSFYVE	(referred	to	as	GFP-FF	from	here	onwards)	co-localises	with	the	early	
endosomal	marker	EEA1	in	HeLa	cells	(Figure	4.2(A)).	Since	the	FYVE	domain	binds	to	
PtdIns(3)P,	 then	 disruption	 to	 the	 generation	 of	 this	 phospholipid	 should	 cause	
endosomal	 proteins	 to	 fall	 off	 the	 endosome.	 This	 is	 shown	 when	 endosomal	
localisation	of	GFP-FF	is	lost	after	treatment	with	the	VPS34	inhibitor	SAR405	(Figure	
4.2(B)).		
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4.2.2.	FYVE	domain	localises	AKAR4	to	endosomes	
	
The	FYVE	domain	was	cloned	from	the	GFP-FF	construct	via	PCR	and	inserted	in	front	
of	 the	AKAR4	construct,	as	demonstrated	 in	 the	schematic	 in	Figure	4.3(A).	AKAR4	
with	 the	cloned	FYVE	domain	 (AKAR4-FF)	showed	co-localisation	with	EEA1	 (Figure	
4.3(B)).	This	localisation	was	lost	following	treatment	with	the	VPS34	inhibitor	SAR405	
as	well	as	the	less	specific	PI-3-K	inhibitor	Wortmannin	(Figure	4.3(C)).		
Figure	4.2	GFP-FENSFYVE	localises	to	early	endosomes.	HeLa	cells	transfected	with	
GFP-FENSFYVE	(FF)	and	(A)	co-stained	with	an	anti-EEA1	antibody.	(B)	HeLa	cells	
transfected	with	GFP-FF	and	treated	for	2	hours	with	either	DMSO	(untreated)	or	
1µM	of	the	VPS34	inhibitor,	SAR405.	Scale	bar	=	10µm.	
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Figure	 4.3	 Localisation	 of	 endosomal	 AKAR4	 to	 early	 endosomes.	 (A)	 Schematic	
diagram	of	cytosolic	and	endosomal	AKAR4,	PKA	FRET	sensors.	Endosomal	AKAR4	
(AKAR4-FF)	was	made	by	attaching	the	FYVE	domain	from	GFP-FF.	(B)	HeLa	cells	
transfected	with	AKAR4-FF	and	co-stained	with	an	anti-EEA1	antibody.	 (C)	HeLa	
cells	 transfected	with	AKAR4-FF	were	 treated	with	either	1	μM	Wortmannin	for	
15mins,	or	1	μM	of	SAR405	for	2	hours.	Cells	underwent	a	Saponin	extraction	prior	
to	PFA	fixation.	Scale	bar	=	10µm.	
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4.2.3.	Generation	of	CFP-only	control	for	the	AKAR4	and	AKAR4-FF	constructs	
	
The	AKAR4	construct	was	generated	using	Venus	and	Cerulean	fluorophores	(Depry,	
Allen	et	al.	2011),	and	thus	the	excitation	spectra	overlap	with	one	another,	as	is	often	
the	case	with	FRET	pairs.	This	means	that	control	measures	need	to	be	taken	in	order	
to	determine	what	proportion	of	the	FRET	Emission	channel	is	due	to	the	appropriate	
fluorophore	 and	 allow	 us	 to	 eliminate	 the	 contaminating	 light	 from	 our	
measurements,	known	as	bleed	through.	In	order	to	determine	the	bleed	through	of	
the	donor	channel,	a	CFP-only	control	was	developed	for	the	AKAR4	constructs.	This	
was	achieved	by	introducing	a	premature	stop	codon	immediately	prior	to	the	Venus	
fluorophore.	The	stop	codon	was	introduced	via	site	directed	mutagenesis.	As	shown	
by	Figure	4.4,	emission	from	the	YFP	is	completely	abolished	in	the	CFP-only	controls	
for	both	AKAR4	and	AKAR4-FF.		
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Figure	 4.4	 Expression	 of	 CFP	 and	 YFP	 fluorophores	 of	 AKAR4	CFP-only	 controls.	
HeLa	cells	transfected	with	full	 length	and	CFP-only	versions	of	the	cytosolic	and	
endosomal	AKAR4	constructs.	Scale	bar	=	10µm.	
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4.2.4.	CFP-only	constructs	for	AKAR4	and	AKAR4-FF	exhibit	 increased	nuclear	
localisation	
	
From	Figure	4.4,	both	of	the	CFP-only	constructs	are	observed	exhibiting	an	increased	
nuclear	 localisation.	This	 is	due	to	the	AKAR4	construct	expressing	a	nuclear	export	
sequence	(NES)	at	its	C-terminus.	This	sequences	acts	as	a	signal	to	exclude	proteins	
from	the	nucleus.	Introducing	a	premature	stop	codon	prior	to	the	Venus	fluorophore	
not	only	removed	the	fluorophore,	but	also	the	NES	from	the	FRET	sensor.	This	issue	
was	 easily	 resolved	with	 further	 cloning,	 by	 reintroducing	 the	NES	 to	 the	CFP-only	
constructs,	 demonstrated	 by	 the	 schematic	 in	 Figure	 4.5(A).	 Exclusion	 of	 the	 FRET	
sensors	from	the	nucleus	is	rescued	by	the	re-addition	of	the	NES	(Figure	4.5(B)).	
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Figure	 4.5	 Re-introducing	 the	 NES	 on	 the	 CFP-only	 versions	 of	 the	 AKAR4	
constructs.	(A)	Schematic	diagram	depicted	the	loss	and	re-introductions	of	the	NES	
to	 the	AKAR4	CFP-only	 constructs.	 (B)	HeLa	 cells	 transfected	with	 cytosolic	 and	
endosomal	AKAR4	constructs,	with	or	without	the	NES.	YFP	channel	shown.	Scale	
Bar	=	10µm.	
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4.2.5.	FYVE	domain	poorly	localises	ICUE3	to	endosomes	
	
After	successfully	localising	the	AKAR4	construct	to	endosomes	with	the	FYVE	domain	
from	FENS,	the	same	method	was	employed	for	the	ICUE3	cAMP	FRET	sensor.	Despite	
cloning	 the	 FYVE	 domain	 into	 ICUE3	 exactly	 the	 same	way	 as	with	 AKAR4-FF,	 the	
construct	displayed	unusual	 localisation	(Figure	4.6).	 ICUE3	with	the	attached	FYVE	
domain	(ICUE3-FF)	co-localised	poorly	with	EEA1	and	appeared	to	be	distributed	to	
puncta	in	the	nucleus.	It	is	unclear	if	this	construct	has	localised	specifically	to	a	subset	
of	endosomes	or	if	a	portion	of	endosomes	have	been	redistributed	to	the	perinuclear	
region	due	to	the	presence	of	the	ICUE3-FF	construct.		
	
	
	
	 	
Figure	4.6	ICUE3-FF	localises	poorly	to	early	endosomes.	(A)	Schematic	diagram	of	
cytosolic	 and	 endosomal	 ICUE3,	 cAMP	 FRET	 sensors.	 ICUE3-FF	 was	 made	 by	
attaching	the	FYVE	domain	from	GFP-FF.	(B)	HeLa	cells	transfected	with	ICUE3-FF	
and	co-stained	with	an	anti-EEA1	antibody.	Scale	Bar	=	10µm.	
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4.2.6.	RA	domain	from	Epac2	improves	localisation	of	endosomal	cAMP	FRET	
sensor.	
	
To	determine	the	cause	of	the	mis-localisation	of	ICUE3-FF,	I	decided	to	look	into	the	
literature	surrounding	Epac	 localisation.	Epac	 is	activated	 in	 the	presence	of	cAMP	
and,	in	turn,	leads	to	the	activation	of	Rap1,	a	Ras	super	family	member.	For	efficient	
activation	 of	 Rap1,	 Epac1	 requires	 the	 interaction	 of	 Ran	 and	Ran	 binding	 protein	
(RanBP).	 This	 interaction	 occurs	 through	 the	 Ras	 associated	 (RA)	 domain	 and	 also	
anchors	Epac1	to	the	nuclear	pore.	Interestingly,	when	comparing	the	localisation	of	
both	Epac	isoforms,	Epac1	displays	localisation	to	the	nuclear	envelope,	while	Epac2	
does	not	(Liu,	Takahashi	et	al.	2010).	Since	the	RA	domain	is	the	region	responsible	for	
interaction	with	the	nuclear	pore	protein	Ran,	the	authors	speculated	that	differences	
in	 this	 region	were	responsible	 for	 the	altered	distribution	of	 the	two	 isoforms.	By	
replacing	the	RA	domain	of	Epac1	with	the	RA	domain	of	Epac2	(RA2),	they	effectively	
abolished	the	nuclear	localisation	of	Epac1.	Here,	this	strategy	was	employed	with	the	
endosomal	ICUE3	construct	by	swapping	the	RA	domain	with	that	from	Epac2	(RA2)	
to	 create	 a	 new	 construct	which	will	 now	be	 termed	 ICUE4,	 demonstrated	by	 the	
schematic	in	Figure	4.7(A).	Though	this	did	not	completely	abolish	the	nuclear	staining	
seen	 with	 ICUE3-FF,	 it	 did	 effectively	 redistribute	 the	 construct.	 The	 ICUE4-FF	
construct	 displayed	 puncta	 in	 the	 cell	 periphery,	 which	 co-localised	 with	 EEA1.	
Furthermore,	these	peripheral	puncta,	but	not	the	nuclear	localisation,	disappeared	
following	 treatment	with	Wortmannin	 and	 SAR405	 (Figure	 4.7(B)).	 From	 this	 I	 can	
confidently	 conclude	 that	 the	 ICUE4-FF	 construct	 localises	 to	 PtdIns(3)P	 positive	
endosomes.		
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Figure	 4.7	 Localisation	 of	 endosomal	 ICUE4	 to	 early	 endosomes.	 (A)	 Schematic	
diagram	of	how	ICUE4-FF	was	made	by	exchanging	the	RA2	domain	from	Epac1-
RA2	with	the	RA	domain	of	ICUE3.	(B)	HeLa	cells	transfected	with	ICUE4-FF	and	co-
stained	with	an	anti-EEA1	antibody.	(C)	HeLa	cells	transfected	with	ICUE4-FF	were	
treated	with	either	1	μM	Wortmannin	for	15mins,	or	1	μM	of	Sar405	for	2	hours.	
Cells	underwent	a	Saponin	extraction	prior	to	PFA	fixation.	Scale	bar	=	10µm.	
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4.2.7.	ICUE4	construct	is	still	functional	as	a	cAMP	biosensor.	
	
A	mutated	version	of	the	ICUE3	cAMP	sensor	was	created	by	Zhangs	group,	which	is	
unable	 to	 open	 up	 and	 remains	 in	 an	 always	 closed	 conformation.	 Further	
examination	 of	 the	 ICUE4	 construct	 generated	 showed	 that	 the	 point	 mutation	
responsible	for	preventing	the	sensor	from	opening	up,	and	thus	function,	would	fall	
within	the	RA	region	exchanged	in	order	to	improve	the	localisation	of	the	biosensor.	
This	raised	the	question	as	to	whether	or	not	the	new	ICUE4	biosensor	could	function	
at	all	as	a	sensor	for	cAMP.	To	test	this,	the	emission	ratio	of	both	the	ICUE4	and	the	
ICUE3	 biosensors	 was	 measured	 after	 treatment	 of	 the	 β2-adrenergic	 receptor	
agonist,	 isoproterenol.	 Treatment	 with	 isoproterenol	 causes	 an	 increase	 in	 cAMP	
levels.	The	cAMP	then	interacts	with	the	biosensor	and	allow	it	to	open	up,	as	long	as	
it	is	still	able	to	undergo	a	conformational	change.	This	should	lead	to	a	measurable	
decrease	 in	 FRET.	 The	 ICUE4	 still	 exhibited	 changes	 to	 the	 emission	 ratios	 of	 the	
fluorophores,	 due	 to	 changes	 in	 FRET	 (Figure	 4.8).	 This	 suggests	 that	 the	 ICUE4	
biosensor	can	still	undergo	a	conformational	change	in	the	presence	of	cAMP.		
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4.2.8.	Generation	of	CFP-only	control	for	cAMP	sensors.	
	
As	with	the	AKAR4	constructs,	a	CFP-only	control	is	necessary	to	determine	the	bleed	
through	of	the	CFP	emission	into	the	FRET	transfer	channel.	As	seen	in	Figure	4.9,	the	
YFP	emission	is	abolished	in	the	CFP-only	controls.	Unlike	with	the	AKAR4	constructs,	
the	ICUE	constructs	exist	in	a	closed	conformation	initially,	before	opening	up	in	the	
presence	of	cAMP.	This	means	the	FRET	is	high	in	low	cAMP	conditions	and	explains	
why	the	CFP	emission	is	low	in	the	full	length	construct	and	becomes	stronger	once	
the	acceptor	fluorophore	is	removed,	and	thus	removes	the	FRET	transfer	with	it.		
	
Figure	 4.8	 ICUE4	 construct	 still	 able	 to	 undergo	 a	 conformational	 change	 in	
response	 to	 cAMP.	 (A)	 Schematic	 diagram	 showing	 the	 point	 mutation,	 that	
prevents	ICUE3	from	opening,	in	the	region	that	is	exchanged	to	create	ICUE4.	(B)	
Emission	ratio	time	course	of	ICUE3	and	ICUE4	in	response	to	10µM	isoproterenol	
(Iso).	Error	bars	represent	range.	N	=	1-2.	
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Figure	4.9	Expression	of	CFP	and	YFP	fluorophores	of	ICUE4	CFP-only	controls.	HeLa	
cells	 transfected	 with	 full	 length	 and	 CFP-only	 versions	 of	 the	 cytosolic	 and	
endosomal	ICUE4	constructs.	All	images	levelled	to	the	same	for	comparison.	Scale	
bar	=	10µm.	
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4.2.9.	Generation	of	FRET	biosensor	cell	lines	
	
Many	 endosomal	 proteins	 rely	 on	 FYVE	 domains	 binding	 to	 PtdIns(3)P	 for	 their	
localisation.	Due	to	this,	it	is	important	to	be	careful	when	expressing	proteins	with	
these	domains,	as	seen	with	the	dominant	negative	effects	of	HRS	over-expression.	
Therefore,	stably	expressing	cell	lines	for	the	cAMP	and	PKA	biosensors	were	made.	
Furthermore,	 the	 cell	 lines	 would	 provide	 more	 consistent	 intensities	 of	 the	
fluorophores	 from	 cell	 to	 cell.	 This	 is	 important	 as	 relative	 intensities	 of	 the	
fluorophores	can	have	an	impact	on	FRET	measurements	and	uniform	expression	will	
improve	the	reliability	of	the	measurements.		
	
The	FRET	biosensors	were	introduced	into	HEK293	cells	via	random	integration	and	
single	 colonies	 picked	 to	 generate	 clones.	 This	 would	 produce	 clones	 which	 were	
expressing	the	sensors	at	different	levels,	allowing	me	to	choose	one	that	would	be	
appropriate	for	further	experiments.	Figure	4.10	shows	the	YFP	acceptor	expression	
levels	for	each	cell	line	generated.	For	cytosolic	versions	of	the	FRET	sensors,	the	exact	
expression	doesn’t	need	to	be	as	stringently	controlled.	For	these	cell	lines	the	clones	
which	showed	the	brightest	expression	were	chosen.	For	the	AKAR4	cell	lines,	this	was	
clone	AK-3,	and	for	the	ICUE4	cell	 lines,	this	was	either	clone	IC-2	or	 IC-7.	 IC-7	was	
chosen	due	to	the	fact	that	IC-2	grew	at	a	very	slow	rate.	The	cell	lines	expressing	the	
endosomal	 version	of	 the	FRET	 sensors	need	 to	be	chosen	more	carefully.	 For	 the	
AKAR4-FF	cell	lines,	clones	AKF-3,	AKF-5,	AKF-9	and	AKF-10	gave	a	very	low	expression	
level.	These	cell	lines	would	be	difficult	to	get	FRET	measurements	from	and	so	were	
discounted.	 Clone	 AKF-4	 exhibited	 enlarged	 endosomes,	 indicating	 that	 normal	
endosomal	function	was	disrupted.	Due	to	this,	clone	AKF-2	was	used	for	the	following	
experiments.	For	the	ICUE4-FF	cell	lines,	only	ICF-3	and	ICF-9	were	bright	enough	to	
obtain	FRET	measurements.	Despite	the	clone	ICF-3	being	brighter,	clone	ICF-9	was	
chosen	because	the	ICF-3	clone	appeared	to	be	a	mixed	population	of	cells,	with	some	
cell	being	brighter	than	others.		
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4.2.10	Endosomal	cAMP	and	PKA	biosensor	struggle	to	distinguish	endosomal	
signals	from	the	total	signal	
	
In	 order	 to	 test	 whether	 the	 endosomal	 FRET	 biosensors	 were	 giving	 solely	 an	
endosomal	measurement	for	cAMP	and	PKA	activity,	a	dynamin	inhibitor	was	utilised	
to	 block	 endocytosis	 and	 see	 how	 this	 may	 affect	 endosomal	 and	 cytosolic	 FRET	
measurements	 after	 stimulation	 with	 the	 β2-adrenergic	 receptor	 agonist,	
isoproterenol.	 A	 Laplacian	 filter	 was	 applied	 to	 images	 of	 cells	 expressing	 the	
endosomal	 FRET	 sensor	 in	 order	 to	 solely	 measure	 endosomal	 cAMP	 and	 PKA	
signalling.	As	 is	seen	 in	Figure	4.11,	after	stimulation	with	10µM	isoproterenol,	 the	
CFP/YFP	ratio	of	both	the	ICUE4	and	ICUE4-FF	cAMP	sensors	 increases,	 indicating	a	
decrease	in	FRET	and	an	increase	in	the	levels	of	cAMP.	In	the	presence	of	the	dynamin	
inhibitor,	Dyngo,	the	cytosolic	cAMP	sensor	showed	a	slightly	slower	increase	in	the	
CFP/YFP	ratio	compared	to	the	DMSO	control.	Though	I	hypothesized	that	there	would	
not	be	any	change	 in	 this	measurement,	a	small	change	 like	 the	one	observed	can	
easily	 be	 explained	 by	 the	 dynamin	 inhibitor	 preventing	 the	 endosomal	 produced	
cAMP	from	being	generated.		
	
Issues	 begin	 to	 arise	 when	 examining	 the	 endosomal	 cAMP	 sensor.	 The	 ICUE4-FF	
shows	similar	kinetics	to	the	cytosolic	biosensor,	which	shouldn’t	be	the	case	as	the	
β2-adrenergic	receptors	first	need	to	be	endocytosed	in	order	to	begin	signalling	from	
the	endosome.	This	would	only	occur	after	a	few	minutes.	Secondly,	upon	treatment	
with	 30µM	Dyngo,	 the	 endosomal	 sensor	 only	 shows	 a	 very	 small	 decrease	 in	 the	
CFP/YFP	ratio.		
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With	 the	 PKA	 sensor,	 no	 significant	 difference	 is	 seen	 when	 the	 cytosolic	 AKAR4	
expressing	 cell	 line	 is	 treated	with	 the	dynamin	 inhibitor,	Dyngo,	 compared	 to	 the	
DMSO	 control	 (Figure	 4.12).	 This	 result	 was	 what	 was	 expected	 and	 could	 point	
towards	a	difference	in	preferences	for	the	PKA	pathway	at	the	plasma	membrane	as	
no	reduction	in	the	YFP/CFP	ratio	is	seen	with	the	presence	of	Dyngo,	despite	a	small	
decrease	in	total	cAMP	production.	As	with	the	endosomal	cAMP	sensor,	AKAR4-FF	
also	shows	no	significant	decrease	in	the	measured	YFP/CFP	ratios	when	the	cells	are	
pre-treated	 with	 Dyngo.	 The	 kinetics	 of	 the	 endosomal	 AKAR4-FF	 biosensor	 are	
different	to	the	cytosolic	version	of	AKAR4.	The	AKAR4-FF	biosensor	appears	to	show	
higher	levels	of	FRET	for	longer.	This	contrasts	from	the	ICUE4	biosensor	where	the	
cytosolic	and	endosomal	biosensors	exhibit	the	same	kinetics	as	each	other.		
	
Figure	 4.11	 Proof	 of	 principle	 experiment	 for	 endosomal	 cAMP	 biosensor.	 (A)	
Pseudo-coloured	images	of	endosomal	ICUE4-FF	expressing	cells.	Red	represents	a	
high	amount	of	FRET	and	therefore	low	levels	of	cAMP.	(B	&	C)	Normalised	CFP/YFP	
ratios	of	the	(B)	cytosolic	ICUE4	and	(C)	endosomal	ICUE4-FF	biosensors	after	the	
addition	 of	 10µM	 isoproterenol	 at	 0	 minutes.	 Scale	 bar	 =	 10µm.	 Error	 bars	
represent	SEM.	N	=	3.	Data	analysed	using	multiple	T-tests,	P	<	0.05.	
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To	examine	the	difference	in	FRET	kinetics,	the	Laplacian	filter,	which	was	used	for	the	
FRET	analysis,	was	applied	to	generate	the	pixel	intensity	for	the	FRET	pseudo	colour	
images.	This	creates	an	image	that	highlights	the	endosomes	and	reduces	the	intensity	
of	the	cytosol	pixels	(Figure	4.13).	Comparing	the	two	pseudo	colour	images,	certain	
regions	 of	 the	 binary	 mask	 image	 appeared	 to	 stand	 out	 (highlighted	 by	 white	
arrowheads).	Some	of	these	regions	matched	up	with	the	endosomes	indicated	by	the	
Laplacian	 filter.	 Suggesting	 that	 PKA	 signalling	 at	 some	 of	 the	 endosomes	may	 be	
distinguishable	from	the	cytosol	based	on	their	FRET.	These	endosomes	identified	in	
the	binary	image	are	still	difficult	to	distinguish	by	eye.	
	
Figure	4.12	Proof	of	principle	experiment	for	endosomal	PKA	biosensor.	(A)	Pseudo-
coloured	 images	of	endosomal	AKAR4-FF	expressing	cells.	Red	represents	a	high	
amount	 of	 FRET	 and	 therefore	 high	 levels	 of	 PKA	 activity.	 (B	 &	 C)	 Normalised	
YFP/CFP	ratios	of	the	(B)	cytosolic	AKAR4	and	(C)	endosomal	AKAR4-FF	biosensors	
after	the	addition	of	10µM	isoproterenol	at	0	minutes.	Scale	bar	=	10µm.	Error	bars	
represent	SEM.	N	=	3.	Data	analysed	using	multiple	T-tests,	P	>	0.05.	
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4.3.	Summary	of	results	
	
• The	FYVE	domain	was	 sufficient	by	 itself	 to	 localise	 the	AKAR4	construct	 to	
endosomes.	
• Additional	 modifications	 were	 required	 to	 localise	 the	 ICUE3	 construct	 to	
endosomes,	resulting	in	the	generation	of	the	ICUE4	construct.	
• The	 FRET	 biosensors	 localised	 to	 endosomes	 were	 unable	 to	 effectively	
distinguish	endosomally	derived	cAMP	generation	or	PKA	signalling.		
	
Figure	 4.13	 FRET	 from	 AKAR4-FF	 expressing	 cells	 visualised	 using	 different	
methods.	HEK293	cells	stably	expressing	the	endosomal	AKAR4-FF	biosensor	after	
9	minutes	of	stimulation	with	isoproterenol.	Both	images	depict	the	same	cells	with	
the	pseudo	colour	image	generated	by	different	methods.	The	hue	for	each	image	
is	 generated	 from	 the	 FRET	 analysis	 carried	 out	 by	 slidebook.	 On	 the	 left,	 the	
intensity	of	each	pixel	is	generated	from	a	binary	mask	and	so	is	either	0	or	1.	On	
the	right,	the	intensity	of	each	pixel	comes	from	a	Laplacian	filter	of	the	acceptor	
channel.	Scale	bar	=	10µm.	See	supplementary	movies	1	and	2	for	FRET	pseudo	
colour	videos	using	both	of	these	methods.	
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4.4.	Discussion	
	
The	 aim	 of	 this	 chapter	 was	 to	 develop	 tools	 that	 would	 allow	 me	 to	 study	 the	
endosomal	generation	of	cAMP	and	its	downstream	signalling	pathways.	This	area	of	
research	is	one	that	has	gained	interest	over	the	last	few	years	and	there	is	a	need	to	
improve	upon	the	existing	tools.		
	
Ultimately,	I	was	unable	to	generate	the	endosome	localised	FRET	based	biosensors	
that	 could	 reliably	 differentiate	 PKA	 activity	 or	 cAMP	 produced	 specifically	 at	 the	
endosome	(Figures	4.11	and	4.12).	The	development	of	such	tools,	however,	may	be	
a	 challenging	 endeavour	 due	 to	 the	 nature	 of	 the	 molecules	 being	 measured,	
particularly	 with	 regards	 to	 cAMP.	 cAMP	 is	 a	 small,	 diffusible	 second	 messenger	
molecule,	and	as	a	result	could	be	too	diffusible	to	spatially	differentiate	the	various	
sub-populations.	 Discrete	 microdomains	 have	 been	 well	 established	 for	 Ca2+	
signalling.	However,	 the	diffusion	 rate	of	Ca2+	 is	 approximately	10x	 lower	 than	 the	
diffusion	rate	of	cAMP	(50µm2s-1	opposed	to	500µm2s-1)	 (Zaccolo,	Magalhaes	et	al.	
2002).	This	would	explain	why	 ICUE4-FF	would	have	 similar	 kinetics	 in	 response	 to	
isoproterenol	 to	 its	cytosolic	counterpart.	Diffusion	 is	a	much	quicker	process	 than	
endocytosis,	providing	a	reason	as	to	why	the	endosomal	signals	were	not	abolished	
when	endocytosis	was	supposedly	blocked	by	the	dynamin	inhibitor.	cAMP	would	still	
be	generated	at	the	plasma	membrane,	and	this	pool	is	detectable	by	the	FRET	sensor	
localised	at	the	endosomes.	I	had	hoped	that	phosphodiesterases	would	contain	the	
second	messenger	into	distinct	microdomains,	but	this	appears	not	to	be	the	case	in	
the	above	experiments.	Blocking	of	endocytosis	by	Dyngo	was	not	properly	validated,	
however,	raising	doubt	over	the	validity	of	the	results.	
	
The	duration	of	PKA	activation	determined	by	the	endosomal	PKA	biosensor	differed	
from	the	cytosolic	version.	Furthermore,	it	is	possible	to	distinguish	endosomes	from	
the	FRET	measurements.	It	may,	therefore,	be	possible	to	further	improve	upon	the	
current	 endosomal	 AKAR4	 biosensor.	 The	 cell	 lines	 expressing	 the	 biosensor	 still	
displayed	a	relatively	large	cytosolic	background.	Further	work	may	be	able	to	reduce	
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this	 background	 and	 ultimately	 improve	 the	 signal-to-noise	 ratio.	 Expressing	 the	
biosensor	 in	 cells	 using	 a	 Flp-In	 system	 that	 allows	 for	 inducible	 expression	 may	
provide	more	stringent	control	over	the	expression	of	the	sensor	in	order	to	provide	
a	better	signal	for	FRET	measurements.	An	additional	approach	could	be	to	improve	
the	 affinity	 of	 the	 FRET	 sensor	 for	 endosomes.	 The	 FYVE	 domain	 of	 HRS	 alone	 is	
insufficient	 to	 localise	 GFP	 to	 endosomes,	 but	 by	 doubling	 this	 FYVE	 domain,	
endosomal	localisation	is	achieved	(Gillooly,	Morrow	et	al.	2000).	The	FYVE	domain	of	
FENS,	used	here,	has	a	higher	affinity	for	PtdIns(3)P	than	the	FYVE	domain	of	HRS.	a	
single	copy	of	FENS	FYVE	domain	 is	sufficient	to	 localise	GFP	to	endosomes	(Figure	
4.2).	Doubling	the	FENS	FYVE	domain	on	the	biosensors	should	improve	their	affinity	
to	PtdIns(3)P	further	and	reduce	the	cytosolic	background.		
	
As	 I	 was	 also	 experiencing	 difficulty	 confirming	 the	 interactions	 between	 HRS	 and	
various	G-proteins,	at	this	point	I	decided	to	move	on	from	this	approach	and	examine	
other	areas	of	HRS	function	not	related	to	the	crosstalk	of	RTKs	and	GPCRs.	
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Chapter	five:	HRS	dynamics	in	response	to	
growth	factor	stimulation	
	
Conventionally,	 it	 is	 believed	 that	 the	 function	 of	 HRS	 is	 to	 corral	 ubiquitylated	
receptors	 via	 interactions	 through	 its	UIM	and	VHS	domains	 (Raiborg,	Bache	et	 al.	
2002,	Urbé,	Sachse	et	al.	2003).	HRS	can	also	bind	to	TSG101	of	the	ESCRT-I	complex,	
via	a	PSAP	motif	(Pornillos,	Alam	et	al.	2002,	Bache,	Brech	et	al.	2003).	This	allows	HRS	
to	pass	the	ubiquitylated	receptors	to	the	rest	of	the	ESCRT	machinery	and	ultimately	
leads	to	degradation	of	 the	receptors.	Depletion	or	overexpression	of	HRS	 leads	to	
disruption	of	normal	degradation	processes	(Chin,	Raynor	et	al.	2001,	Urbé,	Sachse	et	
al.	2003).	This	prevents	receptor	down	regulation	leading	to	an	accumulation	of	the	
receptor	at	endosomes.		
	
More	recently,	we	have	been	able	to	show	that	HRS	also	plays	a	role	in	the	recruitment	
of	 WASH	 to	 endosomes	 (MacDonald,	 Brown	 et	 al.	 2018).	 The	 WASH	 complex	 is	
responsible	for	generating	actin	rich-domains	on	endosomes	(Derivery,	Sousa	et	al.	
2009).	Depletion	of	HRS	led	to	a	decreased	localisation	of	WASH	to	endosomes	and	
disruption	of	constitutive	recycling	of	both	the	EGFR	and	the	metalloproteinase	MT1-
MMP.	This	suggests	that	HRS	could	have	a	much	more	central	role	in	the	sorting	of	
transmembrane	proteins	at	endosomes,	by	being	responsible	for	the	recruitment	of	
recycling	machinery,	such	as	the	WASH	complex,	as	well	as	the	other	components	of	
the	ESCRT	machinery.		
	
The	HRS/WASH	axis	controls	the	sorting	of	the	EGFR,	but	since	HRS	is	phosphorylated	
downstream	 of	 EGFR	 activation,	 the	 dynamics	 of	 this	 relationship	 between	 the	
receptor	 and	 the	 HRS/WASH	 axis	 is	 currently	 unknown	 (MacDonald,	 Brown	 et	 al.	
2018).	 If	 HRS	 is	 involved	 in	 the	 recruitment	 of	 both	 degradation	 and	 recycling	
machinery,	how	is	this	balance	controlled?	How	does	HRS	react	to	the	incoming	cargo?	
Furthermore,	trafficking	of	the	EGFR	is	altered,	depending	on	the	ligand	to	which	it	
binds	(Roepstorff,	Grandal	et	al.	2009).		
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The	function	of	HRS	phosphorylation	is	a	topic	that	is	still	controversial.	Studies	have	
shown	that	the	distribution	of	HRS	is	altered	dependent	on	its	phosphorylation	state.	
A	larger	portion	of	phosphorylated	HRS	is	found	in	the	cytosol	compared	to	membrane	
bound	fractions,	despite	the	fact	that	phosphorylation	occurs	at	the	endosomes	(Urbé,	
Mills	et	al.	2000).	Could	the	phosphorylation	of	HRS	be	important	to	how	it	reacts	to	
the	incoming	cargo?	Is	the	recruitment	of	the	degradation	and	recycling	machineries	
altered	by	HRS	phosphorylation?	
	
In	order	to	ascertain	answers	to	some	of	these	questions,	I	use	the	GFP-tagged	HRS	
Flp-In	cell	 lines	described	 in	chapter	three.	These	cells	express	the	GFP-tagged	HRS	
constructs	at	near	endogenous	levels.	This	is	important	in	order	to	look	at	normally	
functioning	endosomes,	as	over-expression	of	HRS	leads	to	a	dominant-negative	effect	
that	disrupts	the	endosomes	normal	function	and	dynamics.	This	is	due	to	the	fact	that	
many	 proteins	 localise	 to	 endosomes	 through	 interactions	 with	 PtdIns(3)P.	 Over-
expression	of	a	FYVE	domain	containing	protein	leads	to	sequestration	of	PtdIns(3)P,	
changing	the	stoichiometry	of	endosomal	proteins.	As	these	cells	express	GFP-tagged	
HRS,	 they	 allow	 for	 real-time	 observations	 of	 HRS	 recruitment	 and	 dynamics	 at	
endosomes.	
	
5.1.	Objectives	
	
The	objective	of	this	chapter	is	to	investigate	the	dynamic	response	of	HRS	to	growth	
factor	 stimulation	 and	 determine	 the	 subsequent	 effect	 on	 the	 recruitment	 of	
downstream	effectors.	By	using	the	same	GFP	cell	lines	described	in	chapter	three,	I	
aim	to	determine	if	the	tyrosine	mutant	(YYFF)	behaves	differently	to	wild	type	HRS.	
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5.2.	Results	
	
5.2.1.	EGF	stimulation	leads	to	an	increase	in	HRS	positive	endosomes	
	
The	GFP-HRS	Flp-In	cell	lines	are	powerful	tools	for	the	study	of	HRS.	They	allow	for	
the	visualisation	of	HRS	without	the	disruption	associated	with	overexpression.	These	
cells	were	used	to	assess	the	effect	of	EGF	on	HRS	in	real	time.	20ng/ml	of	EGF	was	
added	to	GFP-HRS	cell	line	and	the	cells	were	visualised	continually	on	a	spinning	disk	
confocal	for	the	next	10	minutes	(Figure	5.1).	An	increase	in	the	number	of	fluorescent	
puncta	was	observed	after	the	addition	of	the	EGF.	This	does	not	necessarily	suggest	
that	EGF	leads	to	an	increase	in	the	number	endosomes,	but	shows	an	increase	in	the	
number	 of	 HRS	 positive	 endosomes.	 See	 supplementary	 video	 3	 for	 the	movie	 of	
Figure	5.1.	
	
	
	
5.2.2.	HRS	positive	endosome	increase	is	not	dependent	on	phosphorylation	
	
After	 seeing	 the	 number	 of	 HRS	 positive	 endosomes	 increase	 in	 response	 to	 EGF	
stimulation,	I	decided	to	see	if	there	might	be	any	difference	with	the	phosphorylation	
mutant	HRS	cell	line.	This	cell	line	has	two	tyrosine	residues,	Y329	and	Y334,	mutated	
to	 phenylalanine	 residues.	 Both	 cell	 lines	 were	 stimulated	 with	 EGF	 and	 imaged	
continuously	over	the	next	30	minutes.	The	number	of	endosomes	was	counted	using	
the	Trackmate	plug-in	on	ImageJ.	As	can	be	seen	in	Figure	5.2,	there	was	no	significant	
difference	to	the	increase	in	HRS	positive	endosomes	in	response	to	EGF	between	the	
Figure	 5.1	 Time-lapse	 of	 GPF-HRS	 positive	 endosomes	 in	 response	 to	 EGF	
stimulation.	GFP-HRS	expressing	HeLa	cells	were	stimulated	with	20ng/ml	of	EGF	
and	immediately	placed	on	the	microscope	for	live-cell	imaging.	Scale	bar	=	10µm.	
See	supplementary	movie	3	for	a	video	of	the	time-lapse	images.	
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wild	type	and	the	phosphorylation	mutant	HRS.	The	analysis	also	shows	that	there	was	
an	increase	of	about	40%	in	the	number	of	HRS	positive	endosomes.	
	
	
5.2.3.	Transferrin	does	not	lead	to	an	increase	in	HRS	positive	endosomes	
	
To	confirm	that	 the	 increase	 in	HRS	positive	endosomes	 is	 in	response	to	EGF,	 the	
effect	stimulating	the	GFP-HRS	cell	 lines	with	EGF	was	compared	to	the	addition	of	
Transferrin.	GFP-HRS	Flp-In	cells	were	imaged	immediately	after	the	addition	of	either	
EGF	or	Transferrin	and	the	number	of	HRS	positive	endosomes	was	counted	(Figure	
5.3(A)).	 As	 seen	 before,	 the	 number	 of	 HRS	 positive	 endosomes	 increased	 with	
stimulation	of	EGF.	With	the	addition	of	Transferrin,	however,	there	was	no	increase	
in	the	number	of	HRS	positive	endosomes.	Interestingly,	there	was	actually	a	gradual	
decrease	 in	 the	 number	 HRS	 positive	 endosomes	 over	 the	 time,	 resulting	 in	
Figure	5.2	Response	of	wild	type	and	mutant	HRS	to	EGF	stimulation.	(A)	GFP-HRS	
and	 GFP-YYFF	 expressing	 HeLa	 cells	 were	 stimulated	 with	 20ng/ml	 of	 EGF	 and	
immediately	placed	on	the	microscope	for	live-cell	imaging.	Scale	bar	=	10µm.	(B)	
The	number	of	HRS	positive	endosomes	was	counted	and	displayed	as	a	percentage	
of	the	original	number.	Error	bars	represent	SEM.	N	=	5.	Data	points	after	every	5	
minutes	were	analysed.	T-test,	P	>	0.05	at	all	time	points.	
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approximately	 half	 the	 number	 of	 puncta	 after	 10	 minutes.	 This	 is	 likely	 due	 to	
bleaching	of	 the	GFP.	However,	due	 to	 the	 lack	of	biological	 repeats	 there	was	no	
significant	difference	between	the	two.	
	
	
5.2.4.	EGF	does	not	increase	PtdIns(3)P	positive	endosomes	
	
HRS	 is	 localised	 to	 endosomes	 via	 its	 FYVE	 domain.	 The	 FYVE	 domain	 binds	 to	
PtdIns(3)P	on	early	endosomes.	If	the	number	of	HRS	positive	endosomes	is	increasing	
Figure	5.3	Endosome	count	control	experiments.	(A)	GFP-HRS	expressing	HeLa	cells	
were	treated	with	20ng/ml	of	EGF	or	transferrin	(Trf)	and	immediately	placed	on	
the	microscope	for	live-cell	imaging.	The	number	of	HRS	positive	endosomes	was	
counted.	(B)	HeLa	cells	transiently	transfected	with	GFP-FENSFYVE	(GFP-FF)	were	
stimulated	with	20ng/ml	of	EGF.	The	number	of	GFP-FF	positive	endosomes	was	
counted.	Error	bars	represent	range.	N	=	2.	
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in	response	to	EGF,	a	logical	explanation	for	this	is	that	EGF	is	increasing	the	activity	of	
the	 PI-3-kinase,	 VPS34,	 in	 order	 to	 increase	 the	 amount	 of	 PtdIns(3)P	 positive	
endosomes.	To	assess	this,	HeLa	cells	were	transfected	with	the	endosomal	marker,	
GFP-FENSFYVE	 (Figure	5.3(B)).	 The	 FYVE	domain	 from	FENS	 is	 sufficient	 enough	 to	
localise	 to	 PtdIns(3)P	 by	 itself,	 enabling	 it	 to	 act	 as	 a	marker	 for	 early	 endosomes	
(Ridley,	 Ktistakis	 et	 al.	 2001).	 The	 GFP-FF	 positive	 endosomes	 showed	 no	 distinct	
increase	in	the	number	of	endosomes	in	response	to	EGF.	There	does	appear	to	be	a	
slight	gradual	 increase	over	time,	however	this	 is	 insignificant	 in	comparison	to	the	
increase	in	HRS	positive	endosomes.	This	suggests	HRS	is	being	specifically	recruited	
to	 endosomes	 in	 response	 to	 EGF	 stimulation,	 without	 a	 general	 increase	 in	 the	
number	of	endosomes,	or	their	PtdIns(3)P	status.	
	
5.2.5.	HRS	is	recruited	to	EGF	positive	vesicles	
	
If	HRS	is	being	specifically	recruited	to	endosomes	without	this	increase	being	simply	
down	to	an	 increase	 in	the	number	of	endosomes,	the	question	arises,	how	is	HRS	
being	recruited	to	the	endosomes?		One	function	of	HRS	is	to	bind	to	ubiquitylated	
receptors	in	order	to	corral	them	together	into	specific	microdomains	for	degradation.	
Could	the	incoming	cargo,	i.e.	activated	EGFR,	therefore	be	responsible	for	recruiting	
HRS?	To	examine	this,	the	GFP-HRS	cell	line	was	stimulated	with	EGF	that	had	been	
conjugated	to	the	fluorescent	dye	Alexafluor-555	(AF555).	By	using	this	fluorescent	
dye,	the	endocytosed	receptors	could	be	visualised	as	they	were	being	transported	to	
endosomes	(Figure	5.4).	As	shown	by	the	time-lapse	 image,	The	EGF-AF555	can	be	
seen	 at	 the	 plasma	membrane	 at	 the	 start	 of	 the	 experiment.	 As	 the	 experiment	
progresses,	the	fluorescent	protein	starts	to	be	internalised	into	the	cell	 in	vesicles.	
Following	an	individual	vesicle	(arrowheads)	it	can	clearly	be	seen	that	the	magenta	
puncta	(EGF-AF555)	slowly	starts	to	become	white,	indicating	the	accumulation	of	the	
green	fluorescence	from	GFP-HRS.	There	does	not	appear	to	be	a	fusion	event	with	
nearby	GFP-HRS	positive	endosomes	but	rather	the	gradual	recruitment	of	HRS	to	the	
cargo	containing	vesicles.		
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5.2.6.	WASH	is	recruited	to	endosomes	in	response	to	EGF		
	
As	mentioned	above,	our	group	was	able	to	show	that	HRS	is	responsible	for	recruiting	
WASH	to	endosomes	(MacDonald,	2018).	Because	of	this,	I	wondered	if	WASH	would	
react	in	a	similar	manner	to	HRS	in	response	to	EGF.	I	hypothesised	that	the	number	
of	WASH	positive	endosomes	would	increase	in	response	to	EGF	to	a	similar	extent	as	
HRS	positive	endosomes.		
	
To	 begin	 with,	 the	 number	 of	 WASH	 positive	 endosomes	 starts	 to	 increase	 after	
stimulation	with	EGF	(Figure	5.5).	However,	this	increase	is	short	lived	and	very	quickly	
begins	to	go	down.	It	is	possible	that	this	immediate	increase	may	be	an	artefact	from	
Figure	5.4	Recruitment	of	GFP-HRS	after	stimulation	with	fluorescent	EGF.	(A)	Time-
lapse	of	GFP-HRS	expressing	HeLa	cells	after	stimulation	with	EGF-AF555.	Scale	bar	
=	 1µm.	 (B)	 The	 fluorescent	 intensities	 of	 both	 channels	 was	 measured	 for	 the	
vesicle	indicated	by	the	arrowheads.	Black	arrow	indicates	an	upward	inflection	in	
GFP	intensity.	See	supplementary	movie	4	for	a	video	of	the	time-lapse	images	in	
(A).	
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the	imaging.	As	can	be	seen	in	Figure	5.5(A),	the	background	intensity	increases	after	
the	 first	 image.	 The	downward	 trend	of	 the	number	of	WASH	positive	endosomes	
begins	while	HRS	is	still	being	recruited	to	endosomes.	Furthermore,	the	number	of	
WASH	positive	endosomes	continues	to	decrease	below	pre-stimulated	levels,	ending	
at	approximately	66%	of	the	original	number	by	the	end	of	the	experiment,	while	the	
number	of	HRS	positive	endosomes	remains	above	its	original	levels.	From	the	images,	
it	 can	 clearly	 be	 seen	 that	 GFP-WASH	 is	 displaying	 a	 more	 cytosolic	 localisation	
compared	to	the	beginning.		
	
	
	
	 	
Figure	5.5	Response	of	WASH	to	EGF	stimulation.	(A)	Time-lapse	of	GFP-WASH	and	
GFP-HRS	 expressing	 HeLa	 cells	 after	 stimulation	 with	 20ng/ml	 EGF.	 Live-cell	
imaging	 took	 place	 immediately	 after	 stimulation.	 Scale	 bar	 =	 10µm.	 (B)	 The	
number	 of	HRS	 and	WASH	positive	 endosomes	with	 in	 the	 cells,	 displayed	 as	 a	
percentage	 of	 the	 original	 number.	 Error	 bars	 represent	 SEM.	 N	 =	 3.	 See	
supplementary	movie	5	for	a	video	of	 the	GFP-WASH	cells	from	(A).	Data	points	
after	every	5	minutes	were	analysed.	T-test,	P	<	0.05	at	10,	15,20	and	25mins.	
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5.2.7.	TGFα	increases	the	number	of	HRS	positive	endosomes	similarly	to	EGF	
	
Different	 EGFR	 ligands	 have	 different	 effects	 on	 the	 trafficking	 of	 the	 receptor	 in	
response	to	stimulation	(Roepstorff,	Grandal	et	al.	2009).	EGF,	for	example,	leads	to	a	
proportion	 of	 the	 internalised	 receptors	 being	 degraded,	 with	 the	 remaining	
receptors	recycled	back	to	the	plasma	membrane.	Stimulation	with	TGFα,	however,	
leads	to	recycling	of	almost	all	of	the	internalised	EGFR,	with	very	little	being	directed	
towards	degradation.		
	
Due	to	the	fact	that	WASH	was	recruited	to	endosomes	differently	than	HRS,	I	decided	
to	examine	whether	the	recruitment	of	HRS	differed	in	response	to	TGFα	instead	of	
EGF.	GFP-HRS	cells	were	stimulated	with	equal	concentrations	of	EGF	and	TGFα	and	
measured	the	number	of	HRS	positive	endosomes	over	time.	Over	the	first	10	minutes,	
the	number	of	HRS	positive	endosomes	increased	at	the	exact	same	rate	with	both	
EGF	and	TGFα	(Figure	5.6).	At	the	later	time	points,	TGFα	appeared	to	show	a	small	
decrease	in	the	number	of	HRS	positive	endosomes	compared	to	EGF,	but	this	did	not	
reach	significance.		
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5.2.8.	The	HRS	phosphorylation	mutant	shows	a	smaller	increase	in	endosomes	
with	TGFα	
	
The	HRS	 phosphorylation	mutant	 (YYFF)	 shows	 no	 difference	 in	 its	 recruitment	 to	
endosomes	compared	to	wild	type	HRS	when	stimulated	with	EGF.	As	activation	of	
different	RTKs	lead	to	differential	phosphorylation	patterns	of	the	receptor	and	HRS	
(Row,	2005),	I	wanted	to	determine	whether	the	phosphorylation	mutant	would	react	
to	 TGFα	 in	 a	 similar	manner	 to	 EGF,	 as	 seen	 with	 the	 wild	 type	 HRS	 cells.	When	
stimulated	with	EGF	the	number	of	HRS	positive	endosomes	increase	by	40-60%	with	
both	the	wild	type	and	the	phosphorylation	mutant.	However,	when	stimulated	with	
TGFα	the	HRS	(YYFF)	cells	appeared	to	exhibit	a	smaller	increase	in	the	number	of	HRS	
Figure	5.6	The	effect	of	EGF	and	TGFα	on	HRS.	(A)	Representative	images	of	GFP-
HRS	expressing	HeLa	cells	after	stimulation	of	20ng/ml	stimulation	of	EGF	or	TGFα.	
Scale	bar	=	10µm.	(B)	The	number	of	HRS	positive	endosomes	in	the	cells,	displayed	
as	a	percentage	of	the	original	number.	Error	bars	represent	SEM.	N	=	3.	Data	points	
after	every	5	minutes	were	analysed.	T-test,	P	>	0.05	at	all	time	points.	
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positive	 endosomes,	 increasing	 by	 approximately	 25%	 (Figure	 5.7),	 however	 this	
difference	 did	 not	 reach	 statistical	 significance.	 The	 peak	 number	 of	 positive	
endosomes	 occurred	 earlier	with	 TGFα	 than	with	 EGF	 and	 subsequently	 began	 to	
decrease	gradually	over	 time.	After	25	minutes	of	TGFα	simulation,	 the	number	of	
HRS	positive	endosomes	had	almost	returned	to	the	original	levels.	Further	biological	
repeats	could	increase	the	power	of	the	experiment.	
	
	
	
	
Figure	5.7	The	effect	of	EGF	and	TGFα	on	mutant	HRS	(YYFF).	(A)	Representative	
images	of	GFP-YYFF	expressing	HeLa	cells	after	stimulation	of	20ng/ml	stimulation	
of	EGF	or	TGFα.	Scale	bar	=	10µm.	(B)	The	number	of	HRS	positive	endosomes	in	
the	cells,	displayed	as	a	percentage	of	the	original	number.	Error	bars	represent	
SEM.	N	=	3.	Data	points	after	every	5	minutes	were	analysed.	T-test,	P	>	0.05	at	all	
time	points.	
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5.2.9.	APEX2-HRS	cells	allow	for	easy	visualisation	of	the	flat	endosomal	clathrin	
coat	
	
Despite	experiencing	trouble	with	 the	APEX2-HRS	cell	 line	 for	mass	spectrometry,	 I	
decided	to	see	if	I	they	could	be	used	for	electron	microscopy	(EM).	The	APEX2	enzyme	
is	able	 to	generate	diaminobenzidine	 (DAB)	 radicals,	which	aggregate	 together	and	
form	an	electron	dense	stain.	These	cells	should	allow	me	to	visualise	the	sub-cellular	
localisation	of	HRS	by	electron	microscopy.	
	
APEX2-HRS	 cells	 were	 incubated	 with	 DAB	 prior	 to	 fixation.	 The	 cells	 were	 then	
incubated	with	H2O2	 and	 prepared	 for	 EM.	 Figure	 5.8	 shows	multiple	 examples	 of	
APEX2-HRS	staining	on	endosomes.	The	DAB	staining	appears	to	localise	to	a	distinct	
microdomain	 on	 the	 endosomes	 (arrowheads).	 The	 membrane	 within	 this	 region	
appears	flatter	than	the	rest	of	the	endosome.	These	regions	show	the	morphological	
characteristics	of	the	flat	clathrin	coat	present	on	endosomes	(Futter,	Gibson	et	al.	
1998).	 These	 regions	 have	 otherwise	 been	 challenging	 to	 visualise,	 however,	 the	
APEX2-HRS	cell	line	has	provided	a	simple	method	for	imagining	these	regions.		
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5.2.10.	HRS	phosphorylation	does	not	affect	concerted	HRS	recruitment	waves	
	
A	 recent	 paper	 published	 at	 the	 end	 of	 experimentation,	 described	 waves	 of	
recruitment	of	various	components	of	 the	ESCRT	machinery	 (Wenzel,	Schultz	et	al.	
2018).	 By	 analysing	 individual	 endosomes,	 they	 identified	 concerted	 waves	 in	 the	
fluorescence	 intensity	 of	 HRS,	 TSG101	 and	 various	 CHMPs	 in	 response	 to	 EGF	
stimulation.	Analysis	of	the	experiments	described	in	this	chapter	have	focused	on	the	
population	 of	 HRS	 positive	 endosomes	 as	 a	 whole	 and	 not	 at	 an	 individual	 level.	
Retrospective	analysis	of	 the	data	 identified	similar	 recruitment	waves	 for	HRS	and	
also	for	the	HRS	mutant	(YYFF),	suggesting	that	phosphorylation	at	Y329	and	Y334	has	
no	effect	on	this	concerted	recruitment	pattern	(Figure	5.9).		
	
Interestingly,	recruitment	of	HRS	to	a	newly	formed	EGF	positive	vesicle	did	not	appear	
to	 demonstrate	 these	 waves	 of	 recruitment	 (Figure	 5.4(B)),	 with	 only	 established	
endosomes	displaying	this	characteristic.		
Figure	 5.8	 Electron	 microscopy	 of	 APEX2-HRS	 expressing	 HeLa	 cells.	 (i-iv)	
Representative	images	of	endosomes	with	APEX2-HRS	expressed.	Staining	induced	
by	incubation	with	1mg/ml	DAB	and	10mM	H2O2	for	30	minutes.	Scale	bar	=	200nm.	
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5.3.	Summary	of	results	
	
• EGF	stimulation	leads	to	an	increase	in	the	number	of	HRS	positive	endosomes	
in	wild	type	and	mutant	cells	
• Recruitment	of	HRS	occurs	on	nascent	vesicles.	
• Phosphorylation	plays	a	role	in	the	response	of	HRS	to	TGFα	but	not	to	EGF.	
• Despite	HRS	being	responsible	for	recruiting	WASH	to	endosomes,	WASH	is	not	
recruited	in	response	to	EGF.	
• Clathrin	microdomains	can	be	clearly	visualised	in	APEX2-HRS	expressing	cells.	
	
5.4.	Discussion	
	
The	aim	of	this	chapter	was	to	study	HRS	dynamically	 in	response	to	growth	factor	
stimulation.	 This	 has	 previously	 been	 difficult	 to	 study	 due	 to	 the	 fact	 that	
overexpression	of	HRS	 leads	to	a	dominant	negative	effect	on	endosomal	 function.	
Here,	 I	 used	HeLa	 cells	which	 are	 stably	 expressing	 either	wild	 type	GFP-HRS	 or	 a	
phosphorylation	mutant	GFP-HRS	(YYFF).	These	proteins	were	 introduced	using	the	
Flp-In	system,	generating	isogenic	cell	lines	which	express	the	tagged	proteins	at	near	
endogenous	 levels.	 These	 cells	 have	 allowed	 me	 to	 study	 the	 dynamics	 of	 HRS	
recruitment	without	disruption	to	endosome	morphology	or	function.		
Figure	5.9.	Concerted	 recruitment	waves	of	wild	 type	and	mutant	HRS.	 (A	&	B)	
Fluorescent	intensities	of	individual	vesicles	from	(A)	wild	type	and	(B)	mutant	HRS	
expressing	HeLa	cells	after	stimulation	with	20ng/ml	of	EGF.		
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A	study	from	Haugen	et	al.	at	the	end	of	2017	examined	the	binding	kinetics	of	HRS	
and	Eps15	and	how	this	regulated	RTK	degradation	(Haugen,	Skjeldal	et	al.	2017).	They	
show	a	transient	drop	in	fluorescence	intensity	of	endosomal	HRS	around	8	minutes	
after	EGF	stimulation.	They	also	 report	a	decrease	 in	 the	 immobile	 fraction	of	HRS	
after	performing	FRAP	experiments.	These	findings	fit	 in	with	previous	finding	from	
my	laboratory	that	show	a	greater	proportion	of	phosphorylated	HRS	in	the	cytosol	
than	 on	 endosomes	 (Urbé,	 Mills	 et	 al.	 2000).	 However,	 this	 transient	 drop	 in	
endosomal	HRS	fluorescence	is	a	finding	which	I	have	been	unable	to	observe	in	the	
experiments	 described	 above.	 Furthermore,	 FRAP	 experiments	 performed	 by	 a	
colleague	 found	the	opposite	effect	on	 the	 immobile	 fraction	of	HRS,	observing	an	
increase	in	the	immobile	fraction	after	stimulation	with	EGF	(Macdonald,	unpublished	
results).	The	results	did	show	that	the	HRS	phosphorylation	mutant	had	no	change	to	
its	 immobile	 fraction	 in	 response	to	EGF	stimulation,	which	 is	 in	accordance	to	 the	
data	from	Haugen	et	al.	(Haugen,	Skjeldal	et	al.	2017).		
	
The	findings	of	this	chapter	disagree	with	some	of	the	results	reported	by	Haugen	et	
al.,	 despite	 the	 fact	 that	 both	 studies	 use	 stably	 expressing	 cell	 lines	 to	 study	HRS	
dynamics.	This	drop	 in	 fluorescence	may	be	a	phenotype	of	human	fibroblast	 (M1)	
cells	used	in	their	study	and	therefore	not	present	in	the	HeLa	cells	used	here	(Haugen,	
Skjeldal	et	al.	2017).	Another	explanation	for	the	discrepancies	could	be	due	to	their	
co-expression	of	a	MHC-class-II-associated	chaperone	invariant	chain	(Ii-Mep4),	which	
leads	to	enlarged	endosomes.	This	is	an	alternative	to	enlarging	endosomes	with	the	
Rab5	mutant,	Rab5(Q79L),	and	therefore	doesn’t	affect	Rab5	to	Rab7	conversion	or	
EEA1	binding	dynamics	(Skjeldal,	Strunze	et	al.	2012).	It	may	also	be	possible	that	the	
observations	found	within	this	study	are	an	artefact	of	enlarging	endosomes.		
	
Binding	dynamics	of	HRS	was	studied	in	another	paper	from	2018.	Wenzel	et	al.	used	
lentivirus-generated	 cell	 lines	 expressing	 various	 ESCRT	 components	 tagged	 to	
fluorescent	markers	(Wenzel,	Schultz	et	al.	2018).	This	resulted	in	the	expression	of	
mCherry-HRS	at	near	endogenous	levels.	Importantly,	this	study	doesn’t	manipulate	
endosomes	 in	any	other	way.	Wenzel	et	 al.	 showed	 that	HRS,	 TSG101	and	various	
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CHMPs	are	recruited	to	endosomal	membranes	in	concerted	waves.	Each	wave	results	
in	the	formation	of	an	intraluminal	vesicle	(ILV).	It’s	worth	noting	that	this	study	used	
HeLa	cells	and	also	didn’t	observe	a	drop	in	fluorescence	intensity	after	8	minutes	of	
stimulation	with	EGF.	Retrospective	analysis	of	the	data	in	this	chapter	reveals	similar	
waves	of	HRS	recruitment,	 though	the	waves	are	 less	clear	than	those	reported	by	
Wenzel	et	al.	This	is	most	likely	due	to	the	slight	differences	in	the	experimental	set	
up.	 The	 study	 from	 Wenzel	 et	 al.	 stimulated	 with	 a	 high	 concentration	 of	 EGF	
(200ng/ml	opposed	to	20ng/ml)	for	2	minutes	before	washing	the	growth	factor	out	
and	imaging	the	cells.	In	my	experiments	EGF	wasn’t	washed	out	and	was	present	in	
the	media	throughout	imaging.		
The	increase	in	HRS	positive	endosomes	appears	to	be	due	to	the	recruitment	of	HRS	
to	newly	formed	vesicles	containing	the	endocytosed	receptor.	These	vesicles	appear	
not	to	be	positive	for	PtdIns(3)P,	as	the	number	of	GFP-FF	positive	endosomes	did	not	
increase	with	stimulation	of	EGF.	This	somewhat	contradicts	a	study	from	early	2018	
which	 examined	 the	 activation	 of	 an	 AGC	 kinase	 family	 member,	 SGK3	 (Malik,	
Macartney	et	al.	2018).	The	study	found	that	stimulation	with	50ng/ml	of	IGF1	would	
increase	the	levels	of	PtdIns(3)P.	This	was	performed	on	fixed	samples	in	HEK293	cells	
and	with	a	purified	PtdIns(3)P	probe,	so	did	not	dynamically	examined	the	effect	of	
IGF1	on	the	levels	of	PtdIns(3)P.	It	is	feasible	to	believe	the	effect	on	PtdIns(3)P	is	cell	
type	and	growth	factor	dependent.	
	
Recruitment	of	HRS	appears	to	be	mediated	by	the	incoming	cargo.	HRS	interacts	with	
ubiquitylated	receptors	via	double-sided	UIM	and	VHS	domains	(Raiborg,	Bache	et	al.	
2002).	This	interaction	could	be	responsible	for	recruitment	of	HRS	to	endosomes	in	
response	to	EGF	stimulation.	Ubiquitin	has	previously	been	shown	to	be	sufficient	for	
the	 recruitment	 of	 the	HRS	 binding	 partner,	 Eps15	 (Gucwa	 and	 Brown	 2014).	 It	 is	
possible	that	these	two	proteins	are	recruited	to	endosomes	 in	a	similar	fashion	to	
one	 another.	 Equally,	 recruitment	 of	 either	 protein	 could	 be	 mediated	 by	 the	
interaction	with	the	other.	
	
Different	growth	factors	provide	different	phosphorylation	profiles	on	both	HRS	and	
STAM	(Row,	Clague	et	al.	2005,	Francavilla,	Papetti	et	al.	2016).	This	may	provide	an	
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explanation	 for	 why	 the	 HRS	 phosphorylation	 mutant	 reacted	 differently	 to	
stimulation	with	EGF	and	TGFα.	With	recruitment	and	phosphorylation	of	HRS	being	
mediated	by	the	incoming	cargo,	it	suggests	that	the	endocytosed	RTK	is	priming	HRS	
to	recruit	the	appropriate	downstream	effectors.	EGF	pushes	the	EGFR	more	towards	
degradation	while	TGFα	encourages	the	receptor	to	be	recycled	back	to	the	plasma	
membrane	(Roepstorff,	Grandal	et	al.	2009).	Therefore,	it	is	possible	that	stimulation	
with	 EGF	 will	 encourage	 the	 recruitment	 of	 the	 rest	 of	 the	 ESCRT	machinery	 and	
stimulation	with	TGFα	will	lead	HRS	to	recruit	the	WASH	complex.		
	
The	APEX2-HRS	cell	lines	allowed	HRS	to	be	visualised	by	electron	microscopy.	They	
reveal	 distinct	 microdomains	 that	 resemble,	 flat	 clathrin	 coated	 domains	 (Futter,	
Gibson	 et	 al.	 1998,	 Sachse,	 Urbé	 et	 al.	 2002).	 These	 domains	 can	 be	 difficult	 to	
visualise.	HRS	appears	to	be	confined	to	microdomains	on	flat	regions	of	endosomes.	
Further	 studies	 from	our	collaborators	have	visualised	 the	phosphorylation	mutant	
(YYFF)	by	EM	(data	not	shown).	The	heavy	staining	from	the	DAB	in	the	APEX2-YYFF	
expressing	cells	appeared	to	be	less	confined	and	was	present	on	tubular	regions	of	
endosomes.	Phosphorylation	of	HRS	at	Y329	and	Y334	may	be	responsible	for	defining	
the	distinct	clathrin	microdomains	on	endosomes.	These	domains	are	present	in	non-
stimulated	cells,	however,	so	it	is	unclear	how	phosphorylation	of	HRS	will	impact	this	
process.	
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Chapter	six:	Final	discussion	
6.1.	APEX2	cell	lines	as	tools	
	
The	APEX2	enzyme	is	a	reagent	for	proximity	ligation	that	offers	advantages	over	the	
previously	established	BioID	method	due	to	its	short	labelling	time	(Mehta	and	Trinkle-
Mulcahy	2016).	Tagging	with	biotin	occurs	within	minutes	as	opposed	to	hours,	and	
therefore	provides	a	‘snapshot’	of	 interacting	proteins.	This	enzyme	was	developed	
for	 the	 study	 of	 mitochondria	 and	 has	 been	 very	 effective	 at	 labelling	 the	 whole	
proteome	 of	 the	 organelle	 matrix.	 The	 mitochondria	 are,	 however	 enclosed	
organelles,	limiting	the	diffusion	of	biotin-phenol	free	radicals.	Extra	precautions	are	
required	in	order	to	examine	the	cytosolic	face	of	organelles,	including	mitochondria,	
and	thus,	there	are	limited	studies	to	my	knowledge	that	utilise	this	enzyme	on	the	
cytosolic	 facing	membrane	 of	 organelles	 (Hung,	 Zou	 et	 al.	 2014,	 Hung,	 Lam	 et	 al.	
2017).	The	first	example	of	this	kind	of	study	was	for	the	 investigation	of	signalling	
events	 in	primary	 cilia	 (Mick,	 Rodrigues	 et	 al.	 2015).	Access	 to	 the	primary	 cilia	 is,	
however,	 tightly	 controlled.	 Though	 this	 study	 is	 the	 first	 to	 demonstrate	 that	
proximity	labelling	can	be	applied	to	proteomics	of	non-membrane	bound	organelles,	
this	isn’t	a	truly	open	example	of	proximity	labelling	proteomics.		
	
In	2017,	Lobingier	et	al.,	demonstrated	that	APEX2	can	be	used	on	endosomes	and	
show	 that	 the	 enzyme	 can	 also	 be	 used	 to	 examine	 a	 specific	 protein	 network	
(Lobingier,	Huttenhain	et	al.	2017).	The	authors	tagged	the	β-adrenergic	receptor	with	
APEX2	to	examine	the	proteins	which	engage	with	the	receptor	as	it	traffics	from	the	
plasma	membrane	 to	 the	 endosome.	 They	 targeted	 the	 APEX2	 enzyme	 to	 various	
compartments	to	use	as	 ‘compartment	references’	 in	order	to	spatially	 resolve	the	
specific	protein	network	from	what	they	term	as	‘bystanders’,	i.e.	proteins	which	are	
present	 in	 close	 proximity	 to	 the	 protein	 network	 but	 are	 not	 directly	 involved	
(Lobingier,	 Huttenhain	 et	 al.	 2017).	 This	 approach	works	well	 for	 the	 β-adrenergic	
receptor,	 since	 it	 is	 a	 transmembrane	 receptor,	 and	 therefore	 only	 exists	 on	 lipid	
membranes.	 The	 additional	 challenge	 faced	 when	 applying	 these	 approaches	 to	
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proximity	ligation	of	HRS	interactors,	is	that	the	membrane	interaction	of	HRS	is	very	
dynamic,	 with	 a	 large	 pool	 of	 HRS	 existing	 in	 the	 cytosol.	 This	 makes	 the	 task	 of	
deciding	which	compartment	reference	to	use	difficult.		
	
More	recently,	a	study	investigating	interactors	of	Rab21,	utilised	the	APEX2	enzyme	
for	proximity	labelling	proteomics	(Del	Olmo,	Lauzier	et	al.	2019).	As	with	HRS,	Rabs	
also	have	a	dynamic	association	with	membranes.	The	study	expressed	APEX2	tagged	
Rab	proteins	using	Flp-In	T-REx	cells.	This	allows	the	expression	of	the	APEX2	enzyme	
to	 be	 modulated	 by	 stimulation	 with	 doxycycline.	 The	 study	 doesn’t	 provide	 a	
comparison	between	the	endogenous	or	APEX2-tagged	Rabs,	so	it	isn’t	clear	how	the	
expression	of	the	APEX2	enzyme	compares	to	the	experiments	described	in	chapter	
three	of	this	thesis.	The	number	of	proteins	identified	in	this	study	was	much	higher	
than	in	the	APEX-HRS	cell	line	dataset,	which	leads	me	to	believe	that	APEX2	may	have	
been	expressed	at	higher	levels	than	in	my	own	experiments.	This	is	further	supported	
by	the	fact	that	‘bystanders’	typically	seen	at	endosomes,	such	as	EEA1,	were	absent	
from	my	APEX2	cell	line	dataset	(Figure	3.10).	The	Flp-In	T-REx	system	may	provide	a	
better	system	for	expressing	APEX2-HRS	constructs	as	it	provides	more	control	over	
the	expression	levels	of	the	enzyme.	
	
As	mentioned	in	section	3.4,	it	may	be	possible	that	HRS	is	poorly	labelled	when	using	
the	APEX2	enzyme	for	proximity	labelling.	HRS	and	STAM	tyrosine	residues	are	highly	
phosphorylated	 in	 response	 to	 EGF	 stimulation	 (Omerovic,	Hammond	et	 al.	 2012).	
Biotin-phenol	radicals	generated	by	APEX2	preferentially	bind	to	tyrosine	(Hung,	Zou	
et	al.	2014).	This	 raises	 the	question	of	whether	tyrosine	phosphorylation	prevents	
APEX2	from	 labelling	HRS	with	biotin-phenol.	 In	addition,	 tyrosine	 is	a	hydrophobic	
amino	acid	and	as	a	result	only	about	~15%	of	tyrosine	residues	are	surface	accessible	
in	folded	proteins	(Lins,	Thomas	et	al.	2003).	In	contrast,	biotin	radicals	generated	by	
BioID	label	lysine	residues	(Li,	Li	et	al.	2017).	Lysine	residues	are	approximately	50%	
surface	accessible,	suggesting	that	proximity	labelling	by	BioID,	may	be	able	to	label	
proteins	to	a	much	larger	extent.	With	the	advent	of	TurboID,	a	version	of	the	BioID	
system	 that	 is	 capable	 of	 labelling	 proteins	 with	 biotin	 within	 10	minutes,	 it	 may	
provide	a	better	option	moving	forward	than	the	APEX2	enzyme	(Branon,	Bosch	et	al.	
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2018).	It	is	worth	noting	that	HRS	also	experiences	ubiquitin	modifications,	and	so	a	
combination	of	the	two	approaches	may	be	required.		
	
For	electron	microscopy,	these	APEX2	cell	lines	did	work	well.	The	images	shown	in	
Figure	5.8	show	HRS	localised	in	regions	which	resemble	flat	clathrin	microdomains.	
This	raises	the	question	of	why	the	enzyme	did	not	work	as	well	for	analysing	protein-
protein	interactions	as	it	did	for	EM.	The	reason	is	most	likely	due	to	how	the	heavy	
stain	is	generated.	The	APEX2	enzyme	generates	DAB	free	radical,	similar	to	creating	
biotin-phenol	free	radical.	However,	the	DAB	free	radical	species	is	not	then	tagging	
neighbouring	proteins.	It	forms	a	precipitate	at	the	site	where	it	was	formed	(Martell,	
Deerinck	et	al.	2012).	This	mitigates	the	potential	labelling	issues	found	when	labelling	
HRS	with	biotin-phenol.	
	
6.2.	HRS	recruitment	to	endosomes	
	
6.2.1.	DTX3L	and	HRS	recruitment	
	
Recruitment	 of	 the	 ubiquitin	 E3	 ligase,	 DTX3L,	 to	 endosomes	 has	 previously	 been	
reported	after	stimulation	with	CXCL12	(Holleman	and	Marchese	2014).	Furthermore,	
when	DTX3L	is	knocked	down	by	siRNA,	cells	which	have	been	stimulated	with	CXCL12	
show	reduced	recruitment	of	ESCRT-0	proteins	onto	endosomes.	I	have	now	shown	
that	DTX3L	interacts	with	HRS	in	an	EGF	dependent	manner	(Figure	3.10).	It’s	possible	
that	this	interaction	acts	to	modulate	the	levels	of	HRS	ubiquitylation	and	prevent	HRS	
exhibiting	 auto-inhibition	 of	 itself	 through	 the	 UIM	 binding	 to	 its	 own	 ubiquitin	
modifications	 (Hoeller,	 Crosetto	 et	 al.	 2006),	 allowing	 the	 UIM	 to	 be	 open	 for	
interactions	with	other	ubiquitylated	proteins.	This	 interpretation	is	consistent	with	
both	my	observations	and	the	observation	from	Holleman	and	Marchese	that	ESCRT-
0	exhibits	a	reduced	endosomal	 localisation	due	to	DTX3L	siRNA	KD	(Holleman	and	
Marchese	2014).		
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In	 the	 work	 presented	 in	 chapter	 five,	 I	 show	 that	 HRS	 is	 recruited	 directly	 to	
endocytosed	vesicles	 containing	EGF.	My	 leading	hypothesis	 for	 this	observation	 is	
that	HRS	is	recruited	to	these	vesicles	by	the	interaction	between	the	ubiquitylated	
EGFR	and	the	UBDs	of	HRS.	Traditionally,	recruitment	of	HRS	to	endosomes	is	thought	
to	be	mediated	by	its	FYVE	domain	(Raiborg,	Bremnes	et	al.	2001),	however,	the	effect	
of	EGF	stimulation	on	the	levels	of	PtdIns(3)P	don’t	correlate	with	the	recruitment	of	
HRS.	Since	DTX3L	has	been	shown	to	modulate	the	level	of	ubiquitylation	of	HRS	and	
STAM	by	AIP4,	it	would	therefore	be	interesting	to	incorporate	this	finding	into	the	
work	described	in	chapter	five	regarding	HRS	recruitment.	
	
6.2.2.	HRS	recruitment	in	response	to	TGFα	
	
Stimulation	with	EGF	leads	to	an	increase	in	the	number	of	HRS	positive	puncta.	This	
recruitment	was	unaffected	in	the	HRS	phosphorylation	mutant	(YYFF)	(see	figure	5.2).	
EGF	leads	to	a	proportion	of	the	internalised	EGFR	to	be	degraded,	with	the	remainder	
recycled	back	to	the	plasma	membrane.	Stimulation	of	the	EGFR	with	TGFα	however	
leads	to	the	majority	of	the	receptor	to	be	recycled	(Roepstorff,	Grandal	et	al.	2009).	
When	assessing	the	recruitment	of	HRS	in	response	to	TGFα	stimulation,	I	found	that	
the	HRS	mutant	(YYFF)	to	be	recruited	less	than	wild	type	HRS	(Figure	5.7).	This	leads	
me	 to	 suggest	 that	 tyrosine	 residues	 329	 and	 334	 may	 be	 involved	 in	 recruiting	
recycling	machinery	to	endosomes.	Endosomal	recruitment	of	the	recycling	complex	
WASH	 is	mediated	 in	 part	 by	 HRS,	 though	 the	mechanism	 by	which	 this	 occurs	 is	
unclear	(MacDonald,	Brown	et	al.	2018).		
	
Recycling	 of	 the	 EGFR	 when	 stimulated	 with	 TGFα	 is	 believed	 to	 be	 due	 to	 the	
dissociation	rate	between	the	ligand	and	the	receptor.	TGFα	dissociates	from	the	EGFR	
at	a	less	acidic	pH	than	EGF	and	so	is	uncoupled	from	the	EGFR	at	the	early	endosome	
(Ebner	 and	 Derynck	 1991).	 This	 was	 thought	 to	 encourage	 the	 recycling	 of	 the	
receptor	rather	than	its	degradation.	The	data	described	in	the	present	study	suggests	
that	 this	 may	 be	 a	 more	 active	 process	 and	 dependent	 on	 the	 particular	
phosphorylation	status	of	HRS.		
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6.3.	HRS	‘priming’	
	
This	leads	me	to	a	working	model	to	guide	future	work,	whereby	HRS	plays	a	more	
central	 role	 in	 endosomal	 sorting	 and	 is	 ‘primed’	 to	 respond	 depending	 on	 the	
incoming	cargo	(Figure	6.1).	HRS	is	primed	based	on	the	phosphorylation	and	ubiquitin	
code,	 determined	 by	 upstream	 signalling	 molecules.	 Receptors	 that	 are	 primarily	
degraded,	 phosphorylate	 HRS	 in	 a	 way	 that	 primes	 it	 for	 degradation	 processes,	
encouraging	HRS	 to	 recruit	 the	 degradation	machinery.	 Conversely,	 receptors	 that	
need	 recycling	 will	 lead	 to	 a	 different	 pattern	 of	 phosphorylation	 and	 ubiquitin	
modification	 that	 encourage	 the	 recruitment	 of	 recycling	 machinery	 components,	
such	as	WASH.	The	particular	pattern	of	post-translational	modifications	 leads	 to	a	
differential	response	with	regards	to	endosomal	sorting,	trafficking	and	signalling.	
	
	
Figure	 6.1	 A	 working	 model	 for	 HRS	 ‘priming’.	 The	 activated	 receptors	 being	
trafficked	 to	 the	 endosomes	 ‘primes’	 HRS	 by	 inducing	 a	 particular	 pattern	 of	
phosphorylation	 (red	 circles)	 and	 ubiquitin	 (purple	 circles)	 modifications.	 This	
profile	of	modifications	then	determines	the	response	of	HRS	to	the	incoming	cargo	
by	 recruitment	 of	 either	 degradation	 machinery,	 recycling	 machinery	 or	 other	
signalling	molecules.	
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6.4.	Future	work	
	
6.4.1.	Further	advancements	of	the	APEX2	and	FRET	cell	lines	generated	
	
The	development	of	molecular	tools	and	cell	lines	was	a	major	objective	of	the	work	
undertaken.	 Further	 work	 is,	 however,	 required	 in	 order	 to	 improve	 upon	 those	
generated	here.	Measurements	of	cAMP	at	endosomes	may	be	a	more	challenging	
endeavour	due	to	the	diffusion	rate	of	the	second	messenger.	Regulation	of	PKA	is	
more	 tightly	 controlled	 and	 so	 improvements	 to	 the	 cell	 lines	 generated	 may	 be	
possible.	I	had	generated	cell	 lines	by	random	integration	so	that	I	could	choose	an	
appropriately	expressing	cell	line.	With	hindsight,	it	may	have	been	more	beneficial	to	
use	inducible	Flp-In	cell	lines	such	as	the	Flp-In	T-REx	system.	This	would	have	allowed	
for	more	stringent	control	over	the	expression	of	the	cytosolic	and	endosomal	PKA	
biosensors.	
	
Generation	 of	 the	 APEX2-HRS	 cell	 lines	 using	 the	method	 described	was	 the	most	
applicable	 in	 terms	 of	 HRS	 biology.	 It	 led	 to	 the	 expression	 of	 the	 APEX2-HRS	
constructs	at	near	endogenous	 levels.	This	was	appropriate	 for	 the	use	of	 the	cells	
lines	in	electron	microscopy	but	may	have	led	to	the	APEX2	enzyme	being	expressed	
at	too	low	of	a	level	to	achieve	reliable	labelling	with	biotin	phenol.	Utilising	the	Flp-In	
T-REx	system	may	also	allow	for	better	control	over	the	expression	of	these	constructs.	
This	would	allow	for	the	expression	to	be	fine-tuned	to	better	manage	the	balance	
between	APEX2	expression	and	negatively	impacting	HRS	function.	
	
As	 HRS	 is	 heavily	 tyrosine	 phosphorylated	 in	 response	 to	 many	 growth	 factors,	
labelling	with	biotin	phenol	by	APEX2	may	 lead	to	the	poor	 labelling	of	HRS.	 In	this	
vein,	it	may	be	more	appropriate	to	use	the	turboID	enzyme	for	proximity	labelling	of	
HRS	 interactors,	 as	 this	 enzyme	 leads	 to	 the	 labelling	 of	 lysine	 residues	 instead	 of	
tyrosine.	The	reduced	labelling	time	of	this	enzyme	over	its	predecessors,	may	allow	
for	 appropriate	 time	 resolution	 that	 is	 required	 for	 studying	 the	 EGF	 dependent	
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binding	partners	of	HRS.	However,	since	HRS	also	experiences	ubiquitin	modification,	
the	combination	of	both	enzymes	used	in	conjunction	may	be	required.	
	
6.4.2.	Further	work	on	the	recruitment	of	HRS	
	
My	leading	hypothesis	for	the	recruitment	of	HRS	to	EGF	positive	vesicles	is	through	
interaction	of	 its	UBDs	with	ubiquitylated	receptors.	An	obvious	next	step	to	assess	
this	 notion	 would	 be	 to	 repeat	 the	 endosomal	 recruitment	 experiments	 with	
perturbations	to	the	UIM	and	VHS	domain	of	HRS,	as	well	as	to	the	FYVE	domain.	If	
the	EGF	dependent	increase	in	HRS	positive	puncta	is	abolished	with	the	UBD	mutants,	
this	would	provide	strong	evidence	that	incoming	cargo	is	responsible	for	the	initial	
recruitment	of	HRS.		
	
It	would	also	be	interesting	to	see	how	DTX3L	affects	HRS	recruitment.	Assessing	how	
treatment	with	DTX3L	siRNA	would	affect	the	dynamics	of	HRS	recruitment	would	take	
the	work	by	Holleman	and	Marchese	a	step	further.	The	experiment	described	by	their	
study	was	in	the	context	of	CXCL12	stimulation,	it	would	also	be	interesting	to	see	if	
acute	 stimulation	 with	 this	 ligand	 also	 had	 an	 impact	 on	 HRS	 recruitment.	
Furthermore,	DTX3L	was	 identified	 in	the	mass	spectrometry	dataset,	which	was	 in	
the	 context	 of	 EGF	 stimulation.	 DTX3L	 is	 recruited	 to	 endosomes	 in	 response	 to	
CXCL12	 stimulation,	 it	 may	 also	 be	 recruited	 to	 endosomes	 in	 response	 to	 EGF	
stimulation.	Visualisation	of	DTX3L	recruitment	may	provide	further	insights	into	the	
regulation	of	HRS	recruitment.	
	
6.4.3.	Further	work	on	assessing	HRS	‘priming’	
	
HRS	has	previously	been	shown	to	be	partly	responsible	for	the	recruitment	of	WASH	
(MacDonald,	Brown	et	al.	2018).	EGF	stimulation	didn’t	lead	to	an	increase	in	WASH	
positive	puncta	despite	increasing	the	number	of	HRS	positive	puncta.	As	mentioned	
above,	TGFα	is	an	EGFR	ligand	that	encourages	the	receptor	to	be	recycled	rather	than	
degraded.	It	would	be	intriguing	to	determine	if	TGFα	would	have	a	different	effect	on	
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the	recruitment	of	WASH	than	EGF.	I	hypothesise	that	the	different	responses	of	HRS	
are	due	to	differential	phosphorylation	and	ubiquitin	modifications	to	HRS.	Differential	
phosphorylation	 profile	 of	 HRS	 has	 been	 observed	 with	 different	 growth	 factor	
receptors	(Row,	Clague	et	al.	2005,	Francavilla,	Papetti	et	al.	2016).	Tyrosine	residues	
329	and	334	were	used	in	this	study	due	to	their	identification	by	Urbé	et	al.	(Urbé,	
Sachse	 et	 al.	 2003).	 Phosphorylation	 at	 these	 residues	 appeared	 to	 affect	 the	
recruitment	of	HRS	 in	response	to	TGFα	but	not	EGF	(Figures	5.6	and	5.7).	Further	
tyrosine	mutants	could	be	generated	to	determine	if	any	of	them	are	involved	in	the	
EGF	induced	recruitment	of	HRS.	
	
The	 identification	 of	 the	 E3	 ligase	 DTX3L	 highlights	 the	 potential	 role	 of	 HRS	
ubiquitylation	in	ligand-induced	HRS	recruitment.	Manipulation	to	the	ubiquitylation	
of	HRS	is	likely	to	alter	the	dynamics	of	its	recruitment.	This	can	be	achieved	through	
perturbations	 to	DTX3L,	 AIP4	or	 by	 direct	manipulations	 to	 lysine	 residues	 on	HRS	
itself.	The	resulting	experiments	would	hopefully	provide	further	evidence	to	support	
the	concept	of	HRS	‘priming’	as	well	as	provide	further	mechanistic	insights	into	this	
process.	
	
6.5.	Concluding	remarks	
	
The	 aim	 of	 the	 work	 described	 in	 this	 thesis,	 was	 to	 establish	 HRS	 as	 a	 signalling	
adaptor	involved	in	the	crosstalk	between	RTKs	and	GPCRS,	as	well	as	ascertain	the	
function	 of	 HRS	 phosphorylation.	 I	 was	 unable	 to	 confirm	 the	 EGF	 dependent	
interactions	of	HRS	with	the	collection	of	G-proteins	 found	 in	the	preliminary	work	
described	 in	 the	 beginning	 of	 chapter	 three.	 I	 did,	 however,	 identify	 a	 connection	
between	HRS	and	the	E3	ligase	DTX3L.	DTX3L	has	been	implicated	with	the	signalling	
of	CXCR4.	This	interaction	between	HRS	and	DTX3L	provides	supporting	evidence	to	
the	notion	that	HRS	may	be	acting	as	a	signalling	adaptor	in	order	to	mediate	certain	
aspects	of	RTK	and	GPCR	crosstalk.	
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My	 work	 on	 FRET	 based	 biosensors	 for	 the	 measurements	 of	 endosomal	 cAMP	
production	and	endosomal	PKA	signalling	will	need	further	development.	The	purpose	
of	 generating	 these	 tools	 was	 to	 use	 them	 to	 provide	 further	 evidence	 of	 HRS	
mediating	the	crosstalk	between	RTKs	and	GPCRs.	Due	to	the	diffusion	rate	of	cAMP,	
it	may	not	be	possible	to	create	a	tool	specifically	for	the	study	of	endosomal	cAMP	
production.	It	may	still	be	possible	to	improve	the	cell	lines	created	for	endosomal	PKA	
signalling	and	generate	reliable	FRET	measurements.	
	
Finally,	 by	 visualising	 the	 dynamics	 of	 HRS	 recruitment	 in	 response	 to	 acute	
stimulation	of	EGF,	I	show	that	HRS	is	recruited	directly	to	EGF	positive	vesicles,	in	a	
manner	that	appears	to	be	independent	of	PtdIns(3)P	 levels.	Furthermore,	I	show	a	
difference	in	the	recruitment	of	the	tyrosine	mutant	HRS	(YYFF)	compared	to	wild	type	
HRS	 in	 response	 to	 TGFα	 stimulation,	 but	 not	 with	 EGF	 stimulation.	 This	 provides	
evidence	 that	 the	 phosphorylation	 profile	 of	 HRS	may	 dictate	 the	way	 in	which	 it	
responds	to	incoming	cargo.	
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Appendix	
	
Supplementary	movie	1	Pseudo	colour	movie	of	FRET	from	AKAR4-FF	expressing	cells	
stimulated	 with	 Isoproterenol.	 Pixel	 intensities	 derived	 from	 a	 binary	mask	 of	 the	
acceptor	channel.	
	
Supplementary	 movie	 2	 Pseudo	 colour	 movie	 of	 FRET	 from	 the	 same	 AKAR4-FF	
expressing	 cells	 stimulated	 with	 Isoproterenol.	 Pixel	 intensities	 derived	 from	 a	
Laplacian	filter	of	the	acceptor	channel.	
	
Supplementary	movie	3	GFP-HRS	expressing	HeLa	cells	 stimulated	with	20ng/ml	of	
EGF.	Movie	of	time-lapse	images	in	Figure	5.1.	
	
Supplementary	movie	4	GFP-HRS	expressing	HeLa	cells	stimulated	with	EGF-AF555.	
Movie	of	time-lapse	images	in	Figure	5.4.	
	
Supplementary	movie	5	GFP-WASH	expressing	HeLa	cells	stimulated	with	20ng/ml	of	
EGF.	Movie	of	time-lapse	images	in	Figure	5.5.	
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Supplementary	Figure	1	Test	digests	of	 the	 intermediate	vectors	generated	with	
creating	endosomal	ICUE3.	Plasmid	maps	of	the	vectors	used	with	restriction	sites	
can	be	found	in	Supplementary	Figures	2-4.	The	final	generated	vectors	were	sent	
for	sequencing.		
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Supplementary	Figure	2	Plasmid	map	of	pCR4-TOPO-Blunt-FFYVE	vector.	Plasmid	
map	show	the	locations	of	the	restriction	sites	used	in	Supplementary	Figure	1.		
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Supplementary	 Figure	 3	 Plasmid	 map	 of	 pcDNA3.1-ICUE3	 vector.	 Plasmid	 map	
show	the	locations	of	the	restriction	sites	used	in	Supplementary	Figure	1.		
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Supplementary	Figure	4	Plasmid	map	of	pcDNA3.1-ICUE3-FFYVE	vector.	Plasmid	
map	show	the	locations	of	the	restriction	sites	used	in	Supplementary	Figure	1.		
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